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Zur Entwicklung neuer Krebstherauien: 
Selektion und Charakterisierung von Verbindungen, die die Tumorzell-
Proliferation, Angiogenese und Lymphangiogenese hemmen. 
Zusammenfasung 
Aufgrund ihrer geringen Toxizität, des reduzierten Risikos einer Arzneimittelresistenz und 
der erhöhten Anti-Krebswirkung, besitzt die Anti-Angiogenese-Therapie das Potential zu 
einem wichtigen Ansatzpunkt in der Krebshandlung zu werden. Die Mitglieder der vaskulären 
endothelialen Wachstumsfaktoren (VEGF) Familie und ihre Tyrosinkinase-Rezeptoren (RTK) 
sind die am besten charakterisierten Vermittler der Angiogenese, die zur Zeit als potentielle 
Ziele in der Anti-Aniogenese-Strategie eingesetzt werden. Die Tumor-induzierte 
Lymphangiogenese ist ein anderer Prozess, dessen wichtige Rolle bei der Tumorprogression 
und bei der Metastasierung jetzt offensichtlich wird. Es wird angenommen, daß die Tumor-
induzierte-Lymphangiogenese von Mitgliedern der VEGF-Familie, nämlich VEGF-C und 
VEGF-D, welche Signaltransduktion durch die RTK VEGFR-3 iniziieren, reguliert wird. 
Das Ziel dieser Arbeit war es, neue Anti-Krebsagentien zu entwickeln, die das 
Tumorwachstum blockieren indem sie direkt in die Tumorzellproliferation, die Angiogenese 
und/oder Lymphangiogenese eingreifen, und so Tumorwachstum und Metastasierung 
verhindern. Zu diesem Zweck wurde ein in vitro Assay etabliert, der es ermöglicht, kleine 
synthetische Verbindungen, genannt Indolinone, hinsichtlich ihrer Fähigkeit mit der normalen 
Funktion verschiedener RTKs inklusive der VEGFRs, zu interferieren. Um das inhibitorische 
Potential der wirksamsten Indolinone bezüglich VEGFR zu bestimmen, wurden sie in einem 
zellulären Phosphorylierungstest unter Verwendung von Ratten-VEGF-Liganden zu 
Stimulierung von VEGFRs getestet. Die rekombinanten VEGF Proteine wurden in einem 
Drosophila-Expressionssystem hergestellt, über eine Nickel-säule aufgereinigt und ihre 
biologische Aktivität gezeigt. Sie wurden auch in einen Versuch zur Etablierung von 
lymphatischen Endothel in Kultur eingesetzt. 
Durch den Screen wurden potentielle Inhibitoren von VEGFRs, namentlich AE87, AE106, 
MAZSI und MAZSI-2 identifiziert. Alle 4 Indolinone zeigen starke antiangiogene 
Eigenschaften, die durch ihre Fähigkeit, die Endothelzell-Proliferation und deren Sprassung 
zu inhibieren, charakterisiert wurden. Weiterhin zeigten AE87, AE106, MAZSI und MAZSI-
2 die neue Fähigkeit, VEGFR-3 Phosphorylierung zu inhibieren. Da die selbe Inhibition nicht 
im VEGFR-2 zellulären Phosphorylierungstest beobachtet wurde, werden diese Inhibitoren 
nützlich sein für die Unterscheidung des Effekts von VEGF-C und VEGF-D, auf VEGFR-2 
und VEGFR-3. MAZSI und MAZSI-2 stellten sich als die wirksamsten untersuchten 
Indolinone heraus. MAZ51 z. B. induziert die Apoptose in Endothel- und Tumorzellen. Von 
besonderer Bedeutung ist die Unterdrückung des Tumorwachstums in Ratten, wenn MAZSI 
intraperitoneal injiziert wird. 
Eine einführende Charakterisierung der Antitumoreigenschaft des Pflanzenderivats-
Acylphloroglucinol-Typs Hyperforin wurde ebenso durchgefürt. Hyperforin ist flihig, das 
Tumorwachstum zu reduzieren. Zum einen direkt durch die Induktion der Apoptose der 
Tumorzellen und zum anderen indirekt durch die Inhibierung der Proliferation der 
Endothelzellen. 
Die Substanzen, die durch diese Arbeit identifiziert wurden, könnten von pharmazeutischem 
Wert sein und unterstützen die Entwicklung von besseren Krebstherapien. Die zukünftige 
Arbeit sollte sich darauf konzentrieren, die präzisen Reaktionmechanismen der Indolinone 
und von Hyperforin aufzuklären und mögliche Nebeneffekte der Substanzen zu identifizieren. 
Kleinere Modifikationen der Substanzstrukturen sind wahrscheinlich von Nöten, um ihre 
Löslichkeit und Spezifität zu steigern. 
- 1-
Abstract 
Anti-angiogenic therapy, due to its low toxicity, reduced risk of drug resistance and 
increased anti-cancer efficacy, has the potential to become a major approach in 
treating cancer.- Members of vascular endothelial growth factor (VEGF) family and 
their tyrosine kinase receptors (RTKs) are the best-characterised mediators of 
angiogenesis, which are being currently used as potential targets in the anti-
angiogenic strategy. Tumour-induced lymphangiogenesis is another process that is 
now being recognised to play an important role in tumour progression and metastasis. 
It too is thought tobe regulated by members ofthe VEGF family, namely VEGF-C 
and VEGF-D, which signal through the RTK VEGFR-3. 
The goal of this work was to develop novel anti-cancer agents that would block 
tumour growth by targeting tumour cell proliferation directly, angiogenesis and/or 
lymphangiogenesis, thereby preventing its growth and metastasis. To this end, an in 
vitro assay was established which permitted screening of small synthetic compounds 
called indolinones for their ability to interfere with normal functioning of different 
RTKs, including the VEGFRs. To further assess the VEGFR inhibitory potential of 
the mostpotent indolinones, they were tested in a cellular phosphorylation assay using 
rat VEGF ligands to stimulate VEGFRs. The recombinant VEGF proteins were 
produced in a Drosophila expression system, purified via a histidine tag and shown to 
be biologically active. They were also used in an attempt to establish lymphatic 
endothelium in culture. 
The screen identified four potential inhibitors ofVEGFRs, named AE87, AE106, 
MAZ51 and MAZ51-2. All the four indolinones showed potent anti-angiogenic 
properties that were characterised by the ability to inhibit endothelial cell proliferation 
and sprouting in vitro. Furthermore, AE87, AE106, MAZ51 and MAZ51-2 showed 
the novel ability to inhibit VEGFR-3 phosphorylation. Since the sameinhibitionwas 
not observed in VEGFR-2 cellular phosphorylation assays, theseinhibitorswill be 
useful for dissecting the effects of VEGF-C and VEGF-D exerted via VEGFR-2. 
MAZ51 and MAZSI-2 proved to be the most potent of the screened indolinones. 
MAZ51, for instance, induced apoptosis in endothelial and tumour cells. lmportantly, 
when injected intraperitoneally, it could suppress tumour growth in rats. 
Initial characterisation of the anti-tumour properties of the plant-derived 
acylphloroglucinol-type compound hyperforin was also performed. It was found tobe 
able to reduce tumour growth directly by inducing tumour cells to apoptose and 
indirectly via inhibition of endothelial cell proliferation. 
The substances identified in the course of this work may be of pharmaceutical 
value and should assist development of better anti-cancer protocols. Future work 
should concentrate on the elucidation of the precise mechanism of action of the 
indolinones and hyperforin and identification of possible adverse effects of the 
substances. Minor modifications in the substance structure may be necessary to 
improve their solubility and specificity. 
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Chapter 1: Introduction 
1.1 Cancer 
"Cancer". Who of us would not shudder at hearing such a diagnosis? Indeed, this 
disease, accounting for one of five fatalities in the developed countries, in many cases 
still remains largely incurable. Obviously enough, conquering cancer has long been a 
major challenge for researchers throughout the world. Cancer research, however, is 
not only of clinical significance. It also promises to cast light on those fundamental 
mechanisms that determine behaviour ofthe cells in a multicellular organism. 
1.1.1 Tumour generation 
The term "cancer" refers not to a single illness but rather describes a family of 
diseases having common key features. These include uncontrolled cell reproduction 
(i.e. tumour formation), loss of differentiation, aneuploidy, and resistance to 
apoptosis. The process of tumorigenesis is thought to be initiated by distinct genetic 
alterations which can be either inherited or acquired upon exposure of DNA to 
different mutagenic factors (Kinzler and Vogelstein, 1998). Such a genetic insult 
typically results in the mutation, misexpression, or deletion of regulatory genes that 
play essential roles in key cellular processes such as proliferation, differentiation, cell 
cycle progression and apoptosis (Yokota, 2000). With respect to tumorigenesis, such 
affected genes are usually divided into two groups, referred to as proto-oncogenes 
(which usually exert their effect via gain of function) or tumour-suppressor genes 
(whose role is typically associated with loss of function) (Weinberg, 1995). The 
activity of oncogenes and impaired function of tumour suppressor proteins Ieads to 
uncontrolled cell proliferation and escape from apoptotic signals, causing expansion 
of the transformed cell population (e.g. Bishop, 1991). Such tumours may remain 
benign until further genetic alterations take place. These secondary insults to key 
genes are thought to happen in steps and further contribute to the malignant 
transformation ofneoplastic cells (Foulds, 1975; Fearon and Vogelstein, 1990). 
1.1.2 Apoptosis and tumorigenesis 
As can be appreciated from the preceding section, DNA darnage is a driving force 
behind the development of tumours. Cells possess many properties that allow them to 
detect damaged DNA and respond appropriately. One response to DNA darnage is 
apoptosis. Thus, in order to survive with damaged DNA, tumour cells need to 
suppress apoptosis inducing signals (Sigal and Rotter, 2000). Apoptosis, also referred 
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to as programmed cell death, is the most common form of eukaryotic cell death. In 
contrast to necrosis, it is a regulated physiological cell suicide mechanism that 
maintains tissue homeostasis (Wyllie, 1997; Hengartner, 2000). The activation ofthe 
apoptosis programme occurs by the two major pathways: a) the 'extrinsic' cell death 
pathway initiated by external factors through the specialised TNF-family death 
receptors such as the TNF-R1, CD95(Fas) and TRAIL (Ashkenazi and Dixit, 1998) 
and b) the 'intrinsic' cell death pathway activated by the release of pro-apoptotic 
factors from mitochondria which include cytochrome c and Apaf-1 (Green and Reed, 
1998). The gross effect of either pathway is characterised by the activation of specific 
proteases called caspases and endogenous endonucleases, resulting in the DNA 
fragmentation, nuclear and cytoplasm condensation, membrane blebbing referred to as 
zeiosis and disintegration of the cell into apoptotic bodies (Hengartner, 2000). An 
important feature of apoptosis is the Iack of the necrosis-associated inflammation as 
the apoptotic bodies are efficiently fagocytised by other cells (Hengartner, 2000). 
In order to grow progressively, tumour cells have to circumvent apoptosis, which is 
one of the cellular responces to DNA darnage (Pucci et al., 2000). Consequently, 
mutations in proteinssuch as p53 which regulate the expression of genes involved in 
apoptosis have been identified in the majority of cancers (Sigal and Rotter, 2000). It is 
therefore thought that the ability to restore the normal apoptosis mechanisms in 
tumour cells might potentially lead to the elimination of the cancer (Sigal and Rotter, 
2000). 
1.1.3 Tumour progression and metastasis 
It is the ability of cancer to metastasise that makes it so hard to eliminate, as some 
tumours, for example melanoma, start to metastasise while measuring only several 
millimetres in diameter and thereby are very difficult to detect before they have begun 
to disseminate. The onset of metastasis is associated with poor prognosis since many 
vital organs become targeted and subsequently destroyed by the disease. 
In order to become metastatically competent, a tumour cell must acquire several 
properties (reviewed in Sleeman, 2000). Tumour cells metastasise via three main 
routes: by direct extension, through the blood circulation and through the lymphatic 
system. Therefore, the major three properties that are thought to be necessary for a 
tumour cell to leave the primary tumour and enter a cavity or a capillary are 
adhesiveness, ability to produce andlor activate proteases, and motility. Thus, changes 
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in adhesive properties permit detachment of metastatic cells from neighbouring cells 
and establishment of new contacts with the extracellular matrix (ECM) and host cells 
they encounter on their way of invasion. The production and activation of proteases 
are required to degrade the ECM and thereby allow the metastatic cells to invade 
surrounding tissues. Finally, tumour cells need to become actively motile in order to 
migrate away and enter vessels of the circulatory system. Further metastatic 
dissemination occurs in steps which include intravasation ( enter into a lymphatic or 
blood vessel), transport in the blood or lymphatic stream, extravasation ( exit from the 
blood stream into the surrounding tissues) and formation of secondary tumours (Fig. 
1.1). Therefore, during their voyage tumour cells need further cellular properties if 
they are to survive and reach their target organ(s) (Sleeman, 2000). 
How do tumour cells acquire the properties they require if they are to successfully 
metastasise? During tumour progression from a benign lesion to malignancy, 
mutations in the regulatory genes such as p53 (Hollstein et a/., 1991) can Iead to 
disruption of those control mechanisms that ensure the fidelity of DNA replication 
and repair. The Iack of apoptosis, which is normally triggered when DNA is seriously 
damaged, ensures that the tumour cell will continue its passage through the cell cycle 
and undergo mitosis. This Ieads to genetic instability of tumour cells, which is 
presumably reflected in loss of differentiation, high mitotic index, aneuploidy and 
gross chromosomal aberrations often associated with malignancies (Sleeman, 2000). 
Together with the concomitant increase in the mutation rate, the genomic 
abnormalities ensure that the population of the tumour becomes largely heterogeneous 
(Fidler, 1978). Thus, tumours then contain a range of tumour cells with different 
assortments of molecular and cellular properties. It is thought that only those tumour 
cells possessing the properties necessary to overcome the selective pressures they 
encounter as they try to metastasise will be able to successfully form secondary 
tumours. 
1.1.4 Tumour-host interactions 
In both primary tumours and their metastases, cancer cells constantly interact with 
each other as weil as with host cells. Thus, an important prerequisite for tumour 
growth and metastasis formation is the development of stroma, which is composed of 
fibroblasts, blood vessels, immune cells and components of the ECM (Dvorak, 1986; 
Wemert, 1997). Stroma! fibroblasts play an important role in tumour invasion as they 
4 
a Neop/asia b Invasion 
-:,B;-;-:Io=od:;-:v:::es~ ....... J ---
h Micrometastusis 
f Extravasalion 
c Angiogenesis d Intravasalion 
{J 
() 
(J 
Q~ 
e Adhesion to 
b/ood !•esse/ wa/1 
in distant organ 
Figure 1.1 Overview of tumour progression and metastasis. a) As long as neo-
plastic cells are dustered together, tumour remains benign; b) tumour tums into 
malignant state when it acquires an invasive phenotype (i.e. ECM degradation and 
migration); c) tumour induces angiogenesis to secure its own blood supply; d) 
capillaries are entry points for metastatic cells; e) to exit circulation metastatic 
cells have to attach specifically to vascular endothelial cells and t) extravasale 
through the vessel wall; g) to grow successfully, metastatic cells migrate to sites 
proximal to arterioles; h) micrometastasis can remain dormant for prolonged time 
during which angiogenesis is subdued; i) secondary tumour site angiogenesis 
releases the metastatic colony from the dormancy and allows its rapid growth. 
For simplicity, only hematogenous spread of metastatic cells is shown ( adopted 
from Zetter, 1998). 
5 
Chapter 1: lntroduction 
participate in the degradation of the ECM by secreting matrix degrading proteases as 
well as their downstream-activators. Moreover, factors derived from the stromal cells 
and ECM such as scatter factor/hepatocyte growth factor (SF/HGF) as weil as 
interactions between neoplastic cells and the ECM can play a role in both tumour cell 
migration and proliferation. Another important aspect of tumour host interactions is 
reflected in the evasion of tumour cells from the surveillance of the immune system. 
To escape from the immunological destruction, tumours need to further change their 
properties. These include downregulating or shedding tumour-associated antigens, 
decreasing or losing expression of MHC antigens (Pawelec et al., 1997), and 
expression of molecules inducing apoptosis in anti-tumour T cells (Walker et a/., 
1997). 
1.1.5 Tumour angiogenesis and lymphangiogenesis 
Perhaps the most important tumour-host interaction 1s the induction of 
angiogenesis. As illustrated by Figure 1.1, forasolid tumour to grow successfully, it 
also must secure its own blood system to supply tumour cells with nutrition as weil as 
to relieve the growing mass from hypoxia (Folkman et al., 1963; Folkman, 1972). 
This process, referred to as tumour-induced angiogenesis, is mediated via soluble 
growth factors either secreted by tumour cells or derived from the host tissue. The 
established capillary network also permits tumour cells endowed with an "invasive" 
phenotype to enter capillary beds and subsequently be transported in the circulation. 
Since many human tumours metastasise at least initially via the lymphatic system 
the induction of new lymphatics is thought to be an important step in tumour 
progression, too (Sleeman, 2000). Lymphangiogenesis may be invoked to help tumour 
cope with rising interstitial pressure (Jain, 1987). Recent studies demonstrate that the 
tumour-induced lymphangiogenesis can promote metastasis formation (Mandriota et 
a/., 2000; Skobe et al., 2001; Stacker et al., 2001). 
1.1.6 Approaches to anti-cancer therapy 
Better understanding of the processes occurring in the tumour cell may make it 
possible to design various therapies aimed at altering or inactivating key tumour cell-
specific genes, which would cause tumour cells to apoptose or revert from their 
malignant phenotype. Another potential line of anti-cancer research is to inhibit 
tumour-host interactions, which would indirectly interfere with tumour growth. For 
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instance, anti-angiogenesis therapies are being developed to deprive the tumour of the 
blood supply, causing its regression and, most optimistically, complete ablation 
(Kerbel, 2000). Furthermore, since the vast majority of human carcinomas tend to 
metastasise via the lymphatics (Beitz and Calabresi, 1993), the development of anti-
lymphangiogenesis approaches might block metastatic spread via the lymphatics. 
In this thesis I have characterised and investigated the potential anti-tumour effects 
of a number of chemical compounds that may act directly on tumour cells and/or 
inhibit important tumour-host interactions. Since the work in this thesis is partly 
concerned with the development of anti-angiogenic and anti-lymphangiogenic 
therapies, the following sections will review the existing Iiterature on the processes of 
tumour-induced angiogenesis and lymphangiogenesis. The current state of the clinical 
utility ofthe knowledge on tumour-induced angiogenesis will also be addressed here. 
1.2 Angiogenesis 
1.2.1 Vasculogenesis vs. angiogenesis 
The circulatory system appeared early in the evolution of multicellular organisms. 
Gradually it evolved into a complex and highly specialised organ system playing a 
central role in the maintenance of organism homeostasis. Thus in vertebrates, the 
circulatory system is not restricted to transporting oxygen, nutrients, carbon dioxide 
and metabolic wastes but also serves as a means of communication between tissues 
and organs ensuring an adequate response ofthe organism to the environment. 
The circulatory system is one of the earliest organ systems to develop and become 
functional during embryogenesis. Embryonie vasculature develops in two successive 
steps (Fig. 1.2). In the first step, termed vasculogenesis, multipotent mesodermally-
derived precursors called hemangioblasts differentiate in situ. to become endothelial 
cells (Wanger, 1980; Risau, 1997) that later organise into a primary capillary plexus 
(Risau and Flamme, 1995). During the second step, called angiogenesis, the sprouting 
and remodelling of the primary plexus as well as the recruitment of periendothelial 
cells (such as smooth muscle cells and pericytes) occurs to create a mature 
arteriovenous vascular system (Risau, 1997; Folkman, 1995a). 
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1.2.2 Molecular mechanisms of angiogenesis regulation 
Whereas vasculogenesis is restricted to early stages of embryogenesis, 
angiogenesis can be found in both embryonie development and postnatal life. Adult 
angiogenesis is, however, kept to a minimum. It is triggered during physiological 
processes such as wound healing and the female reproductive cycle, but is turned off 
after these processes are completed (Folkman, 1995). It therefore appears that 
physiological angiogenesis is constantly being tuned via a dynamic balance of 
positive and negative factors that operate within the vascular microenvironment 
(Pepper, 1997; Iruela-Arispe and Dvorak, 1997). In certain pathological conditions, 
however, this fine balance is disturbed leading to excessive proliferation of 
endothelial cells. Such abnormal angiogenesis is a characteristic feature of major 
diseases such as diabetic retinopathy, arthritis, psoriasis, ischimia, atherosclerotic 
plaques, and cancer (Gamer, 1994; Folkman, 1995). 
1.2.2.1 Positive regulators of angiogenesis 
The development of various in vitro and in vivo angiogenesis assays as well as 
genetic manipulation of the mouse genome has allowed a rather large panel of 
positive regulators of angiogenesis to be identified during the past several years 
(Table 1.1). Typically, angiogenic factors secreted in a paracrine or autocrine fashion 
bind to and activate their corresponding receptors expressed on the surface of 
endothelial cells. Thereby activated endothelial cells become capable of proliferation, 
migration, and differentiation resulting in the formation of new capillaries (Klagsbrun 
and D' Amore, 1996). Besides direct endothelial cell stimulation, however, 
angiogenesis can be promoted by activation of other cell types such as smooth muscle 
cells (SMC) and pericytes that further contribute to vessel formation and maturation 
(Rissau, 1997). In the following section I will describe some ofthe best-characterised 
regulators of angiogenesis. 
a) Vascular endothelial growth tactor (VEGF) tamily and VEGFR receptors 
VEGF family members (Fig. 1.3) are important regulators of angiogenesis and 
lymphangiogenesis. The VEGF family consists of six known members: VEGF, PIGF, 
VEGF-B, VEGF-C, VEGF-D and VEGF-E (orfvirus VEGF; Ogawa et al., 1998). All 
of them share a common feature, namely the presence of regularly spaced eight 
cysteine residues, which constitute the so-called cysteine knot motif. Their receptors, 
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called VEGFRs, belong to the PDGF receptor class, within which they form a distinct 
receptor subfamily characterised by seven lg-homology domains, a transmembrane 
sequence and an intracellular portion containing a split kinase domain (Shibuya et al., 
1990). 
Vascular endothelial growth factor (VEGF, or VEGF-A), previously known as 
vascular permeability factor (VPF) and vasculotropin (V AS), is by far the best-
characterised endothelial-specific mitogen, playing a pivotal role in the positive 
regulation of angiogenesis (Dvorak et al., 1995; Klagsbrun and D' Amore, 1996). 
VEGF is a 34-45 kDa cysteine-linked homodimeric glycoprotein represented by five 
isoforms derived by alternative exon splicing of a single VEGF gene: VEGF121, 
VEGF145, VEGF16s, VEGFI89, and VEGF2o6 (Parket al., 1993; Poltorak et al., 1997). 
The five isomorphic proteins vary in their heparin-binding ability resulting in the 
different extracellular matrix (ECM) immobilisation, and hence bioavailability, of the 
VEGF molecules. Thus VEGF 121 is a freely diffusible protein. VEGF 145 and VEGF 16s, 
the major isoform, are partially bound to the cell surface and the ECM. VEGF 189 and 
VEGF206 are almost completely sequestered in the ECM. All the forms of VEGF are 
mitogenic towards vascular endothelial cells in a paracrine mannerbothin vitro (e.g. 
Pepper et al., 1992; Nicosia et al., 1994) and in vivo (e.g. Leung et al., 1989; 
Tolentino et al., 1996). VEGF is also known to induce vascular permeability of blood 
vessels (Dvorak et al., 1995) and expression of different proteases by vascular 
endothelial cells (Pepper et al., 1991; Unemori et al., 1992). The latter two VEGF-
mediated processes ultimately Iead to profound alterations in the ECM that facilitate 
endothelial cell migration and therefore promote angiogenesis. 
VEGF exerts its angiogenic effect in a dose-dependent fashion as was 
demonstrated by heterozygous mutations inactivating the VEGF gene (Carmeliet et 
al., 1996; Perrara et al., 1996), where the Iack of only a single VEGF allele resulted in 
embryonie lethality in day 11.5-12.5 mice due to abnormal angiogenesis and 
hematopoiesis. Conversely, overexpression of VEGF in developing avian embryos led 
to the formation of a hyperfused vascular network and vascularisation of normally 
avascular embryonie areas (Drake and Little, 1995). It seems, therefore, that the 
maintenance of appropriate VEGF Ievels is of vital importance for both the embryo 
and adult. Thus, diverse molecular mechanisms are responsible for the regulation of 
VEGF expression (Breier et al., 1997). VEGF expression is triggered by different 
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pathophysiological factors ranging from hypoxia (Shweiki et al., 1992; Forsythe et 
al., 1996), hypoglycaemia (Klagsbrun, 1999) and certain cytokines such as EGF and 
TGF -ß (Frank et al., 1995) to oncogenes such as ras (Rak et a/., 1995) and mutated 
tumour-suppressor genes such as p53 (Kieser et al., 1994) and von Hippel-Landau 
gene (Wizigmann-Voos et al., 1995). 
Ligand 
VEGF family 
VEGF 
PIGF 
VEGF-B 
VEGF-C 
VEGF-D 
FGF family 
FGF-1 
FGF-2 
Angiopoietins 
Angl 
Ang2 
? 
PDGF family 
PDGF-AA 
PDGF-BB 
PDGF-AB 
TGF-ß1 
TNF-a. 
SF/HGF 
Receptor(s) 
VEGFR-1, VEGFR-2 
VEGFR-1 
VEGFR-1 
VEGFR-2, VEGFR-3 
VEGFR-2, VEGFR-3 
FGFR-1, FGFR-2, FGFR-3, FGFR-4 and HSPGs 
FGFR-1, FGFR-2 and HSPGs 
Tie-2ffek 
Tie-2ffek 
Tie-1 
PDGFR-aa 
PDGFR-aa, PDGFR-aß, PDGFR-ßß 
PDGFR-aa, PDGFR-aß 
TGFR I, TGFR Il, endoglin 
p55,p75 
c-met receptor 
EGF EGFR 
Table 1.1 Positively acting angiogenic factors ( adopted from Ahrendt et al., 1998). 
VEGF activates endothelial cells by binding to its cognate VEGF receptors 
(VEGFRs). They are subclass-III receptor tyrosine kinases (RTKs), homologous to 
the PDGF-receptor family. Two high-affinity VEGF RTKs, almost exclusively 
expressed on the cells of endothelial lineage (Hanahan, 1997), have been described so 
far: VEGFR-1 (also denoted fms-like kinase, Flt-1) (de Vries et al., 1992) and 
VEGFR-2 (also called KDR (human) and Flk-1, foetal liver kinase-1 (murine)) 
(Terman et a/., 1992). Both VEGFR-1 and VEGFR-2 have seven Ig-like domains in 
the extracellular domain, a single transmembrane region and a consensus tyrosine 
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Figure 1.3 Schematic representation of VEGF receptor family and their 
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domain homologous to coagulation factors V and VIII; green octagon, 
MAM domain (takenfrom Petrova et al., 1999). 
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kinase sequence interrupted by a kinase-insert domain (Shibuya et al., 1990; 
Matthews et al., 1991; Terman et al., 1991). This structural similarity defines the 
subfamily of vascular endothelial growth factor receptors that contains an additional 
member called VEGFR-3 (Flt-4), which, however, is not a receptor for VEGF 
(Mustonen and Alitalo, 1995). In fact, another VEGF-binding receptor, neuropilin-1 
(NP-I), which is a cell surface glycoprotein that binds collapsins/semaphorins and 
mediates axonal guidance during embryonie development and does not belong to the 
VEGFR family, was described more recently (Soker et al., 1998). NP-1 appears to 
modulate VEGF binding to VEGFR-1 and VEGFR-2 acting as an isoform-specific 
VEGF 165 receptor (Soker et al., 1998). 
Gene knockout sturlies in mice have clearly shown the importance of both 
VEGFR-1 and VEGFR-2 for vasculogenesis. However, temporal signalling through 
these two receptors seems tobe quite different. Thus, VEGFR-2 knockoutmicedie in 
utero between embryonie day 8.5 and 9.5, displaying defects in both angioblastic and 
hematopoietic lineages (Shalaby et al., 1995). On the other hand, in VEGFR-1-null 
mice, which also die between E8.5 and 9.5, it is still possible to detect migrating and 
proliferating angioblasts, although they fail to assemble into functional vessels (Fong 
et al., 1995). Interestingly, although VEGFR-1 binds VEGF with a 10-fold higher 
affmity than VEGFR-2 (Terman et al., 1992; de Vries et al., 1992), it does not seem 
to transduce the VEGF signal efficiently (Seetharam et al., 1995; Kroll and 
Waltenberger, 1997, Gerber et al., 1998). This suggests that VEGFR-1 may serve as a 
negative regulator of angiogenesis by sequestering VEGF. Consistent with this 
hypothesis, and in contrast to the aforementioned VEGFR-1-null mice, transgenic 
mice expressing a truncated form of VEGFR-1, which lacks the tyrosine kinase 
domain, develop normally (Hiratsuka et al., 1998). 
Placenta growth factor, another member of the VEGF family abundantly 
expressed in placenta, has two isoforms (PlGF 131 and PlGF 152), which differ only by 
the insertion of a heparin-binding 21-aa stretch resulting in different ECM binding 
properties (Maglione et al., 1993; Hauser and Weich, 1993). Unlike the VEGF 
homodimer, which can bind to both VEGFR-1 and VEGFR-2, the PlGF homodimer 
binds only to VEGFR-1 (Cao et al., 1996). PlGF can form, however, heterodimers 
with VEGF thereby acquiring VEGFR-2-binding properties (Cao et al., 1996). 
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Vascular endothelial growth factor-B (VEGF-B), also known as VEGF-related 
factor (VRF, Grimmond et al., 1996), like PIGF, is a selective Iigand for VEGFR-1. 
Its isoforms (VEGF-B167 and VEGF-B1 86) are produced as disulphide-linked 
homodimers with high affinity for VEGFR-1 (Olofsson et al., 1996; Olofsson et al., 
1996a). Although experimental data suggest it has a mitogenic activity towards 
endothelial cells in vitro (Olofsson et al., 1996), its exact in vivo function remains 
obscure. 
Vascular endothelial growthfactor-C (Joukov et al., 1996) (also known as VEGF-
related protein, VRP; Lee et al., 1996), and vascular endothelial growth factor-D 
(originally called Fos-induced growth factor, FIGF; Orlandini et al., 1996) are two 
VEGF -related proteins that appear to play a role in both angiogenesis and 
lymphangiogenesis. Their signalling specificity is regulated proteolytically. 
Unprocessed VEGF-C and VEGF-D are initially able to bind only their 
lymphangiogenesis-specific receptor VEGFR-3 (Joukov et al., 1997; Stacker et al., 
1999). After proteolytic maturation they acquire the ability to bind to and activate 
VEGFR-2, which can Iead to angiogenesis (Joukov et al., 1997; Stacker et al., 1999) 
(Fig. 1.4). Since VEGF-C and VEGF-D can bind to and activate VEGFR-2, they may 
also be involved in the regulation ofVEGF-mediated signalling. 
b) Fibroblast growth (actor {FGF) {Qmilv and receptors 
Fibroblast growth factor 1 (FGF-1, acidic FGF, aFGF) and jibroblast growth 
factor 2 (FGF-2, basic FGF, bFGF) (Folkman and Shing, 1992; Femig and Gallagher, 
1994) are another example of proteins involved in the positive regulation of 
angiogenesis. Both FGF-1 and FGF-2 are members of a family of 17 structurally 
related proteins (Botta et al., 2000; Powerset al., 2000). Interestingly, unlike the other 
family members, they Iack signal sequences, which poses the question of how they are 
secreted. Different isoforms of FGF-2 (18, 22, 22.5, and 24 kDa) that result from 
alternative translation initiation have been described (Florkiewicz and Sommer, 1989; 
Prats et al., 1989). FGF-1 is also represented by 3 isoforms: 154 aa and truncated 
forms of 140 and 134 aa (Esch et al., 1985; Gimenez-Gallego et al., 1985; Burgesset 
al., 1986; Harper et al., 1986). The different isoforms (which are the result of 
differential regulation of translation) may be important in the fine modulation of 
angiogenic signalling by these molecules. 
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In ordertobe able to transduce their signals, FGF-1 and FGF-2 must bind to their 
cognate receptors. FGF-1 binds with high affinity to all four FGF tyrosine kirrase 
receptors (FGFR-1, FGFR-2, FGFR-3, and FGFR-4), whereas FGF-2 binds with 
higher affinity to FGFR-1 and FGFR-2. The FGFRs have a common structure (Lee et 
al., 1989; Dionne et al., 1990; Keegan et a/., 1991; Partanen et a/., 1991): their 
extracellular portion consists of two or three Ig-like loops, with an acidic region 
between the first and second Ig loops. The intracellular domain includes the catalytic 
tyrosine kirrase domain split by a short kirrase insert. As another Ievel of signalling 
regulation, multiple isoforms of the FGFRs are generated via alternative splicing, 
which include soluble and truncated receptors having impaired signaHing functions 
(Johnson and Williams, 1993). 
FGF-1 and FGF-2, like other family members, can also bind to another class of 
low-affinity receptors called heparan sulphate proteoglycans (HSPGs), which are 
present in abundance on the cell surface andin the ECM (Saksela et a/., 1988; Vigny 
et a/., 1988; Bashkin et a/., 1989; Kiefer et al., 1990). Interaction with the HSPGs is 
thought to stabilise and protect FGF-1 and FGF-2 from proteases (Saksela et al., 
1988; Sommer and Rifkin, 1986) as well as to provide a reservoir for the growth 
factors ensuring their long-term action (Flaumenhaft et a/., 1989; Presta et a/., 1989). 
The importance of low affinity, heparin-like binding sites for binding ofFGF-2 to its 
high affinity receptors has further been studied in heparan sulfate-deficient cells. 
When transfected with a cloned FGF receptor cDNA, these mutants failed to bind 
FGF-2 unless free heparin or heparan sulfate were present in cell medium. It was 
therefore proposed that an obligatory interaction of low and high affinity receptors 
constitutes a novel mechanism for the regulation of growth factor-receptor 
interactions (Yayon et a/., 1991). 
Similar to other growth factor tyrosine kirrase receptors, FGFRs are activated by 
dimerisation. Signalsmediated by FGF-1 and FGF-2 via the FGFRs and transduced 
farther via signal transduction pathways (for review, see Schlessinger and Ullrich, 
1992) ultimately Iead to endothelial cell mitogenesis and migration as well as to the 
production of proteases capable of digesting components of the basement membrane 
(Friesel and Maciag, 1995). Flamme and Risau (1992), in an avian model system, also 
demonstrated that FGF-1 and FGF-2 are able to induce differentiation of ventral 
mesodermal cells into hemangioblasts, substantiating the importance of FGF -1 and 
FGF-2 in vasculogenesis. Furthermore, both FGF-1 and FGF-2 have been shown tobe 
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mitogenic for smooth muscle cells (Isner, 1996). This suggests they play a role in 
periendothelial cell recruitment. 
c) Indirectly acting angiogenic tactors 
Unlike the direct-acting angiogenic factors (i.e. the members of the VEGF and 
FGF growth factor families) some other angiogenic mediators are non-mitogenic for 
endothelial cells and even inhibitory for their proliferation in vitro (Folkman and 
D' Amore, 1996). This action is rather indirect, resulting in the up-regulation of the 
expression of direct-acting factors from endothelial, stromal or other cells. For 
example, TGF-ßs, a large family of homodimeric peptides, play a roJe in embryonie 
angiogenesis by inducing the differentiation of mesenchymal cells into the smooth 
muscle cell/pericyte lineage and promoting matrix deposition (Sato et a/., 1990; 
Folkman and D' Amore, 1996). Although TGF-ß1 inhibits endothelial cell growth in 
vitro, it can indirectly stimulate angiogenesis by inducing the expression of several 
angiogenic growth factors such as VEGF and FGF -2 by smooth muscle cells 
(Flaumenhaft et al., 1992; Isner, 1996; Cockerill et a/., 1995). 
PDGF, another indirectly-acting angiogenic factor expressed by endothelial cells, 
serves as a mitogen for underlying smooth muscle cells (Banai et al., 1994) 
subsequently promoting smooth muscle cell expression of VEGF (Goad et a/., 1996). 
PDGF is also thought to be involved in the recruitment of pericytes and in the 
differentiation of endothelial cell precursors (Hirschi and D' Amore, 1996). 
d) Tie receptors and angiopoietins 
Signalling of the aforementioned growth factors and cytokines results in the 
activation of endothelial cells manifested by their increased proliferation, release of 
proteases degrading vascular basement membrane, migration towards the angiogenic 
stimuli, and coalescence into new vessel structures (Fig. 1.2). Once the early vascular 
network is established, it undergoes several maturation steps. One of these steps is 
thought to involve attraction of smooth muscle cells and pericytes around the 
endothelium. Interaction of endothelial and perivascular cells, in turn, results in 
inhibition of endothelial cell proliferation and subsequent vessel maturation (Beck and 
D' Amore, 1997). A novel family of RTKs, the Tie (.Iyrosine kinase with 
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Immunoglobulin and .Epidermal growth factor homology domains), and its 
angiopoietin ligands have been implicated in this process. 
To date, two members of the Tie family, Tie-1 and Tie-2 (also known as Tek), 
have been identified (Dumont et al., 1992; Sato et al., 1993). Like the members of 
VEGF tyrosine kinase receptor family, expression of the Tie receptors is almost 
exclusively restricted. to the endothelial cell lineage (Hashiyama et al., 1996). The 
gene knockout strategy helped to unveil the critical role the Tie receptors play during 
embryonie angiogenesis. Thus, mice lacking Tie-1 die perinatally displaying severe 
oedema and subsequent haemorrhage caused by hyperactivity of endothelial cells 
failing to form mature blood vessels (Puri et al., 1995; Sato et al., 1995). 
Unfortunately, due to the Iack of identified ligands for Tie-1 its precise function in 
angiogenesis signaHing remains rather vague. 
Tie-2/Tek seems to play even more crucial role as demonstrated by the finding that 
transgenic mice deficient in Tie-2 allelesdie earlier (between embryonie day 9.5 and 
10.5) due to defects in blood vessel architecture. These defects (more severe than in 
the Tie-1-deficient mice) are characterised by malformations in cardial endothelial 
celllining, reduction in total endothelial cell number, failure to recruit pericytes, lack 
of a branching network, and an inability to remodel the primary capillary plexus into 
large and small vessels (Dumont et al., 1994; Sato et al., 1995). Thus, Tie-2 is thought 
to be important in mediating interactions between endothelial cells and the ECM as 
weH as peripheral stromal cells - necessary prerequisites for stabilisation and 
maturation of blood vessels. 
Two ligands for the Tie-2 receptor (referred to as angiopoietins) have been 
identified to date. Angiopoietin-1 (Ang1), a secreted 75 kDa glycoprotein, can induce 
autophosphorylation of Tie-2 in vitro. However, this does not lead to either 
endothelial cell mitogenesis or tube formation (Davis et al., 1996). Ang1 was rather 
shown to play a role in regulating the assembly of non-endothelial vessel wall 
components during embryonie angiogenesis, consistent with findings in the Tie-2 
knockout mice (Suri et al., 1996). In contrast to Ang1, angiopoietin-2 (Ang2) has 
been demonstrated to suppress the kinase activity of Tie-2 at low concentrations, 
acting as an Ang1 antagonist, which does not block endothelial cell proliferation 
(Maisonpierre et al., 1997). Kim et al. (2000) were able to demonstrate, however, that 
at high concentrations Ang2 does induce phosphorylation of Tie-2, acting as an 
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apoptosis survival factor for endothelial cells during serum-deprivation-induced 
apoptosis. Thus the role of Ang2 in signalling angiogenesis is still controversial. 
e) lntewin receptor familv 
Angiogenesis is a complex multistep process that involves endothelial cell 
survival, proliferation, migration as weil as the functional ma~ration of newly formed 
blood vessels. All these steps rely upon the intimate interaction between endothelial 
cells and between endothelium and the surrounding ECM. These interactions are 
mediated by various cell adhesion molecules, of which integrins seem to be the most 
prominent ones (Brooks, 1996; Brooks et a/., 1994; Bischoff, 1997). 
lotegrins are heterodimeric cell-surface receptors constituted by two non-
covalently bound transmembrane glycoproteins ( cx. and ß) that connect components of 
the cytoskeleton to the ECM or immunoglobulin family molecules expressed on the 
surface of other cells through short peptide sequences such as ROD (Arg-Gly-Asp) 
present in their ligands (Ruoslahti and Pierschbacher, 1986). While integrins are weil 
known to mediate cellular adhesion and migration (Hynes, 1992), they also participate 
in regulating the cell cycle (Guadango et al., 1993; Vamer et al., 1995). One member 
of the integrin family, namely cx.vßJ, has been demonstrated to be almost exclusively 
expressed on the surface of endothelial cells and smooth muscle cells in newly-
formed blood vessels, but is absent in mature or quiescent vessels (Brooks et al., 
1994; Clark et a/., 1996). A requirement for cx.vß3 during the development of new 
capillaries has been shown experimentally. Interference with the interaction of the 
integrin CX.vß3 with its ECM Iigand by anti-cx.vß3 antiborlies or RGD-containing peptide 
antagonists induced apoptosis in proliferating endothelial cells of nascent vessels, 
leading to the inhibition of angiogenesis (Brooks et al., 1994a). This phenomenon is 
currently being utilised in the development of anti-angiogenesis therapies. 
1.2.2.2 Negative regulators of angiogenesis 
ECM is known to participate in the negative regulation of angiogenesis. Thus 
extracellular matrix components and in particular certain proteoglycans bind and store 
endothelial cell growth factors, thereby making them inaccessible to endothelial cells 
(Vlodavsky et a/., 1991 ). For example, both bFGF and VEGF bind to heparan 
sulphate proteoglycan. Furthermore, a number ofendogenaus negative regulators of 
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endothelial cell proliferation and angiogenesis represent fragments of different ECM 
proteins, such as fibronectin (Homandelberg et al., 1985), thrombospondin-1 (Tolsma 
et al., 1993; Weinstat-Saslow et al., 1994), and collagen XVIII (i.e. endostatin, 
O'Reilly et al., 1997). 
Interestingly, some other non-ECM anti-angiogenic factors have been described 
that are fragments of larger proteins which themselves are devoid of inhibitory 
activity. They include angiostatin (38 kDa fragment ofplasminogen, O'Reilly et al., 
1994 ), vasostatin ( calreticulin fragment, Pike et al., 1998), 16 kDa fragment of 
prolactin (Clapp et al., 1993), 7.8 kDa fragment of platelet factor 4 (Gupta et al., 
1995) and a fragment of murine EGF (Nelson et al., 1995). These data suggest that 
there may be a generat mechanism by which inhibitors of endothelial growth can be 
produced locally by specific proteolytic cleavage of a larger protein. 
Several other negative angiogenesis modulators have been identified to date. They 
include thrombospondin-2 (Streitet al., 1999), a-interferon (Zetter, 1998; Sidky and 
Borden, 1987), tissue inhibitors of metalloproteinases (Johnson, 1994), and 
epigallocatechin-3-gallate (Cao and Cao, 1999). 
Fragments of other proteins 
ECM components 
29 kDa fragment of fibronectin 
thrombospondin-1 fragment 
endostatin (fragment of collagen XVIII) 
Non-ECM factors 
angiostatin (38 kDa fragment ofplasminogen) 
vasostatin (fragment of calreticulin) 
16 kDa fragment of prolactin 
7.8 kDa fragment ofplatelet factor 4 
Thrombospondin-1 and 2 
<X-interferon 
tissue inhibitors of metalloproteinases 
epigallocatechin-3-gallate 
Table 1.2 Negatively acting angiogenic factors. 
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1.2.3 Tumour angiogenesis 
In the early 1970s Judah Folkman, a ptoneer in the field of angiogenesis, 
postulated that the continued growth of solid tumours and the process of metastasis 
are dependent on the formation of new blood vessels (Folkman, 1971). This 
hypothesis was based on the observations that tumours fail to grow beyond the size of 
1-3 mm in diameter without inducing angiogenesis (Algire and Chalkley, 1945; 
Folkman et a/., 1963). Therefore, during the prevascular phase, many tumours may 
remain dormant and clinically undetectable, as the cell proliferation rate in the 
avascular tumour is counterbalanced by the rate of cell apoptosis (Holmagem et al., 
1995; O'Reilly et a/., 1996). However, continued genetic change in tumour cells can 
eventually result in the so-called "angiogenic switch", which triggers the growth of 
new capillaries towards the tumour mass (Hanahan and Folkman, 1996). This switch 
is characterised by induction of the proteolytic process, which disrupts the local host 
microvasculature, the release of diffusible angiogenic factors (e.g. VEGF, FGF-2, 
etc.) and/or the down-regulation of angiogenesis inhibitors (e.g. thrombospondin and 
angiostatin). 
Upon angiogenic stimulation, blood vessels growing into tumour form by 
sprouting or intussusception• from pre-existing vasculature. Tumour cells, however, 
can also recruit angioblasts, circulating endothelial precursors shed from the vessel 
wall or mobilised from the hone marrow, thus mimicking the process of 
vasculogenesis (Takashi et al., 1999; Peichev et a/., 2000; Rafii, 2000; Asahara et a/., 
2000). In addition to angiogenesis, tumour cells have been shown tobe able to coopt 
host vessels especially during metastasis (Holash et a/., 1999). 
VEGF is one of the most prominent angiogenic factors up-regulated in tumours. 
Indeed, numerous tumour celllines have been shown to express the VEGF mRNA 
and secrete the VEGF protein in vitro (Senger et al., 1986; Rosenthai et al., 1990). 
Also, mosthuman tumours show up-regulation of VEGF at the mRNA Ievel (e.g. 
Olson et a/., 1994; Brown et a/., 1993; Brown et al., 1995). It is thought that during 
tumour growth concomitant oxygen deprivation (hypoxia) plays one of the leading 
roles in the induction ofVEGF expression (Shweiki et al., 1992; Plate et a/., 1992). 
' Intussusception (L. intus within + susception), as opposed to sprouting, is another mechanism of 
angiogenesis in which interstitial tissue columns get inserted into the Iumen of pre-existing vessels and 
partition the vessel Iumen (Patan et a/., 1996). 
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The hypoxia-induced rise in VEGF expression 1s due both to increased 
transcription mediated by HIF-1 (hypoxia-inducible factor-1) and an increase in 
VEGF mRNA stability (Semenza, 1996). Interestingly, expression of oncogenic ras 
potentiated the induction ofVEGF by hypoxia (Mazure et al., 1996). Moreover, loss 
of tumour-suppressor genessuch as the von Hippel-Lindau gene has been shown to 
result in stabilisation of VEGF mRNA in the absence of hypoxia (Gnarra et al., 1996). 
Hypoglycaemia seems to be another environmental factor playing a role in the 
induction of VEGF expression in tumours as it regulates gene expression in an 
overlapping pattem with hypoxia (Stein et al., 1995). 
The role of VEGF in tumorigenesis was further substantiated by experiments in 
which the growth of human tumour cell lines injected subcutaneously into nude mice 
was dramatically reduced by treating the animals with VEGF -specific monoclonal 
antiborlies (Kim et al., 1993; Warren et al., 1995). Since VEGF isapotent vascular 
permeability factor, many vessels found in tumours are hyperpermeable to plasma 
proteins and to other circulating macromolecules (Dvorak, 1986). Therefore, in 
addition to its direct endothelial cell stimulation effect, VEGF may promote tumour 
angiogenesis by causing pre-existing blood vessels to become leaky leading to the 
formation of an extravascular fibrin gel, a substrate for endothelial and tumour cell 
growth (Dvorak et al., 1987). 
FGF-2 isanother angiogenic factor described in tumours (Folkman and Klagsbrun, 
1987). It is secreted by tumour cells as weil as tumour-associated macrophages (Lewis 
et al., 1995), or mobilised from the ECM by proteases. Thus, its release has been 
detected in various human tumours, which was correlated with the extent of their 
vascularisation (Kandelet al., 1991; Li et al., 1994; Nanus et al., 1993). Abnormally 
elevated Ievels of FGF-2 were also detected in the serum and urine of patients with a 
variety of solid tumours, leukaemias, and Iymphomas (Nguyen et al., 1994). 
Furthermore, a number of other angiogenic factors have been described as being 
overexpressed in different tumours including scatter factor (SF/HGF) (Rosen et al., 
1994; Yamashita et al., 1994; Joseph et al., 1995), EGF (Ebert et al., 2000), and 
PDGF (Hermanson et al., 1992). 
Consistent with the hypothesis that tumours may down-regulate endogenous 
inhibitors of angiogenesis, down-regulation of thrombospondin 1 (TSP1) has been 
documented in various tumour systems (Good et a/., 1990; Dameron et al., 1994; 
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Zabrenetzsky et al., 1994). Decreased TSP1 production has been linked to the loss of 
a tumour suppressor gene in several tumour celllines (Dameron et a/., 1994). 
The newly formed microvessels generally resemble normal vessels but have 
several important differences (D' Amore and Thompson, 1987): blood vessels of the 
tumour usually Iack pericytes, their base membrane composition is altered and the 
endothelial cells are larger and irregular. As a consequence, these vessels have 
increased permeability, which may contribute to tumour metastasis. Thus, entering the 
vascular phase, tumours acquire the potential for rapid growth, invasion into host 
tissue, and metastasis (Weidner et al., 1991; Zetter, 1998). Indeed, multiple studies 
have confirmed a direct correlation between the degree of tumour vascularisation and 
metastasis (Weidner et al., 1991; Weidner et a/., 1993; Brawer, 1996; Yamakazi et 
a/., 1994; Angeletti et a/., 1996; Maeda et a/., 1995; Wiggins et al., 1995; Gaspariniet 
a/., 1993; Hollingsworth et a/., 1995). 
1.3 Lymphangiogenesis 
1.3.1 Lymphatic system and its function 
The circulatory system of higher vertebrates consists of blood and lymphatic 
vessels that differ in their structural and functional features. The primary structural 
characteristics of the lymphatics, which distinguish them from the blood vessels, are 
the discontinuous or absent basal Iamina, intricate overlapping intercellular junctional 
complexes, and specialised anchoring filaments which hold the vessel open as tissue 
pressure rises (Casley-Smith and Florey, 1961; Leak, 1970; Leak, 1972). These 
attributes allow the lymphatics to play their physiological role by re-absorbing large 
biological macromolecules, cellular particles and interstitial fluid, thereby maintaining 
homeostasis and a constant colloid osmotic pressure within the interstitial tissue 
(Ryan, 1987; Guyton and Hall, 1996). The lymphatic system is also important in the 
absorption of Iipids from the small intestine. Furtherrnore, it serves as a filter for the 
entry of pathogens into the circulation and as a site where T -cell clonal expansion 
occurs in response to activated antigen-presenting cells (Guyton and Hall, 1996). 
The lymphatics have also been implicated in a variety of pathological events 
including lymphoedema, inflammation, infectious and immune diseases, fibrosis and 
tumours such as Kaposi's sarcoma and lymphangioma (Witte et al., 1997). In 
addition, due to their highly permeable nature and poorly developed basement 
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membranes, the lymphatics have been proposed to be the main routes for tumour 
dissemination (Cann et al., 1995). Indeed, the majority of human carcinomas 
metastasise at least initially via the lymphatic vessels (Beitz and Calabresi, 1993). 
Moreover, active interactions of tumour cells with the lymphatics in vivo could be 
demonstrated (Papoutsi et al., 2000; Mandriota et al., 2000; Skobe et al., 2001; 
Stacker et al., 2001). 
1.3.2 Lymphangiogenesis in embryo and adult 
The growth of lymphatic vessels from a pre-existing lymphatic network is termed 
lymphangiogenesis. In the human embryo, lymphatics appear later than blood vessels 
(i.e. 6- to 7-week-old embryos) taking their origin from endothelial-lined lymph sacs, 
which are located immediately adjacent to veins (van der Putte, 1975). However, due 
to the Iack of specific markers, the origin of the lymph sacs still remains controversial 
(Y offey and Courtice, 1970; van der Putte, 1975). Two alternative hypotheses have 
been proposed. One of them suggests the existence of lymphangioblast precursors of 
lymphatic endothelium originating from the early mesenchyme (Huntington, 1908; 
Kampmeier, 1912). The other maintains that embryonie lymphatics derive from 
centrat veins by sprouting (Ranvier, 1895; Sabin, 1909). The latest report from Wigle 
and Oliver (1999) strongly supports the second hypothesis (Fig. 1.2). 
In the adult organism, lymphangiogenesis occurs after tissue injury (Strange et al., 
1989; Junghans and Collins, 1989) and obstruction or darnage of the lymphatic 
vessels (Battezzati and Donini, 1972), where it serves to reduce the increased 
interstitial fluid pressure associated with oedema and inflammation (Anthony et al., 
1997). An increasing amount of evidence suggests the existence of the tumour-
induced lymphangiogenesis, mediated by soluble lymphangiogenic factors, VEGF-C 
and VEGF-D, and their receptor VEGFR-3 (Salven et al., 1998; Stacker et al., 2001; 
Skobe et al., 2001; Mandriota et al., 2001 ). 
1.3.3 Signalling lymphangiogenesis 
Until recently, little was known about the molecular mechanism by which 
lymphangiogenesis is induced and maintained. However, following the identification 
of VEGFR-3, a receptor tyrosine kirrase whose expression has been shown to be 
largely restricted to the lymphatic endothelium in the adult (Finnerty et al., 1993; 
Kaipairren et al., 1995), and its corresponding ligands VEGF-C and VEGF-D, the 
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mechanisms underlying the growth and development of new lymphatic vessels are 
beginning to be deciphered. 
1.3.3.1 Role ofVEGFR-3 in lymphangiogenesis 
VEGFR-3 (also known as foetalliver kinase-4, Flt4), a member of the VEGFR 
family of type III receptor tyrosine kinases (Fig. 1.3), was cloned from human 
placental and erythroleukimia cell cDNA libraries (Aprelikova et al., 1992; Pajusola 
et al., 1992; Galland et al., 1992; Galland et al., 1993). It shows 31% and 36% 
homology with VEGFR-1 and VEGFR-2, respectively. Like the other VEGFR 
members, VEGFR-3 has an extracellular portion consisting of seven immunoglobulin-
like domains and the intracellular portion containing a split kinase domain, 
characteristic of type III receptor tyrosine kinases (Pajusola et al., 1992). In humans 
VEGFR-3 is present in 2 forms due to alternative splicing giving rise to 5.8 and 4.5 kb 
species of mRNA (Pajusola et al., 1993; Borget al., 1995). The unique feature of 
VEGFR-3 among the other VEGFRs, however, isthat the translated protein is further 
processed via cleavage of the first immunoglobulin loop which remains re-associated 
to the remaining molecule via a disulphide linkage (Fig. 1.3). 
During mouse embryogenesis, VEGFR-3 mRNA is localised at E8.5 in the 
developing blood vessels and in the angioblasts of the head mesenchyme, becoming 
confined to the lymphatic endothelium during E14.5 (Kaipainen et al., 1995). Prior to 
the emergence ofthe lymphatic vessels, VEGFR-3 is thought to play an essential role 
in the development of the cardiovascular system. Thus, mice lacking functional 
VEGFR-3 die in utero after embryonie day 10 displaying defects in vascular re-
modelling and maturation of large vessels and cardiovascular failure (Dumont et al., 
1998). Although VEGFR-3 plays an apparent role in angiogenesis, its importance for 
the development of the lymphatics has also been shown, when a congenital hereditary 
lymphoedema, known as "Milroy disease", was traced to certain missense mutations 
in the VEGFR-3 tyrosine kinase domain (Karkkainen et al., 2000; Irrthum et al., 
2000). Consistent with these findings, the expression of a soluble form of VEGFR-3 
in the skin of transgenic mice inhibited foetal lymphangiogenesis and induced a 
regression of already formed lymphatic vessels, which resulted in swelling of feet, 
oedema and dermal fibrosis. Interestingly, development of blood vasculature was not 
affected. 
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The latest studies emphasise the role of VEGFR-3 signalling in 
lymphangiogenesis. Thus, the ectopic expression of either of VEGFR-3 ligands as 
well as a VEGFR-3-specific mutantunder the keratin 14 promoter in the skin resulted 
in the specific induction of lymphangiogenesis but did not cause angiogenesis (Jeltsch 
et al., 1997; Veikkola et al., 2001). These results indicate that VEGFR-3 activation is 
sufficient to induce specifically lymphangiogenesis in vivo, which however may 
depend on the context ofVEGFR-3 expression (Jeltsch et al., 1997; Veikkola et al., 
2001). Thus, consistent with the apparent role ofVEGFR-3 in lymphangiogenesis, in 
the adult, physiological VEGFR-3 expression is restricted to lymphatic endothelial 
cells, some high endothelial venules and hematopoietic cells primarily of the 
megakaryoblastoid and erythroid lineage (Kaipainen et al., 1995; Kukk et al., 1996). 
However, VEGFR-3 has also been shown to be expressed in some fenestrated 
endothelia (Partanen et al., 2000) as well as in blood vessels of chronic wounds 
(Paavonen et al., 2000) and tumours (Valtola et al., 1999). lmportantly though, the 
overall pattern ofVEGFR-3 expression suggests that VEGFR-3 may potentially serve 
as a useful marker of lymphatic vessels under normal physiological conditions. 
1.3.3.2 VEGF-C and VEGF-D in lymphangiogenesis 
VEGF-C and VEGF-D, the two known ligands for VEGFR-3, share 48% amino 
acid sequence identity (Achen et al., 1998). They belong to the VEGF/PDGF family 
of growth factors with which they share a high degree ofhomology (i.e. they possess 
a VEGF-homology domain belonging to the cysteine knot family and containing six 
distinctly spaced cysteine residues). In addition, however, VEGF-C and VEGF-D also 
have long N- and C-terminal extensions, which are unique for the two VEGFR-3 
ligands (Joukov et al., 1996; Orlandini et al., 1996; Achen et al., 1998). The 
significance ofthese unique regions is unclear, though it is possible that the respective 
VEGF-C and VEGF-D unique peptide sequences may be involved in sequestration of 
the protein to components ofthe ECM (Joukov et al., 1997; Marconcini et al., 1999). 
Upon translation, VEGF-C and VEGF-D produce a protein of 58kD and 60kD, 
respectively. This protein undergoes step-wise proteolysis (Fig. 1.4) via cleavage of 
the N- and C -terminal regions of the translated protein. During this maturation 
process several forms with increased activity towards VEGFR-3 are generated to 
finally give rise to a protein of 21kD (Joukov et al., 1997, Stacker et al., 1999). The 
fully processed mature protein, termed ~N~CNEGF-C (ßN~CNEGF-D) acquires 
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Figure 1.4 Schematic representation of the proteolytic processing of the VEGF-CIVEGF-D proteins. Initially synthesised as 
preproproteins containing N- and C-terminal propeptides (N-pro and C-pro) and a VEGF-homology domain (VHD), VEGF-C and 
VEGF-D undergo stepwise proteolytic processing. Several forms of the proteins with increased binding and activity towards VEGFR-
3 and VEGFR-2 are generated among which the mature forms, coinsisting of dimers of the VHD, bind the receptors with highest 
activity. The processing shown is that for VEGF-D (Stacker et al., 1999) and is similar to that for VEGF-C (Joukov et al., 1997). 
VEGFR-2 is also expressed by at least some lymphatic vessels (Partanen et al., 1999), whereas VEGFR-3 can be detected in angiogen-
ic blood vessels in tumours (Valtola et al., 1999a), taken from Lymboussaki et al. (2000 ). 
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properties which permit its binding to VEGFR-2. Although mature VEGF-C and 
VEGF-D bind VEGFR-3 with a 3-fold higher affinity, they become capable of 
inducing VEGFR-2 signaHing (Joukov et al., 1997, Stacker et a/., 1999). Therefore, as 
already mentioned, both VEGF-C (Witzenbichler et a/., 1998; Cao et a/., 1998; 
Pepper et a/., 1998) and VEGF-D (Achen et a/., 1998; Marconcini et a/., 1999) also 
play a role in modulating angiogenesis. A ANL\CNEGF-C mutant lacking VEGFR-2 
activating property but still able to bind to and activate VEGFR-3 has been described 
(Joukov et a/., 1998). 
VEGF-C was the first protein to be identified as lymphangiogenic (Oh et al., 
1997). When overexpressed in the skin of transgenic mice, VEGF -C resulted in 
lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch 
et a/., 1997). The expression pattern of VEGF-C gene during embryogenesis also 
suggests that VEGF-C plays a role in the development of lymphatics. Thus, VEGF-C 
is expressed in the mesenchymal cells of post-implantation embryos around large sac-
like structures in the jugular area, whereas VEGFR-3 is found lining the borders of 
these sacks (Kukk et a/., 1996). Exactly such venous sac-like structures, according to 
Sabin (1909), are thought tobe the origin ofthe lymphatics. 
Similarly to VEGF-C, VEGF-D has also been anticipated tobe lymphangiogenic, 
given its equal receptor specificity (Lymboussaki et a/., 2000). A direct evidence 
came recently from the VEGF-D transgenic mice, where overexpression ofVEGF-D 
in the skin under the keratin 14 promoter also resulted in the hyperproliferation of 
lymphatic but not blood vessels (Veikkola et a/., 2001). 
The expression pattem for VEGF-D in mouse embryos overlaps with VEGF-C in 
many tissues in a manner complementary to VEGFR-3 (Kaipainen et a/., 1995). 
However, slight differences in the expression of VEGF-C and VEGF-D are reported to 
exist (Lymboussaki et a/., 2000). Interestingly, VEGF-C and VEGF-D have different 
properties with respect to induction of vascular permeability. While VEGF -C is able 
to increase the vascular permeability (Joukov et al., 1997), VEGF-D is void of such 
an activity (Stacker et a/., 1999a). 
1.3.4 Tumour-induced lymphangiogenesis 
Lymphatic (lymphangenous) spread of cancer cells by direct invasion or tumour 
embolisation is a crucial prognostic indicator of tumour aggressiveness used for 
histological staging of many solid organ cancers (Willis, 1952). Furthermore, 
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auxiliary node (so called "sentinel lyrnph node") status is the rnost irnportant 
prognostic information regarding treatrnent and prognosis for breast cancer patients 
(Cabanas, 2000). One can irnagine that the ability of tumours to attract lyrnphatic 
vessel growth would be of great advantage, since it would not just facilitate their 
rnetastasis but would also relieve the interstitial pressure which builds up within the 
turnours (Jain, 1987). However, the existence of lyrnphatics within tumours has long 
been questioned (Zeidrnan et a/., 1955; Jain, 1989; Folkman, 1995a). 
This situation is due to the difficulties in studying the lyrnphatics: inadequate 
rnethods and the Iack of reliable rnarkers for the lyrnphatic endotheliurn. Thus, 
lyrnphangiographic studies in which tracer dyes are injected into the lyrnphatic systern 
or the interstitial space in order to evaluate the uptake of the dye by the tumour 
lyrnphatics generally indicate the absence of lyrnphatics within tumours (Butler et a/., 
1975; Leu et al., 2000). However, the high intraturnoral interstitial fluid pressure 
(which is likely to push the dyes away frorn the turnour) rnay weil influence the 
results of such a lyrnphangiographic study. More irnportantly, the absence of reliable 
rnarkers specific for the lyrnphatic endotheliurn (Sleernan et a/., 2001) have rnade 
histological data on tumour lyrnphatics difficult to interpret. Very recentiy, however, 
using novellyrnphatic endothelial rnarkers VEGFR-3 and L YVE-1, a hyalouronan 
receptor found to be expressed alrnost exclusively on lyrnphatic endothelium (Banerji 
et a/., 1999), functionaliyrnphatics and lyrnphangiogenesis were docurnented within 
tumours (Skobe et a/., 2001; Karpanen et a/., 2001; Stacker et al., 2001). 
In these studies, turnour-induced lyrnphangiogenesis was linked to VEGF-C and 
VEGF-D signalling. Thus, when VEGF-C-overexpressing breast cancer cells were 
orthotopically transpianted onto nude rnice, turnours dernonstrated increased 
intraturnoral Iyrnphangiogenesis and significantly enhanced rnetastasis to regional 
lyrnph nodes and to lungs (Skobe et a/., 2001; Karpanen et al., 2001). Since these 
effects of VEGF-C could be inhibited by a soluble VEGFR-3 fusion protein, the role 
of VEGFR-3 in turnour-induced lyrnphangiogenesis and lyrnphatic rnetastasis was 
substantiated too (Karpanen et al., 2001). Sirnilar results were obtained in 
experirnents with VEGF-D-overexpressing 293EBNA turnours irnplanted into 
irnrnunodeficient rnice. VEGF-D expression in these normally avascular and non-
rnetastatic turnours resulted in the formation of intraturnoral lyrnphatics and lyrnph 
node rnetastasis. Interestingly, VEGF-D expressed by turnour cells also prornoted 
turnour vascularisation, which suggests the involvernent of VEGF-D-rnediated 
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VEGFR-2 signaHing in this tumour model. These effects could be blocked, however, 
with a VEGF-D-specific antibody (Stacker et a/., 2001). 
Experiments with Rip1 Tag2 mice, which are characterised by spontaneaus 
development of pancreatic ß-cell tumours that are neither lymphangiogenic nor 
metastatic, further support the notion that lymphangiogenic factors, when expressed 
by tumours, may Iead to lymphangiogenesis and promote metastasis. Thus, crossing 
Rip 1 Tag2 mice with other transgenics, in which VEGF -C expression is driven by the 
rat insulin promoter (Rip ), gives rise to a mause line, which tend to form tumours 
surrounded by lymphatics and develop pancreatic lymph node metastases. The 
surrounding lymphatic vessels were also shown to frequently contain tumour cell 
masses of ß-cell origin (Mandriota et al., 2001). 
The role of VEGF -C in tumour progression and metastasis has also been studied 
clinically. Its expression by tumour and stromal cells in different types of cancer was 
usually found to correlate with lymphogenaus metastasis and significantly poorer 
prognosis for patients (Ohta et a/., 1999; Yonemura et al., 1999; Fellmer et a/., 1999; 
Tsrusaki et al., 1999; Bunone et a/., 1999; Akagi et a/., 2000; Kabashima et al., 
2001). Consistent with the hypothesis that VEGF-D, like VEGF-C, secreted by 
tumour cells, activates endothelial cell receptors and thereby contributes to the 
regulation oftumour angiogenesis and lymphangiogenesis, VEGF-D positive tumour 
cells were identified in malignant melanoma (Achen et a/., 2001). Controversially, 
however, a report on the clinical significance of VEGF-D in lung adenocarcinoma 
indicates that VEGF-D expression may inversely correlate with the metastatic 
potential ofthe tumours (Niki et a/., 2000). 
Consistent with the proposed role of VEGF-C and VEGF-D in tumour-induced 
lymphangiogenesis, the expression of VEGFR-3 has also been found to be up-
regulated in different tumours. Thus, VEGFR-3 is highly expressed in the putative 
lymphatic endothelium of cutaneous lymphangiomatosis (Lymboussaki et al., 1998), 
in vessels surrounding Iymphomas (Jussila et a/., 1998) andin the vessels ofextemal 
invasive margin of several human breast and prostate carcinoma specimens (Jussila et 
al., 1998; Valtola et al., 1999; Tsurusaki et al., 1999). In oral squamous cell 
carcinoma, VEGFR-3 expressionwas found tobe in correlation with the propensity 
for lymph node metastasis (Moriyama et a/., 1997). In addition, VEGFR-3 is 
expressed in tumours with presumed lymphatic origin including Kaposi's sarcoma 
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(Folpe et al., 2000). Interestingly however, while not being expressed in adult blood 
vessels, VEGFR-3 is induced in some vascular endothelial cells of tumour-bearing 
tissues (Valtola et al., 1999; Partanen et al., 1999). VEGFR-3, therefore, also appears 
to be involved in tumour-induced angiogenesis. Consequently, cancer cells that 
produce VEGF-C or VEGF-D may have a growth advantage because oftheir ability 
to stimulate both blood vascular and lymphatic endothelia, triggering both lymph- and 
angiogenesis. 
1.4 Inhibition of angiogenesis: a novel anticancer therapy 
1.4.1 Role of anti-angiogenic strategy in fighting cancer 
Historically, surgery has been the first treatment for cancer. However, it may not 
bring complete remission for the cancer patient as metastasis often ensues prior to the 
removal ofthe primary tumour. Therefore, at present, following the surgery, radiation 
and chemotherapy, separately or in combination, are used to target the remaining 
cancerous cells in the body. The major drawback of the latter two modalities, 
however, is the Iack of specificity, which jeopardises normal cells of the organism 
(Boehm, 1998). So-called "biological therapy" was the fourth modality to be 
developed in the late 1970s, whose principle is cancer treatment by modification and 
exploitation of the cellular and molecular mechanisms of the natural host defence and 
of the regulation of tissue proliferation, differentiation, and survival (Hersh and 
Stopeck, 1997). The commonly used biological therapies include use of different 
cytokines, monoclonal antibodies, hone marrow growth factors, host defence cells, 
tumour vaccines, immunomodulators, anti-growth factors and gene therapy (Hersh 
and Stopeck, 1997). Thus, biological therapy, besides taking direct anti-tumour 
approaches (e.g. intraturnoral delivery of the gene of interest to change its 
immunogenecity), resorts to another important strategy in the anti-cancer battle: 
namely, alteration of the tumour/host interactions. To this end, inhibition of tumour 
angiogenesis (combining principles of both chemo- and biological therapies) has the 
potential to be a powerful anti-cancer strategy aimed at preventing tumour cells from 
gaining access to vital nutrients and oxygen, thus stopping tumour growth. 
For several reasons anti-angiogenic therapy has the potential of being a better 
treatment for cancer (Folkman, 1972; Folkman, 1996; Sato, 1998). Thus, due to the 
specific targeting of the dividing endothelial cells within angiogenic tumours, 
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inhibition of angiogenesis is likely to cause considerably less side effects (e.g. hone 
marrow suppression, gastrointestinal symptoms, hair loss, etc.) than the standard 
radio- and chemotherapies (Folkman, 1995a). Also, since growth of many tumour 
cells depends on just a few endothelial cells, the efficacy of the anti-angiogenic 
therapy may be considerably higher. Another advantage of the anti-angiogenic 
strategy is to be gained from the fact that therapeutic agents are not required to enter 
the tumour cells or cross blood-brain barrier. It is therefore anticipated that drug 
delivery should be much easier than in the conventional chemotherapy. Furthermore, 
targeting physiological cells ofthe organism (i.e. vascular endothelial cells) avoids the 
problern of genetic instability in cancer cells with the ensuing phenomenon of 
acquired drug resistance (Lengauer et a/., 1998). Finally, since endothelial cells are 
important for the growth of all solid tumours, anti-angiogenic therapy may have a 
broader anticancer spectrum than the other more conventional approaches. 
Although the anti-angiogenic strategy has many advantages in comparison to the 
other currently used therapies, it also has potential drawbacks (Cohen, 1999). For 
example, it may interfere with physiological angiogenesis, such as the female 
reproductive cycle and wound healing. Some anti-angiogenic agents are suspected to 
have teratogenic effects (Phillips, 1998). More importantly, even though inhibition of 
angiogenesis can be employed to render tumours avascular and dormant, it alone is 
unlikely to completely eradicate tumours (Folkman, 1972). Thus, an ernerging 
concept is that anti-angiogenesis therapy should be used in combination with the other 
established cancer treatment protocols such as surgery, radiation, chemotherapy, and 
immunotherapy (Kerbel, 2000). 
1.4.2 Inhibition of angiogenic Iigand signalling 
Following the angiogenic switch, a tumour acquires the ability to express factors 
that are capable of stimulating angiogenesis. To date, members of the VEGF, bFGF 
and angiopoietin families have been demonstrated to play a predominant role in this 
process (Yancopoulos et al., 2000). Consequently, one of the first steps in the 
development of anti-angiogenic approaches has been the search for antagonists of the 
aforementioned positive regulators of angiogenesis. Tothis end, naturally occurring 
or synthetic inhibitors, monoclonal neutralising antibodies, soluble receptors and 
antisense cDNA for the endothelial growth factors have been applied to suppress 
tumour growth in vivo (Witte et al., 1998; Kerbel, 1998). 
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Although inhibition of bFGF (Ensoli et a/., 1994) or angiopoietin/Tie2 (Lin et a/., 
1997; Lin et a/., 1998) have been shown to suppress tumour growth, interference with 
VEGF signalling via its cognate receptors has been by far the most popular line of 
anti-angiogenic research for the last decade. Thus, Kim et al. (1993) demonstrated 
that anti-VEGF monoclonal antiborlies greatly inhibited progression of human 
tumours in nude mice. The validity of this strategy has been confirmed by other 
studies using anti-sense cDNA (Saleh et al., 1996; Oku et al., 1998). Inhibition of 
VEGF action also caused dramatic reduction in metastasis formation by aggressive 
tumour celllines (Warren et a/., 1995; Melnyk et al., 1999). Non-invasive imaging of 
the vasculature revealed complete suppression of tumour-associated angiogenesis in 
animals treated with monoclonal anti-VEGF antibodies, verifying the previous 
observations and providing a direct proof that inhibitiQn of angiogenesis is the 
mechanism by which tumours regress after anti-VEGF treatment (Borgström et al., 
1996). 
Inhibition of VEGF receptor-mediated signal transduction has supplied further 
evidence for the role of VEGF signalling in tumour angiogenesis. Thus, retrovirus-
mediated expression of a dominant-negative VEGFR-2 protein suppressed the growth 
of glioblastoma and other tumour cell lines in vivo (Millauer ef al., 1996). Other 
studies, where soluble extracellular domains ofVEGFR-1 or VEGFR-2 were locally 
expressed in nude mice-bome tumours, demonstrated significant reduction not only in 
tumour growth but also in metastasis and mortality rate (Kong et al., 1998; Goldman 
et al., 1998). 
Given their powerful anti-angiogenic potential, antiborlies against VEGF or its 
receptors are very promising tools for anti-angiogenic therapy. Presently, one such 
"humanised" anti-VEGF antibody (Presta et a/., 1997) is undergoing phase II clinical 
trials. In addition, small chemical compounds that inhibit VEGFR-2 signal 
transduction (e.g. SU5416 and SU6668, Sugen, USA) are undergoing phase II clinical 
trials in cancer patients (Strawn et al., 1996; Fong et al., 1999; Laird et a/., 2000). 
One important problern associated with this anti-angiogenic approach is the 
possibility that tumours, whose growth is suppressed as the result of neutralising the 
action of an angiogenic factor, might be able to activate, after prolonged therapy, 
alternative angiogenic pathways, thereby acquiring resistance to such a treatment 
(Ferrara and Alitalo, 1999). Therefore, use of a range of angiogenesis inhibitors along 
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with direct anti-endothelial agents may be necessary to achieve success in long-term 
inhibition oftumour growth (Maucery et al., 1998). 
1.4.3 Targeting endothelial cell-ECM interactions 
Interaction of endothelial cells with the ECM is an important aspect of 
angiogenesis. Consequently, molecules mediating these interactions are potential 
targets for the anti-angiogenic strategy too. Integrin avß3, for instance, has a unique 
expression pattem in endothelial cells and smooth muscle cells of proliferating vessels 
in healing wounds and in growing tumours. Studies where the function of avß3 
integrin was disrupted by use of <XvßJ-integrin blocking antiborlies indicate that 
tumour growth regression ensues due to induced endothelial cell apoptosis (Brooks et 
al., 1994a; Brooks et al., 1995). Another approach in inhibiting <Xvß3-integrin-
mediated endothelial cell survival and proliferation has been the use of synthetic 
peptides containing an exposed integrin recognition motif RGD, which can also be 
used to specifically target tumour-derived vasculature (Pasqualini et al., 1997; Arap et 
al., 1998). 
Matrix metalloproteinases (MMPs) are a family of enzymes composed of 15 
different membrane-bound zinc-endopeptidases, which are thought to be able to 
degrade almost all ECM components (Birkedal-Hansen et al., 1993; Powell and 
Matrisian, 1996). Since invasive events ( e.g. tumour cell or endothelial cell migration) 
require the ability to cause limited degradation of the ECM, the MMPs sequestered on 
the tumour cell/endothelial cell surface are believed to play a vital role in tumour 
angiogenesis, invasion and metastasis. The naturally occurring tissue inhibitors of 
metalloproteinases (TIMPs) have been shown to inhibit tumour angiogenesis, growth 
and metastasis (Wojtowicz-Praga et al., 1997; Johnson et al., 1994). Pharmaceutical 
companies have synthesised several low-molecular weight MMP inhibitors (e.g. 
Marimastat (British Biotechnologies, USA), COL-3 (Collagenex, USA)) with the 
purpose of preventing new blood vessels from being able to invade surrounding tissue 
(Holmgren and Bicknell, 1997). 
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1.4.4 Direct inhibition of endothelial cell proliferation 
In order to grow progressively, tumours need to induce angiogenesis by the up-
regulation of pro-angiogenic and down-regulation of anti-angiogenic factors. The 
discovery that tumours also generate angiogenesis inhibitors (e.g. angiostatin, 
O'Reilly et al., 1994; endostatin, O'Reilly et a/., 1997) was therefore somewhat 
surprising. This finding, however, was consistent with the observation that the 
removal of a primary tumour can Iead to the rapid growth of previously undetected 
metastases (Sugarbaker et al., 1997; Woodruff, 1990). Therefore, it was proposed that 
tumours generally produce both stimulators and inhibitors of angiogenesis. However, 
the excess of the former in the proximity of the primary tumours stimulates 
angiogenesis, while the excess of the latter, by virtue of its Ionger half-life in the 
circulation, suppresses angiogenesis at distant sites and consequently the growth of 
the secondary tumours (O'Reilly et al., 1994). 
Angiostatin and endostatin are the best examples of such inhibitory molecules. 
These fragments of larger non-anti-angiogenic proteins, putatively generated by the 
action of tumour-derived proteases (Gately et al., 1996; Gately et al., 1996), are 
currently the most potent anti-angiogenic factors, exhibiting strong anti-tumour 
activity in vivo (O'Reilly et a/., 1996; O'Reilly et a/., 1997). Mechanisms of action of 
the two potent tumour-derived inhibitors are being elucidated. It appears that 
angiostatin induces endothelial cell apoptosis by binding to and deactivating 
endothelial A TP synthase, thus blocking cellular energy generation (Moser et a/., 
1999). Endostatin, in turn, was found to induce tyrosine kinase activity leading to 
apoptosis in FGF-treated endothelial cells (Dixelius et al., 2000). Importantly, in 
animal experiments, endostatin did not induce acquired drug resistance after repeated 
cycles of therapy (Boehm et a/., 1997; Blezinger et al., 1999). Owing to its very 
promising anti-angiogenic and anti-tumour performance, endostatin (EntreMed, USA) 
is now undergoing phase I clinical trials in cancer patients. 
There are several examples of drugs currently undergoing clinical trials as possible 
inhibitors of angiogenesis that have been originally developed without the intention of 
inhibiting tumour angiogenesis. These include thalidomide and interferon a (Kerbel et 
al., 2000). Therefore, it may be appealing to screen clinically used compounds for 
their potential anti-angiogenesis properties. On the other band, the ability of anti-
angiogenic drugs to affect tumour cell directly would be a desirable 'side' effect of 
anti-angiogenic therapy. Hyperforin may be one candidate for becoming such a 
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multipurpose drug. This plant derivative, which has long been used as a folk remedy 
for bums and skin injuries (Hänsel et al., 1993), has lately gained a reputation as an 
effective anti-depressant (Linde et al., 1996). It was also shown to inhibit the growth 
of gram-positive bacteria (Gurevich et al., 1971; Schempp et al., 1999). Furtherrnore, 
hyperforin has been reported to exert a potent antiproliferative action on mammalian 
cells in vitro (Schempp et al., 2000). This anti-proliferative effect highlighted the 
possibility that hyperforin may be an anti-cancer agent, acting either directly on 
tumour cells, or indirectly on endothelial cells. This possibility was investigated as 
part of this thesis. 
1.5 Aims of the study 
Anti-angiogenic therapy is currently recognised as a powerful supplement to the 
other established anti-cancer modalities, which has the promise of low toxicity, 
reduced risk of drug resistance and increased anti-cancer efficacy (Folkman, 1999). 
Key molecular mediators of angiogenesis have been identified, among which the 
members of VEGF family and their cognate receptors are thought to play the most 
prominent role (Veikkola et al., 2000; Saaristo et al., 2000). Consequently, targeting 
VEGFR-mediated signalling of VEGF has become an integral element of the anti-
angiogenic strategy in the anti-cancer research (Schlaeppi and Wood, 1999). 
Lymphangiogenesis isanother process that is now being recognised as playing an 
important role in tumour progression and dissemination. Its major known positive 
mediators VEGF-C and VEGF-D signal through the VEGFR-3 receptor which is 
expressed mostly on the lymphatic endothelium and on the vascular endothelium of 
angiogenic tumours. Thus, VEGFR-3 and its ligands may serve as targets for the 
prevention oftumour-induced lymphangiogenesis (Saaristo et al., 2000). 
The anti-proliferative properties of hyperforin suggest that it may have potential in 
the treatment of cancer, perhaps by blocking tumour growth directly, or by interfering 
with tumour-host interactions. For example, hyperforin may have the ability to block 
the proliferation of endothelial cells and thereby inhibit angiogenesis and 
lymphangiogenesis. 
The task of my thesis work was to identify novel anti-tumour agents, which would 
block tumour cell proliferation, angiogenesis and/or lymphangiogenesis, thereby 
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preventing tumour growth and metastasis. Therefore, the specific goals of the original 
study were the following: 
• Cloning, expression and purification of recombinant rat VEGF, VEGF -C and 
VEGF-D proteins; 
• Characterisation of the recombinant proteins in terms of their ability to bind to and 
activate their cognate VEGFR receptors, stimulate proliferation of VEGFR-
expressing cells and promote angiogenesis and lymphangiogenesis in vivo; 
• Establishment of lymphatic endothelial cultures in vitro to check the possibility of 
inhibiting vascular and lymphatic endothelium proliferation with the identified 
substances; 
• Selection and characterisation of indolinanes capable of inhibiting VEGFR-
2NEGFR-3 signalling; 
• Characterisation of anti-tumour properties ofthe plant-derived drug hyperforin; 
• Use of the successful inhibitory substances for the inhibition of tumour growth 
and metastasis in vivo. 
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2.1 Materials 
2.1.1 Chemieals 
All general chemieals were, unless otherwise stated, purchased from Carl Roth GmbH 
+ Co, Karlsruhe, Merck KgaA, Darmstadt, or Sigma Chemie GmbH, Deisenhofen and 
were of the highest quality. All radiochemieals were supplied by Amersham Pharmacia 
Biotech, Freiburg. 
2.1.2 Oligonucleotides 
All the oligonucleotides were made by MWG Biotech GmbH and were all of an 
HPLC-purified grade. 
2.1.3 Antibodies and cytokines 
Antiborlies and cytokines were purchased from the following companies: 
DAKO Diagnostika GmbH: all secondary antiborlies (HRP, biotin or FITC/PE-
conjugated); 
Invitrogen: anti-His (C-term) and anti-His (C-term)-HRP mouse monoclonal 
antibodies; 
Novagen, Inc.: His-Tag mouse monoclonal antibody; 
Pharmingen (BD): anti-rat CD31 (PECAM) and anti-phosphotyrosine mouse 
monoclonal antibodies; 
PromoCell GmbH: recombinant h VEGF, aFGF, bFGF; 
R&D Systems: recombinant hVEGF, aFGF, bFGF; 
Research Diagnostics, Inc.: anti-Flt4 (mouse/rat) and anti-Flt4 (human) rabbit 
polyclonal antibodies; 
Santa Cruz Biotechnology, Inc.: anti-Flt1 (H-225) (mouse, rat and human), anti-Flk1 
(C-1158) (mouse, rat and human), anti-Flt4 (M-20) (mouse/rat) rabbit polyclonal 
antibodies; 
Transduction Laboratories (Becton Dickenson): anti-phosphotyrosine antibody 
(monoclonal, PY20 and RC20:HRPO). 
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2.1.4 Bacteria 
E. coli strain used: 
DH 5a.: supE44ßlacU169(<p80/acZßM15)hsdR17recAJ endAJ gyrA96 thi-1 relA1 
2.1.5 Celllines and media 
Celllines and corresponding media used in the current study are listed in Table 2.1. 
Tissue culture media for mammalian cells were, unless otherwise stated, purchased from 
Life Technologies GmbH, Karlsruhe. Insect cell culture and expression media were 
obtained from Invitrogen, the Netherlands. All media were supplemented with 100 U/ml 
penicillin and 100 J.Lg/ml streptomycin (Life Technologies). Trypsin was purchased from 
Difco Laboratories, Detroit, USA, and was diluted to 0.25% in 15 mM sodium citrate, 
134 mM potassium chloride prior to use. 
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Cell Iine Origin Medium 
Drosophila expression system 
S2 Schneider 2 Drosophila melanogaster cells DES medium (Invitrogen) 
(lnvitrogen, R690-07) 
Endothelial ce/ls 
HDMEC Human dermal microvascular endothelial cells ECGM MV 
(PromoCe/1, c-12210) (PromoCe/1, Heidelberg) 
HUVEC Human umbilical vascular endothelial cells ECGM 
(PromoCe/1, c-12200) (PromoCe/1, Heidelberg) 
PAE Porcine aortic endothelial cells F-12, 10% FCS 
(Kroll and Waltenberger, 1997) 
PAENEGFR-1 PAE transfected with a human VEGFR-1 construct 
(Kroll and Waltenberger, 1997) 
PAENEGFR-2 PAE transfected with a human VEGFR-2 construct 
(Kroll and Waltenberger, 1997) 
PAENEGFR-3 PAE transfected with a murine VEGFR-3 construct 
BSp73-ASML 
BSp73-1AS 
NM081 
MT450 
G 
AT-6.1 
MTLN-3 
MTLy 
Tumour ce/1 lines 
Rat pancreatic carcinoma (Matzku et a/., 1 983) 
Rat pancreatic carcinoma (Matzku et al., 1 983) 
Rat mammary carcinoma (Kim, 1 986) 
Rat mammary carcinoma (Kim, 1986) 
Rat prostatic carcinoma (Isaacs et a/., 1986) 
Rat prostatic carcinoma (Isaacs et a/., 1 986) 
Rat mammary carcinoma (Neri and Nicolson, 1981) 
Rat mammary carcinoma (Neri and Nicolson, 1981) 
Other ce/1/ines 
293 Human embryonie kidney cells (Xie et a/., 1996) 
293/mVEGF 293 transfected with a murine VEGF construct 
(gift of Jaya Krishnan) 
293/mVEGF-C 293 transfected with a murine VEGF-C construct 
F-12, 10% FCS 
F-12, 10% FCS 
F-12, 10% FCS, 
400 J.lg/ml neomycin 
RPMI, 10% FCS 
RPMI, 10% FCS 
DMEM, I 0% FCS 
DMEM, I 0% FCS 
RPMI, IO%FCS, 
250 nM dexamethason 
RPMI, 10% FCS, 
250 nM Dexamethason 
DMEM, 10% FCS 
DMEM, 10% FCS 
DMEM, 10%FCS 
DMEM, I 0% FCS, 
600 J.lg/ml neomycin 
DMEM, 10% FCS, 
(gift of Jaya Krishnan) 600 J.lg/ml neomycin 
Table 2.1 Cell/ines and corresponding cell cu/ture media. 
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2.2 General Methods 
The majority of protocols and recipes for commonly used buffers used in this project 
were taken from the laboratory manual of Sambrook et al. (1989) and Current Protocols 
in Molecular Biology (Ausubel et al., 1989) unless otherwise stated. 
2.2.1 Phenol/Chloroform extraction of nucleic acids 
To remove unwanted protein contaminants from nucleic acids, an equal volume of 
Tris-buffered phenol and chloroform at a ratio of 1:1 (v/v) was added and the mixture 
vortexed. The two phases were separated by centrifugation at 13,000 rpm for 10 min. 
The upper aqueous nucleic acid-containing phase was transferred to a fresh reaction tube 
and subjected to a further round of extraction with phenol/chloroform (1 :1, v/v). 
2.2.2 Ethanol ( or 2-propanol) precipitation of nucleic acids 
In order to recover nucleic acids from solution, the salt concentration was brought to 
200 mM with 3 M Na-acetate (pH 4.8-5.0) and 2.5 volumes of -20°C ethanol or 1 
volume of 2-propanol were added. After 30 min to overnight incubation at - 20°C or 15 
min at- 80°C (only ethanol precipitation), the precipitate was centrifuged at 13,000 rpm 
for 15-20 min. The pellet was washed with 70% ethanol, centrifuged foranother 3 min to 
remove the salt and was then dried. DNA was re-suspended in either H20 or TE buffer 
(10 mM Tris-HCl, pH 8.0, 1 mM EDTA). 
2.2.3 Determination of nucleic acid concentration 
The concentration of nucleic acids was determined by measuring their optical density 
(OD) at 260 and 280 nm. An OD260 = 1 is equivalent to 50 tJ.g/ml double stranded DNA 
or 40 tJ.g/ml RNA or 20 tJ.g/ml single-stranded oligonucleotide. The OD2so is used as an 
indication ofthe purity ofthe nucleic acid; it should be approximately 50% ofthe OD260. 
2.2.4 Total RNA isolation from cells or tissue 
Total RNA was prepared from the cells when they were 60-80% confluent in 15 cm 
culture dishes (Greiner, Frickenhausen). The medium was completely removed and cells 
were lysed by adding 1 ml of peqGOLD RNA Pure solution (Peqlab Biotechnologie 
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GmbH, Erlangen). To lyse tissue-derived cells, 100-mg snap-frozen tissue was placed 
directly into 1 ml peqGOLD solution and homogenised using an ultra-Turrax T25 (/KA-
Labortechnik) homogeniser for 3-5 min. After an incubation period for 5 min at room 
temperature, 0.2 ml chloroform was added to the lysed cells or to the homogenised tissue 
mix and vortexed vigorously. Following a 3-10-min incubation at room temperature, the 
mixturewas centrifuged for 5 min at 4°C at 13,000 rpm and the top aqueous RNA-
containing phase was removed and transferred to a fresh tube. Again 0.2 ml chloroform 
was added and the extraction repeated as above. After one more round of the chloroform 
extraction (altogether 3 rounds were done), the RNA was precipitated by addition 1 ml 
isopropanol, subsequent vortexing, incubation for 5-10 min at room temperature and 15 
min centrifugation at 4°C at 13,000 rpm. The RNA pellet was washed twice with 75% 
ethanol and re-suspended in 50 J . tl H20 for determination of the RNA concentration. The 
RNA preparation was stored at - 80°C. 
2.2.5 Reverse transcription polymerase chain reaction (RT -PCR) 
2.2.5.1 First strand cDNA synthesis 
To create the first strand of cDNA, the SuperScript HIRNase H Reverse Transcriptase 
kit (Life Technologies) was used. Total RNA (1-5 J.Lg) was mixed with 1J.Ll Oligo-(dT)t2-I8 
primer (500 J.Lg/ml) (Promega) and bi-distilled water to give a 12 J.Ll reaction volume. 
After incubation of the mixture at 70°C for 10 min and quick chilling on ice, 4 J.Ll 5x First 
Strand buffer, 2 Jll 0.1 M DTT and 1 J.Ll 10 mM dNTP mix (10 mM each dATP, dGTP, 
dCTP and dTTP, Peqlab) were added to the reaction. The reaction tube was then 
incubated for 2 min at 42°C, followed by the addition of 1 Jll (200 U) SuperScript li. 
Finally, the reaction was incubated at 42°C for 50 min. To inactivate the reaction, the 
tube was heated at 70°C for 15 min. 
2.2.5.2 Amplification offirst strand cDNA by PCR 
In order to amplify a specific cDNA fragment the standard PCR reaction (see below) 
was employed using 1 Jll of the first strand reaction and a specific set of amplification 
primers. The reaction was performed in a 50 Jll volume. 
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2.2.6 Polymerase chain reaction (PCR) DNA amplification 
PCR was performed using the Advantage-HF PCR kit (Clontech Laboratories GmbH, 
Heide/berg). Components ofthe reaction were mixed together as shown in Table 2.2 and 
cycled in a PCR machine using the following parameters: 94°C, 15 sec, 68°C, 4 min for a 
total of30-35 cycles. 
Components 
HF polymerase buffer 
HF polymerase dNTPs 
IOx HF dNTP mix 
Forwardandreverse primers (10 pmol/11! each) 
Template DNA (10 ng/111) 
50x HF polymerase 
Autoclaved distilled water 
Table 2.2 Composition of a PCR reaction. 
2.2. 7 Recombinant PCR 
Volume, f.d 
5 
16 
5 
2 (each) 
3 
upto 50 
A modification of the common PCR protocol was utilised in order to introduce 
mutations into cDNA sequences essentially as described by Higuchi (1990). Typically 
this recombinant PCR method consisted of 3 independent PCRs (Fig. 2.1). Two first 
reactions where done in parallel. One reaction was performed with the following pair of 
oligonucleotides: the forward one was normal and the reverse one was designed in a way 
that the desired mutation was introduced into the central portion of the primer being 
flanked by approximately 20 bps of normal coding sequence on each side. This reaction 
resulted in a PCR product that consisted of a 3'-truncated DNA sequence containing the 
desired mutation. In the other reaction, the reverse primer was normal and the forward 
one was designed in a way that the desired mutation was introduced into the central 
portion of the primer being flanked by 20 bps of normal DNA sequence on each side. 
This reaction resulted in a PCR product that consisted of a 5 '-truncated DNA sequence 
containing the desired mutation. The products of the two reactions purified and then 
mixed in a third PCR reaction in which they were allowed to anneal and extend in one 
cycle in the absence of oligonucleotides. Normal gene-specific primers were then added 
43 
Chapter 2: Materialsand Methods 
and the reaction was resumed as usually. Thus, the PCR fragments retrieved from the 
third reaction largely consisted of full Jength mutated cDNA sequences. 
PCRJ PCRD 
~ ..... 
5' ---c::=:::===:: 3' 5' 
5' 
~ ~ 
targetcDNA targetcDNA 
t 
I 3' 5' I 
PCRill 
5' 5' I 3' 3' 
anneal and extend for 1 cycle 
t 
5' ~, I 3' 3' 
~ 
5'~3' 
mutated cDNA 
t 
3' 
Figure 2.1 Diagram illustrating the sequential steps ofthe recombinant PCR. 
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2.2.8 Restrietion endonuclease digestion of DNA 
Usually 2-3 units of a restrietion enzyme (New England Biolabs GmbH, Franlifurt am 
Main, or Life Technologies) were used for eaeh J.lg DNA. DNA was digested at a 
eoneentration of 1 J..lg/1 0 J.ll in a buffer reeommended by the supplier. Plasmid DNA 
solution was mixed with 0.1 volume restrietion endonuclease. The reaetion was earried 
out for 2 hours to overnight at 37°C (unless otherwise reeommended by the supplier) and 
was stopped by an EasyPure kit (Biozym Diagnostik, Hameln) extraetion. The quality of 
the digest was eontrolled by gel eleetrophoresis. 
2.2.9 DNA ligation 
All ligation reaetions were performed using ligase and buffers supplied by the 
manufaeturer (Life Technologies) in a total of 20 J.ll and ineubated overnight at 14°C, 
followed by heat inaetivation ofthe ligase at 70°C for 5 minutes before storing at- 20°C. 
2.2.10 Sub-cloning 
The cloned fragment of DNA was released from the vector using appropriate 
restrietion endonucleases, purified by agarose gel eleetrophoresis and subsequently 
cloned into the new veetor using eompatible sites or through blunt end ligation. 
2.2.11 Size separation of nucleic acid by agarose gel electrophoresis 
The required amount of agarose (SeaKem, Biozym Diagnostik, Hameln, final 
eoneentration between 0.7 and 2%) was dissolved in 100 ml eleetrophoresis buffer (TBE: 
90 mM Tris-base, 90 mM borie acid, 2.5 mM EDTA, pH 8.3). Ethidium bromidewas 
added at a eoneentration of 0.3 Jlglml. The molten gel was poured into a horizontal 
ehamber. Combs with the appropriate number and size of the teeth were used to make the 
loading slots. Onee the gel was set, electrophoresis buffer was added and the gel was run 
at 35-45 mA (50-100 V) at room temperature for the required time. Sampies were loaded 
onto the gel in loading buffer (10 mM EDTA, 10% glyeerol, 0.1% SDS, 0.02% 
bromophenol blue). DNA was visualised by transillumination with 302 nm ultraviolet 
radiation. 
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2.2.12 lsolation/purification of DNA from agarose gels 
To isolate an appropriate DNA fragment from an agarose gel, Easy Pure DNA 
Purification Kit (Biozym Diagnostik GmbH) was used essentially as recommended by the 
manufacturer. Briefly, the DNA band of choice was cut out from the gel under 1ong wave 
UV light with the aid of a scalpel. The gel piece containing DNA was melted at 65°C in 
the appropriate buffer and the DNA-binding resin was added. After two subsequent 
washing steps the resin with bound DNA was air-dried and the DNA eluted by addition 
of bi-distilled H20. The presence of the DNA fragment in solutionwas confirmed by 
agarose gel electrophoresis. 
2.2.13 E. coli strain maintenance 
A single colony ofthe DH5a was streaked onto a 2xTY-agar (Sambrook et al., 1989). 
Then cells were grown overnight in incubator at 3 7°C and stored at 4 °C for a month. 
2.2.14 Growth of E. co/i culture in liquid medium 
An appropriate vo1ume of 2xTY medium (Sambrook et al., 1989) containing 
ampicillin (100 J.Lg/ml) was inoculated with a singlestock co1ony of E. coli. Cells were 
grown ovemight in a 37°C incubator, with shaking at 250 rpm. 
2.2.15 Preparation of competent bacteria (E. coll) 
2.2.15.1 Chemically competent E. co/i (calcium chloride method) 
A sing1e colony of E. coli DH5a was taken to inocu1ate 5 ml of LB medium (1 0 g/1 
tryptone, 5 g/1 yeast extract, 5 g/1 NaCI) and allowed to grow ovemight at 37°C with 
shaking (250 rpm). Then 4 ml was removed and added directly to 400 ml of LB medium. 
The bacteria were grown to an 0Ds9o of0.375 and then incubated on ice for 10 min. The 
bacteria were sedimented by centrifugation (without brake) at 3,600 x g for 7 min at 4°C. 
The pellet was carefully re-suspended in 20 ml of ice cold 0.1 M CaCh and allowed to 
stand on ice for a further 1 0-15 min. The cells were centrifuged again und er the same 
conditions and re-suspended in a further 20 ml of ice cold CaCh. This process was 
repeated once more and the final pellet re-suspended in 2 ml of ice-cold CaCh with 1 0% 
glycerol. After a short period on ice, the bacteria were dispensed in 1 00 J.Ll aliquots in 
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pre-chilled reaction tubes and snap-frozen in liquid nitrogen before storing at- 80°C. 
2.2.15.2 Electrocompetent E. coli 
As above, a single colony of E. coli DH5a. was taken to inoculate 1 ml of YENB 
medium (7.5 g/1 Bacto yeast extract, 8.0 g/1 Bacto Nutrient broth) and the culture grown 
ovemight at 37°C with shaking. The use ofthismedium is very important as it eliminates 
all the steps needed to remove the salts. Salts are known to reduce the efficiency of 
electro-transformation and cause arcing in the electroporation cuvette. 500 ml of fresh 
YENB medium was inoculated with the 1 ml ovemight culture. Bacteria were grown at 
37°C with shaking and harvested when the OD600 was between 0.5 and 0.9. To harvest 
cells, the bacteria were chilled on ice and centrifuged at 4,000 x g for 10 min at 4 °C. The 
medium was discarded and the pellet was washed in 100 ml of cold water twice and 
centrifuged as previously described. The supematant was discarded and the bacteria re-
suspended in 10 ml of cold 10% glycerol, centrifuged and the supematant discarded. 
Cells were re-suspended in a final volume of 2 ml cold 10% glycerol. The cell number in 
the suspensionwas 1.5-3 x 1010 cells/ml. To freeze competent cells, they were aliquoted 
into reaction tubes ( 40 J.llltube and placed on dry ice until frozen. Frozen 
electrocompetent cells were stored at- 80°C and thawed on ice before use. 
2.2.16 Transformation of E. coli 
2.2.16.1 Chemically 
This type of transformation was used for propagation of different plasmids as follows. 
A DNA sample (0.01-1 J.lg) was added to 45 J.ll MgCh/5 mM Tris-HCl, pH7.4, followed 
by 100 J.ll of the ice-thawed chemically competent cells. After brief vortexing and 
incubation on ice for 1 hour the cells were subsequently heat-shocked for 5 minutes at 
37°C and incubated on ice foranother 1 min. The transformed E. coli cells were finally 
mixed with 400 J.ll 2xTY medium, incubated at 37°C for 1 hour, plated onto 2xTY-agar 
plates supplemented with ampicillin (100 J.lg/ml) and grown ovemight at 37°C. 
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2.2.16.2 E/ectroporation 
This type of transformation was used for ligation reactions as follows. A 2 fll sample 
of ligation mixture was added to 40 fll of the ice-thawed electrocompetent cells. The 
resulting mixture was placed in a pre-cooled electroporation cuvette. The cells were 
electroporated at 1.8 kV using a Rad Gene Pulser (BioRad GmbH, Munich). The cells 
were then immediately re-suspended in 450 fll SOC medium (SOB medium 
supplemented with 0.36% glucose) pre-warmed to 37°C. After incubation at 37°C for 30 
minutes with shaking, the transformed E. coli cells were finally plated onto 2xTY -agar 
plates containing ampicillin (100 flg/ml) and grown overnight at 37°C. 
2.2.17 Plasmid DNA preparation 
2.2.17.1 Sma/1 scale method -1 
A 1.5 ml ovemight culture of E. coli cells harbouring an appropriate plasmid was 
transferred to a microfuge tube and centrifuged at 13,000 rpm for 5 min. The bacterial 
cell pellet was re-suspended in 90 fll GTE buffer (50 mM glucose, 25 mM Tris, pH8.0, 
10 mM EDT A), followed by the addition of 180 fll SDS/NaOH Iysis buffer (1% SDS, 0.2 
M NaOH) and thorough mixing. Subsequently 135 fll potassium-acetate buffer (3 M 
potassium acetate, 2 M acetic acid) was added, followed by thorough mixing and 
centrifugation at 13,000 rpm for 5 min. The supematant was decanted into a fresh tube 
containing 1 ml ethanol. After mixing the sample was centrifuged at 13,000 rpm for 10 
min. The pellet was re-suspended in 100 fll distilled water, followed by the addition of 
100 fll 5 M Li CI. After mixing and incubation on ice for 15-30 min, the sample was 
centrifuged at 13,000 rpm for 10 min. The supematant was transferred to a fresh tube and 
mixed with 500 fll ethanol. After centrifugation at 13,000 rpm for 10 min the pellet 
containing plasmid DNA was re-suspended in 20 fll TE (10 mM Tris-HCI, pH7.4, 1 mM 
EDTA, pH8.0) containing 10 flg/fll RNase. 
2.2.17.2 Sma/1 scale method- 2 
A 1.5-ml overnight culture of E. coli cells harbouring an appropriate plasmid was 
transferred to a microfuge tube and centrifuged at 13,000 rpm for 1 min. The bacterial 
cell pellet was re-suspended in 200 fll TELT buffer (50 mM Tris-HCI, pH8.0, 62.5 mM 
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EDT A, 2.5 M Li CI, 0.4% Triton X-100), followed by the addition of 20 111 Iysozyme 
solution (10 mg/ml in TE buffer) and thorough mixing with a pipette. After incubation for 
3 min at 96°C and subsequent cooling on ice for 5 min, the lysate was centrifuged for 8 
min at 13,000 rpm. To precipitate DNA, the cleared lysate was transferred to a fresh tube, 
100 111 isopropanol was added and the resultant mix was thoroughly vortexed. After 
centrifugation at 13,000 rpm for 5 min the pellet containing plasmid DNA was washed 
once with 70% ethanol and air-dried. The plasmid DNA was finally re-suspended in 20 to 
50 111 TE buffer containing 10 f.lg/f.ll RNase. 
2.2.17.3 Large scale plasmid preparation 
A 200-ml overnight culture of E. coli cells harbouring an appropriate plasmid was 
centrifuged at 4,000 rpm for 10 min. The cell pellet was then used for the plasmid DNA 
preparation. Plasmid DNA was prepared on a large scale using either the Nucleobond AX 
kit PC 500 (Machery-Nagel GmbH & Co. KG) or the Quiagen Plasmid Maxi Kit 
(Quiagen) following the manufacturer's instructions. The resultant DNA preparation was 
further purified using phenol/chloroform extraction followed by ethanol precipitation. 
2.2.18 Sequencing of double-stranded template DNA 
2.2.18.1 Automated (fluorescence) DNA sequencing method 
The VISTRA Thermo Sequenase Pre-mixed Cycle Sequencing Kif (Amersham 
Pharmacia Biotech) was used to routinely sequence cloned DNA on both strands. 
Briefly, 1 f.lg DNA was mixed with 4 pmol of an appropriate Texas-red-labelled primer 
(e.g. T7 Forward universal primer). From this mixture 6 111 was aliquoted into each 
termination vial ('G', 'A', 'T', 'C') containing 2 f.ll ofthe corresponding ddNTP mix (i.e. 
ddGTP, ddATP, ddTTP and ddCTP) containing all the necessary reaction components 
such as polymerase and dNTPs plus the actual ddNTPs. The reaction was cycled in a 
PCR machine using the following parameters: 94 °C, 1 min, 1 cycle; 94 °C, 30 sec, 50°C, 
30 sec and 72°C, 30 sec for a total of 25 cycles. Upon completion, 3 f.llloading buffer 
was added to each reaction mix and the volume of the reaction was reduced to 3 f.ll by 
drying in a vacuum centrifuge. The samples were loaded on a RapidGel-XL-6% gel 
(Amersham) and run with TBE buffer in a DNA Sequencer 725 (Molecular Dynamics & 
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Amersham) for 12 hours. The sequencing data were analysed using Molecular Dynamics 
software. 
2.2.18.2 Manual (radioactive) DNA sequencing method 
The Thermo Sequenase Radiolabelied Terminator Cycle Sequencing Kit (Amersham 
Pharmacia Biotech) was used for the sequencing of DNA templates. The kit combines 
two revolutionary innovations for sequencing DNA. First, the label is incorporated into 
the DNA reaction products by the use offour e3P)-ddNTP terminators and secondly, the 
use of an engineered Thermo Sequenase DNA polymerase that allows for efficient 
incorporation in cycling sequencing protocols. Sequencing of desired templates was 
carried out according to the manufacturer's guidelines. Approximately 1 Jlg of plasmid 
DNA was taken together with 3 pmol of an appropriate sequencing primer with 8 U of 
the Thermo Sequenase polymerase in a total volume of 20 Jll. From this mixture 4.5 Jll 
was aliquoted into each 'termination' PCR vial ('G', 'A', 'T', 'C') containing a mixture 
of 2 Jll dGTP and 0.5 Jll e3P)-ddNTP and cycled in a PCR machine using the following 
parameters: 95°C, 30 sec, 55°C, 30 sec and 72°C, 1 min for a total of 40 cycles. The 
reactions were stopped by the addition of the kit stop solution. After a denaturation step 
(i. e. incubation at 70°C for 5 min), 3 Jll samples were loaded in each lane and resolved 
over a 6% polyacrylamide 6 M urea TBE gel. Once the run had reached the desired 
length, the gel was removed, dried on Whatmann 3MM paper at 80°C for 2 hours on a 
vacuum gel dryer before autoradiography. Films were developed after 18-36 hours 
exposure. 
2.2.19 Cell culture 
All mammalian cells were maintained at 37°C in an incubator (Forma Scientific, 
Laborfeet GmbH, Göttingen) in 5% C02 and 95% air humidity. All cells were grown in 
petri dishes or flasks (Greiner) ofvarying sizes depending on the application. The cells 
were allowed to grow until a confluence of 80-90% had been reached, whereupon the 
cells were subsequently split by trypsinisation and re-seeded at a lower density. Trypsin 
treatment of cells was performed by removal of the culture medium from the cells, 
followed by one wash with Ca2+/Mg2+ free PBS (137 mM NaCl, 2.7 mM KCI, 6.5 mM 
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Na2HP04, 1.5 mM KH2P04). After removal of PBS, 0.25% trypsinwas applied to the 
cells and the cells incubated at 37°C until they became detached as observed under a low-
powered microscope. Fresh medium was then directly applied and the cells re-plated at 
the desired density in new petri dishes. To prepare cells for storage, logarithmically 
growing cells from a large flask were trypsinised, harvested by the addition of medium, 
then the cells were centrifuged at 1,500 rpm. The medium was removed and the cells re-
suspended in 90% FCS and 10% DMSO (Fluka Chemie AG. Switzerland) and placed in 
five 1 ml aliquots in cryovials. After incubation on ice for 1 hour, the cells were 
transferred to- 80°C for several hours before finally being stored in liquid nitrogen. To 
re-propagate cells, the vials were removed from the liquid nitrogen and placed at 3 7°C 
until most of the cells had thawed. The cells were then removed and mixed with 1 0 ml 
fresh medium (to remove the DMSO) followed by centrifugation and seeding on petri 
dishes in fresh medium. Schneider 2 (S2) Drosophila cells were obtained from Invitrogen 
and cultured at 22-24°C in a non-humidified incubator following the supplier's 
recommendations. All cells were routinely screened for mycoplasma contamination using 
the VenorGeM Mycoplasma Detection Kit (Minerca Biolabs GmbH, Berlin) according to 
the manufacturer' protocol and found tobe negative. 
2.2.20 Stahle and transient transfection of cells 
2.2.20.1 Calciumphosphate method 
To transfect Schneider 2 (S2) cells both stably and transiently, the Calcium Phosphate 
Transfeetion kit (Invitrogen) was used. To prepare S2 cells for transfection, they were 
seeded in 3 ml complete DES expression medium at 106 cells/ml. When the cells reached 
a density of approximately 5x1 06 cells/ml they were transfection competent. To prepare 
the transfection mix, Solution A (36 J.ll 2M CaCh, 19 J.ll 1 flg/fll expression vector DNA, 
1 J.ll selection vector (in the case of the stable transfection) and H20 up to 300 J.ll) was 
added drop-wise to Solution B (300 fll 2x HBS) and incubated at room temperature for 
30 min. After the combined solution was thoroughly mixed it was drop-wise added to the 
cells. The calcium phosphate medium was removed from the cells after 12-14 hours and 
replaced with fresh medium. After further incubation of the cells for 48 hours the cells 
were either analysed for the expression of the gene of interest (in the case of transient 
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transfections) or placed under appropriate antibiotic selection (400 Jlglml hygromycin) to 
generate stably transfected clones. After a period of 2-3 weeks, hygromycin-resistant S2 
cell clones were pooled together and a mass culture expressing the desired recombinant 
protein was thus established. 
2.2.20.2 Lipofection 
To stably transfect PAE cells with the murine VEGFR-3 expression construct, 
GenePORTER Transfeetion Reagent (Peqlab) was used. The transfection protocol was 
supplied by the manufacturer and optimised for the given cell line. Briefly, a mixture of 
two solutions A and B (Solution A: 4 Jlg plasmid DNA in 500 J.Ll serum-free F-I2 
medium; Solution B: 20 J.Ll GenePORTER in 500 J.Ll serum-free F-I2 medium) was 
prepared and incubated for 30 min at room temperature. 
The mix was added to 60% confluent P AE cells grown in 6-well dishes after the 
removal of medium from the cells. The cells were incubated with the transfection 
medium for 3-5 hours. After that I ml F-I2/20% FCS medium was added and the cells 
were incubated forafurther 12-I4 hours. Following the addition offresh F-I2/10% FCS 
medium, the cells were incubated for another 24 hours. To generate clones, cells were 
plated into several petri dishes and cultured in selection medium (400 J.Lg/ml neomycin) 
until resistant cells appeared. Individual clones were picked, expanded and analysed for 
the expression ofthe gene ofinterest by Western blot. 
2.2.21 Purification of recombinant His-tagged profeins 
Recombinant His-tagged proteins were purified from insect cell medium supematants 
using Ni-NTA agarose (Quiagen) essentially as described by the manufacturer. Stahle S2 
transfectants expressing a particular His-tagged protein were cultured as recommended 
by the supplier. To facilitate the purification procedure, the cells were grown in serum-
free insect medium (Invitrogen) containing no selective antibiotic for 6 days before the 
purification. The cell supernatant containing the His-tagged protein (as indicated by 
Western blot analysis) was collected after pelleting the S2 cells by centrifugation at I ,500 
rpm for 20 min. The medium supematant was then dialysed at 4°C ovemight against 50 
mM sodium phosphate buffer, pH7.4, 300 mM NaCl, 100 J.LM PMSF followed by the 
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addition of 20 mM imidazole. After dialysis, the pH of the medium was adjusted to 8.0 
with SM NaOH. Ni-NTA resin (Quiagen) was washed three times with Wash buffer (50 
mM sodium phosphate buffer, pH8.0, 300 mM NaCl, 20 mM imidazole, 100 J.!M PMSF) 
and added to the dialysed medium at a ratio of 10 ml Ni-NTA 50% resin slurry per 280 
ml dialysed medium. The mixture was loaded into 500-ml tubes and rotated for 4 hours to 
overnight on a turnhier to allow the resin to bind to the His-tagged proteins. Afterwards 
the mixture was poured into a 20-ml column and the "flow-through" fraction was 
collected. After washing the column three times with ice-cold wash buffer (25 ml each 
wash), the proteins were eluted with ice-cold elution buffer (50 mM sodium phosphate 
buffer, pH8.0, 300 mM NaCl, 300 mM imidazole, 100 J.!M PMSF) due to the high 
imidazole concentration. Ten 2-ml fractions were collected. Fractions which were 
positively evaluated in Western blot analysis were pooled and dialysed ovemight at 4°C 
against PBS. Following protein concentration determination, the proteins were mixed 
with 50 J.lg BSA per every J.lg of the recombinant protein, aliquoted and lyophilised for 
long-term storage at- 80°C. For immediate use, an aliquot ofthe recombinant proteins 
was reconstituted with PBS at 100 J..Lg/ml and further aliquoted to be stored at - 20°C. 
Repeated freeze-thaw cycling was avoided. 
2.2.22 Determination of protein concentration 
Protein concentration was determined using the DC Protein Assay Kit (BioRad GmbH, 
essentially a modification of the Biuret method of protein concentration determination) as 
recommended by the manufacturer. 
2.2.23 Celllysate preparation 
Cells were grown to confluence and then removed from the petri dish by scraping 
using a rubber policeman, or by incubation with PBS (Mg2+ and Ca2+ free) containing 5 
mM EDT A. The cells were counted with a cell counter chamber slide and re-suspended at 
a final concentration of 1 x 10 7 cells/ml in either reducing sample buffer (200 mM Tris-
HCI pH 6.8, 250 mM sucrose, 2.5 mM EDTA, 0.1% (w/v) bromophenol blue, 2% SDS, 
10% 2-mercaptoethanol or 1 OOmM DTT) or non-reducing sample buffer ( containing no 
2-mercaptoethanol or DTT). Sampies were boiled for 5 min and then sonicated for 15 to 
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20 sec to break down chromosomal DNA. 5 x 105 equivalent cell volumes were loaded 
into each gel slot. 
2.2.24 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
Proteins were electrophoretically separated on the basis of size using the method of 
Laemmli ( 1970). The resolving gel containing between 6 to 15% acrylamide ( depending 
on the experiment) and 5% stacking gel were cast according to Sambrook et al. (1989). 
Sampies were run into the stacking gel at 50 V, and then run at 100-200 V during the day 
or 30 V overnight. 
2.2.25 Staining the SDS-PAGE gels 
2.2.25.1 Coomassie staining 
Gels were incubated with Coomassie stain solution (0.25% Coomassie brilliant blue, 
R-250, 50% methanol and 10% acetic acid) for 4-24 hours. To de-stain, the gels were 
incubated in 1 0% acetic acid; 10% methanol for 24 hours or Ionger with several changes 
of the de-stain solution. 
2.2.25.2 Süver staining 
Gels were silver stained using a Silver Staining Kit (Amersham) following the 
manufacturer's guidelines. The gels were then air-dried between two sheets of cellophane 
held in between two gel drying frames (Promega GmbH, Mannheim). 
2.2.26 Western blotting 
After proteins were separated by SDS-PAGE, they were electrically transferred onto 
Immobilon membrane (Millipore, type PVDF, pre-soaked in methanol) at 250-300 mA 
for at least 6 hours in transfer buffer (25 mM Tris, 190 mM glycine, 20% (viv) methanol 
and 0.05% (w/v) SDS). Following the completion of the transfer, in order to reduce 
unspecific binding of the antiborlies to the PVDF membrane, the blot was incubated in 
TBST blocking solution (10 mM Tris-HCI, pH 8.1, 100 mM NaCI, 0.1% Tween 20) 
supplemented with either 4% (wlv) non-fat dried milk (for all but anti-phosphotyrosine 
antibodies) or 1% BSA (for anti-phosphotyrosine antibodies) at room temperature for 30 
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min with shaking. For detection of proteins of interest the membrane was further 
incubated in TBST blocking solution containing the appropriate primary antibody (at the 
manufacturer-recommended dilution) for 1 hour at room temperature or at 4°C for about 
12 hours. After 3 washes in TBST, unless the primary antiborlies were conjugated to 
HRP, the membrane was incubated in TBST solution containing a 1: 1000 dilution of 
HRP-conjugated secondary antibody. Once the membrane has been washed 3-4 times 2 
min each in TBST buffer, detection of specific proteins was achieved by enhanced 
chemiluminescence using ECL Western blotting detection reagents (Amersham) and ECL 
Hyperfilm (Amersham) following the manufacturer's instructions. 
2.2.27 Strippingwestern blot membrane 
To allow more than a single use of westem blot membranes, the membranes were 
stripperl in the following way. They were incubated with a Stripsolution (62.5 mM Tris, 
pH 6.8, 2% SDS, 0. 75% 2-mercaptoethanol) at 55°C for 20 min with shaking. The 
membranes were then washed twice in the TBST for 2 min each time, blocked as usual 
and used for the normal westem blot prohing protocol. 
2.3 Analytical Methods 
2.3.1Jn vitro tyrosine kinase assay 
An ELISA-based protocol was used to screen potential RTK inhibitors in vitro 
essentially as described in Laird et al. (2000). In this assay, test substances were added to 
in vitro substrate phosphorylation reactions catalysed by recombinant GST-kinase fusion 
proteins (KTB Tumorforschungs GmbH, Freiburg). All tests were performed in duplicate. 
ELISA 96-well plates (lmmunon 11, Dynex) were coated with 20 J.lg (1 00 J.ll)/well 
substrate (poly-Glu,Tyr4:I) diluted in 100 mM sodium bicarbonate, pH 9.6 buffer. Plates 
were coated at room temperature ovemight in a humidified sandwich box. The substrate 
solutionwas then removed, the plates washed twice in TBS (10 mM Tris-HCl, pH8.1, 
100 mM NaCl) buffer and blocked by incubation with 150 JJ.l/well 5% BSA/TBS for a 
minimum of 30 min. Again the plates were washed twice with TBS. The reaction mix 
was prepared by combining (in each weil) 50 J.ll test substance (2 or 20 JJ.g/ml in 10% 
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DMSO), 25 J.ll 4x kinase dilution buffer (200 mM HEPES, 100 mM NaCl, 80 J.lM 
Na3V04 and 0.04% BSA) containing an appropriate amount ofrecombinant OST-kinase 
and 25 J.ll 160 J.lM ATP ( diluted in 40 mM MnCh). Hence, the final concentration of the 
test substances in the assay was either 1 or 10 J.lg/ml in 5% DMSO. The addition of ATP 
immediately triggered the reaction that was perforrned at 30°C for 90 min. Tostop the 
reaction, 50 J.ll/well 30 mM EDTA was added. After the plates were washed twice with 
0.05% Tween 20/TBS buffer, 100 J.ll/well anti-phosphotyrosine antibody diluted (1:500) 
in 0.05% Tween 20/TBS buffer (supplemented with 0.5% BSA, 0.025% non-fat dry milk, 
and 100 J.lM Na3 V04) was added and the plate incubated for 1 hour at 37°C. The plates 
were washed three times with 0.05% Tween 20/TBS. Secondary HRP-conjugated 
antibody (1: 1 000) in 0.05% Tween 20/TBS buffer (supplemented with 0.5% BSA, 
0.025% non-fat dry milk, and 100 J.lM Na3V04) was added. After another incubation for 
1 hour at 37°C, the plates were washed three times with 0.05% Tween 20/TBS and 100 
J.lllwell ABTSsubstrate (Roche) was added. After the green colour had developed, the 
plate was analysed by use ofan ELISA plate reader (405 nm filter). 
2.3.2 Cellular phosphorylation assay 
In order to deterrnine the degree of RTK phosphorylation, PAE, PAENEGFR-1, 
PAE/VEGFR-2 or PAENEGFR-3 were seeded into 15-cm tissue culture plates and 
grown to 50% confluence. Cells were then serum-starved with serum-free medium 
(supplemented with 0.2% BSA) for 16-24 hours (PAE, PAE/VEGFR-1 and 
PAENEGFR-3) or 72 hours (PAENEGFR-2). After 30 min pre-incubation with 5-ml 
serum-free medium containing 1 mM Na3 V04, or 1 hour- with 5 ml serum-free medium 
containing inhibitors (0, 0.5, 5 and 50 J.lM), 1 mM Na3 V04, and 5% DMSO, the cells 
were stimulated at 37°C for 5 min (VEGFR-1, VEGFR-2) or 8 min (VEGFR-2) with the 
corresponding RTK ligands (e.g. S2 transfectant conditioned medium or purified 
recombinant growth factors at 200-400 ng/ml). In the inhibitor experiments, the ligand-
containing medium was also supplemented with the test inhibitor and 5% DMSO. 
Afterwards, the cells were quickly washed twice with ice-cold PBS (supplemented with 
100 J.lM Na3VÜ4). lee-cold modified RIPA buffer (30 mM Tris-HCl, pH7.4, 150 mM 
NaCl, 1 mM EDTA, 0.5% (viv) Triton X100, 0.5% (wlv) sodium desoxycholate, 10 mM 
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NaF) freshly supplemented with 1 mM PMSF, 0.1 U/ml aprotinin, 10 ng/ml Ieupeptin 
and 5 mM Na3V04 was added to lyse the cells. The cells were seraperl offthe plates with 
a ruhher-policeman and collected into centrifuge tubes on ice. The lysates were 
soluhilised by pushing them through a syringe fitted with a 25G needle and centrifuged at 
4°C at 13,000 rpm for 15 min to remove theinsoluble matter. The cleared lysates were 
incuhated with 4-J.Lg appropriate anti-receptor antibody at 4°C overnight. To precipitate 
the receptor-antihody complexes, 30-40 J.il/tube 50% slurry of protein A-sepharose 
(Amersham) was added and the incuhation at 4°C was resumed forafurther 2 hrs. The 
heads were then centrifuged for 1 min at 4 °C and washed three times with ice-cold wash 
buffer (30 mM Tris-HCl, pH7.4, 150 mM NaCl, 1 mM EDTA, 0.05% (v/v) Triton XlOO, 
0.5% (w/v) sodium desoxycholate, 10 mMNaF) freshly supplemented with 1 mM PMSF, 
0.1 U/ml aprotinin, 10 ng/mlleupeptin and 5 mM Na3 V04. The remaining wash huffer 
was removed hy suction with a 1-ml syringe fitted with a 27G needle. Finally, the heads 
were re-suspended in 50 J.Ll SDS-PAGE loading huffer, hoiled and loaded on a 6% SDS-
PAGE gel. After the proteins released from the heads had been resolved on the SDS-
PAGE, they were hlotted as descrihed in the western blotting protocol. The hlots were 
first analysed hy prohing with anti-phosphotyrosine antibodies, then the membranes were 
stripperl and re-probed with specific anti-receptor antiborlies to control loading of the 
samples. 
2.3.3 Proliferation assay: eH)-thymidine incorporation 
100 J.il cells were seeded into each weil of a 96-well cell culture plate at 105 cells/ml 
and incuhated at 37°C for approximately 24 hours. The cells were then starved for 24 
hours with 50 J.Ll!well corresponding serum-free medium. To stimulate the cells, serial 
dilutions of 2x-concentrated recombinant growth factors in serum-free medium were 
added to cells at 50 J.Ll/well. In the experiments with inhibitors, cells were pre-incuhated 
for 2 hrs with serial dilutions (0-1 0 J.LM) of the inhihitors and then stimulated with 50 J.Ll 
of either normal culture medium or serum-free medium containing a 2x-concentrated 
specific growth factor and serial dilutions ofthe 2x-concentrated inhihitor. To study anti-
proliferative properties of hyperforin, cells were stimulated with 50 J.Ll of normal culture 
medium containing serial dilutions (0-200 J.Lg/ml) of 2x-concentrated hyperforin or of 
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10%DMSO. 
Each sample was performed in triplicate or quadruplicate. After a 24-hour incubation, 
eH)-thymidine was added to the cells at 1 flCi/well and the incubation was resumed at 
37°C foranother 4-6 hours. To analyse the amount ofincorporated radioactivity, the cells 
were trypsinised for 30 min and harvested onto a glass fibre filter (Wallac Oy, Turku, 
Finland) with the aid of a Harvester 96 cell harvester (Tomtec, Hamden, USA). The filter-
immobilised radioactivity was counted using scintillation liquid and a MicroBeta TriLux 
Liquid Scintillation and Luminescence counter (Wallac). 
2.3.4 Apoptosis detection assay 
To detect apoptosis and quantify the pro-apoptotic effect of different substances, the 
Cell Death Detection ELISAPLUS kit (Roche Diagnostics GmbH, Mannheim) was used. It 
is a photometric enzyme-immunoassay for the qualitative and quantitative in vitro 
determination of cytoplasmic histone-associated-DNA-fragments (mono- and 
oligonucleosomes) produced after programmed cell death (apoptosis). Cells (105 cells/ml) 
were seeded into a 96-well cell culture plate at 50 fll/well and incubated at 37°C for 
approximately 24 hours. Then different 2x-concentrations of test substances diluted in 
normal growth medium were applied to the cells at 50 fll/well. Each sample was 
performed in duplicate. After 24-hour incubation apoptosis was detected and quantified 
following the kit manufacturer's recommendations. 
2.3.5 Cell cycle analysis 
Mg2+ and Ca2+-free PBS was used throughout the experiment. Approximately 1 06 cells 
were harvested by trypsinisation and washed once with PBS. The cells were then re-
suspended in 100 fll PBS supplemented with 5% FCS. The cells were fixed by the 
addition of 100 fll 8% formaldehyde solution in PBS ( containing 2% methanol) and 
incubation for 1 0 min at room temperature. Afterwards cells were permeabilised by the 
addition of 33 fll 0.5% Tween 20 and further incubated for 10 min at room temperature. 
The cells were the washed once with 1 ml PBS supplemented with 5% FCS by 
centrifugation at 5,000 rpm for 3 min and re-suspended in 100 fll PBS supplemented with 
5% FCS and 0.05% Tween 20. After the cellular DNA was stained by the addition of 1 fll 
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4 jlg/ml Höchst 33258 solution, the cell cycle was analysed by measuring the DNA 
contents using a F AC Star flow cytometer (Becton Dickinson). 
2.3.6 Matrtigel-based in vivo angiogenesis assay 
Matrigel, a soluble basement membrane extract ofthe murine EHS (Engelbreth-Holm-
Swarm) sarcoma, is widely used in different angiogenesis assays (Passaniti et al., 1992). 
To test the angiogenic propetlies ofthe recombinant rat VEGFs, different arnounts ofthe 
recombinant rat ßNßCNEGF-C, ßNßCNEGF-C(Cys152Ser) and VEGF proteins (e.g. 
10, 100 and 1000 ng) were mixed with liquid matrigel (Becton Dickenson) at 4°C and 
injected subcutaneously into the back of experimental rats. Matrigel rapidly solidified at 
body temperature, trapping the factors to allow their slow release to surrounding tissues. 
After 14 days the matrigel was extracted and exarnined for the presence of newly grown 
vessels. 
2.3. 7 Induction of lympbangiomas in vivo 
Lymphangiomas were induced in different strains of rats essentially as described by 
Mancardi et al. (1999). Briefly, incomplete Freund's adjuvant in PBS (1:1, v:v) was 
injected intraperitoneally with a subsequent boost after a 14-day period. After an 
additional period of 7 days, the rats were sacrificed and their peritonea exarnined for the 
presence of lymphangiomas. 
2.3.8 Tissue embedding and preparation of sections 
The methods described in this section are modifications of established protocols (e.g. 
Prophet et al., 1994). 
2.3.8.1 Paraffin sections 
Freshly isolated organs or tissue were cut into 4-5 mm pieces, placed into cassettes 
and fixed in 4% paraformaldehyde (in PBS) in a refrigerator for a minimum of 72 hours. 
The cassettes with tissue sarnples were then washed in PBS and embedded into paraffin 
using a Shandon Hypercenter XP embedding machine (Life Seiences International 
(Europe) Ltd, UK). Following mounting, 6 11m sections were prepared from the tissue-
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containing paraffin blocks using the RM 2155 microtome (Leica Instruments GmbH, 
Nussloch). After drying the sections overnight they were stored at room temperature for 
future use. 
2.3.8.2 Frozen sections 
Freshly isolated organs or tissue were placed into a metal tray filled with Polyfreeze 
tissue freezing medium (Polysciences, Inc, Warrington, USA). The latter was allowed to 
solidify by placing the tray onto dry ice. Frozen blocks were removed from the metal 
trays and used to cut 1 0 J.lm sections with the aid of a Cryocut 1800 cryostat microtome 
(Leica). To fix the tissue, the sections were frrst air-dried for 1 hour, then incubated in 
ice-cold acetone for 10 min. The sections were air-dried again for 1 hour and then stored 
at 4°C (for 1-2 months) or- 20°C (for a Ionger term). 
2.3.9 Tissue section staining 
2.3.9.1 Staining with hemotoxylin and eosin (H&E staining) 
To perform H&E staining, the paraffin sections were used. Tissue was deparaffinised 
by successive washes in xylene (2 times, 5 min each), 100% ethanol (1 min), 95% 
ethanol (2 times, 1 min each), 70% ethanol (1 min). After washing the slides with tap 
water for 2 min, the slides were incubated in 0.1% hemotoxylin solution (Sigma) for 1 
min and washed again with tap water for 5 min. Then the slides were incubated in 
alcoholic eosin Y solution (eosinY, 0.1% wlv; phloxine B, 0.1%, w/v; ethanol, 90%, viv) 
for 1 min, washed in 70% ethanol (2 times, 1 min each), 95% ethanol (2 times, 1 min 
each), 100% ethanol (2 times, 1 min each) and xylene (2 times, 1 min each). Stained 
tissue sections were covered with glass slips using Immu-mount mounting medium (Life 
Seiences International) and allowed to dry. 
2.3.9.2 Masson's trichrome staining 
Staining with Masson's trichromewas primarily used to distinguish vessel structures 
from matrigel. The staining procedure was performed using the Accustains Trichrome 
Stains (Masson) kit (Sigma) following the manufacturer's guidelines. Briefly, the tissue 
section slides were deparaffmised as above and incubated overnight in Bouin's solution 
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(Sigma). After extensive washes in running tap water the slides were stained in Working 
Weigert's Iron Hematoxylin Solution (Sigma) for 5 min, washed in running tap water for 
5 min and rinsed in deionised water. Staining with Biebrich Scarlet-Acid Fucshin for 5 
min was performed and the slides were rinsed again in running tap water. After the 
subsequent 5-min staining with Working Phosphotungustic/Phosphomolybdic Acid 
Solution, the slides were placed for 5 min in Aniline Blue Solution. After the final 2-min 
incubation in 1% acetic acid the slides were rinsed in water, dehydrated through 70% 
ethanol (2 times, 1 min each), 95% ethanol (2 times, 1 min each), 100% ethanol (2 times, 
1 min each) and cleared in xylene (2 times, 1 min each). The slides were covered with 
Micromount xylene-based mounting medium (Surgipath, Richmond, USA) and glass 
slips after which they were allowed to dry. 
2.3.9.3/mmmunohistochemistry (IHC) 
In order to detect expression of specific proteins in tissue sections, IHC was performed 
with minor modifications essentially as described elsewhere (Prophet et al., 1994). In 
brief, paraffin-embedded tissue sections where deparaffinised as above, then extensively 
washed in PBS. Frozen sections where placed in PBS to dissolve the freezing medium, 
then also extensively washed in PBS. To unmask antigens, when necessary, sections were 
heated in a microwave with antigen unmasking solution (Vector Laboratories, Inc., 
Burlingame, USA) for 20 sec, then incubated with the hot antigen unmasking solution at 
room temperature for 10-15 min, washed twice with water and once with PBS. Tissue 
sections were then outlined with the DAKO pen (DAKO) (which allows small aliquots 
(1 00-300 f.ll/ section) of antiborlies to be used) and covered for 15 min with blocking 
solution (1 0% normal goat serum in PBS). After a brief wash with PBS, primary antibody 
solution in PBS was applied and sections were incubated at room temperature for 1 hour. 
To remove unbound antibodies, the sections were washed three times with PBS (2 min 
each). The sections were then incubated for 15 min with 3% (v/v) H20 2 (in PBS) to 
quench the intrinsic peroxidase activity, then washed three times with more PBS (2 min 
each). Biotinylated secondary antibody in PBS was then applied to the sections for 30 
min and washed off with PBS (3 times, 2 min each). Streptavidin-biotin-peroxidase 
complex was prepared 30 min in advance (Peroxidase standard kit, Vector Laboratories). 
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It was applied to the sections for 30 min and then washed off with PBS (3 times, 2 min 
each). Colour development was achieved by using the AEC peroxidase substrate kit 
(Vector Laboratories). The sections were incubated with the kit solutions (which were 
mixed according to the manufacturer' s instructions) for up to 20 min until the red colour 
had developed. Then the sections were briefly rinsed with water and counter-stained with 
0.1% hemotoxylin for 2-4 min. Excessive hemotoxylin dye was removed by extensive 
washing with water. The slides were fmally covered with glass slips using Immu-mount 
mounting medium (Life Seiences International) and allowed to dry horizontally for 1 0 
min before they were observed and photographed under the microscope. 
2.3.10 Endotbelial sprouting: in vitro angiogenesis assay 
A modified method ofKorffand Augustin (1999) was used to measure the potential of 
certain angiogenesis-related RTK inhibitors to suppress the growth and differentiation of 
blood endothelial cells in vitro. Endothelial cell spheroids were generated at 37°C 
ovemight by suspending endothelial cells (750 cells/well) in appropriate culture medium 
containing 0.24% (wlv) methylcellulose (4000 centipoises) and seeding them in non-
adherent round bottom 96-well plates. Once the endothelial cell spheroids had formed, 24 
to 48 spheroids were collected with a pipette into a centrifuge tube, centrifuged at 1 ,500 
rpm for 3 min and re-suspended in 0.5 ml culture medium containing 0.48% (w/v) 
methylcellulose, 100 ng/ml VEGF, 2% DMSO and 20 ~M of the corresponding test 
substance. After that 0.5 ml collagen (made by mixing on ice 8 volumes acidic collagen 
extract from rat tails (equilibrated to 4 mg/ml), 1 volume of Hanks' balanced salt 
solution, neutralising with IM NaOH and adding I volume FCS) was added. After gentle 
mixing, the spheroid-containing gel was rapidly transferred into pre-warmed 24-well 
plates and allowed to polymerise for 1 min. Growth medium (200 ~I) was pipetted on top 
of the gel. After 3 days of incubation the outgrowth of capillary-like structures from the 
spheroids ( endothelial cell sprouting) was documented. 
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2.3.11 In vivo tumour growth inhibition experiments 
All studies with laboratory animals were performed in the accredited animal facility of 
the Institut für Toxicologie und Genetik, Forschungszentrum Karlsruhe GmbH and were 
approved by the local Ethical Review Board. 
2.3.11.1 Inhibition oftumour growth by indolinones 
In order to check the anti-tumour effect of indolinones, groups of 8 male and female 
BDlO rats (lAS cell line) or Wistar Furth (MT450 cell line) rats were injected 
subcutaneously with 5x105 tumour cells in PBS. Drug treatmentwas initiated either on 
the next day or 15 days after tumour cell injection. The animals received 4 mg/kg/day 
(lAS tumour experiments) or 8 mg/kg/day (MT450 tumour experiments) indolinone 
solution in 100% DMSO (AE87, eight per group; AE106, eight per group; MAZ51, eight 
per group) or the carrier alone (100% DMSO, eight per group). Daily injections of the 
drug/control were administered intraperitoneally for 2-4 weeks. Tumours were measured 
with a micrometer calliper every fifth day throughout the study (Sleeman, 1999). 
2.3.11.2 Inhibition oftumour growth by hypetforin 
In order to check the possible anti-tumour effect of hyperforin, female Wistar Furth 
rats were injected subcutaneously with 5xl05 MT450 cells in PBS. Drug treatmentwas 
initiated 15 days after tumour cell injection, a time at which tumours were readily 
detectable and could easily be measured. In one experiment, the animals received 100 J..Ll 
of 2 mM drug solution in 10% DMSO (hyperforin, eight per group; paclitaxel, eight per 
group) or the solvent (10% DMSO, eight per group). In the other experiment, the animals 
received 100 J..Ll of 4 mM drug solution in nanoemulsion (hyperforin, eight per group) or 
the carrier alone (nanoemulsion E80 Mig 23201: 2.8 mg/ml E80 Iipid, 7 mg/ml miglyol 
812, 0.1 mg/ml tocopherol; eight per group). Hyperforin and paclitaxel were kindly 
supplied by Dr. Christoph Schempp. Daily injections of the drug/control were 
administered subcutaneously at the site of the tumour cell injection for two weeks. 
Tumours were measured with a micrometer calliper every fourth-fifth day throughout the 
study (Sleeman, 1999). 
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PART I 
Creation of a cellular system for analysing anti-tumour substances 
with anti-angiogenic and/or anti-lymphangiogenic properties 
For cancer therapy, it would be desirable to identify substances capable ofblocking 
either tumour growth directly or inhibiting tumour-host interactions such as 
angiogenesis and lymphangiogenesis. The members ofVEGFR tyrosine kinase family 
are expressed on the surface of the vascular and lymphatic endothelial cells, where 
they play pivotal roles in both physiologic and pathologic angiogenesis and 
lymphangiogenesis. Antibodies or synthetic compounds that block VEGFR-2 
activation, for instance, have been shown to exert anti-angiogenic effect, emphasising 
the role oftbis receptor in angiogenesis (Witte et al., 1998; Vajkoczy et al., 1999; 
Drevs et al., 2000). Targeting the receptors of the VEGFR family has, therefore, the 
potential to interfere with the tumour-induced angiogenesis and lymphangiogenesis 
(Saaristo et al., 2000). 
Small chemical compounds such as indolinanes have been shown to block 
different RTKs including VEGFR-2 (Mendel et al., 2000; Sun et al., 2000). I 
therefore decided to Iook through a panel of synthetic indolinanes made in the Institut 
ftir Organische Chemie, Karlsruhe University, in order to identify VEGFR-2 and 
VEGFR-3 inhibitors. In order to screen for indolinanes interfering with VEGFR 
signalling, a cellular system in which the functional VEGF receptors could be 
expressed in an appropriate cellular context and which could be specifically activated 
was necessary. Activation of VEGFRs with specific ligands in the presence of 
inhibitory substances would allow one to measure the effects ofthe VEGFR inhibition 
such as decreased receptor phosphorylation and ensuing deficiency in endothelial cell 
survival, proliferation, migration, and differentiation. 
To create such a system, I aimed to produce specific ligands for VEGFRs, namely 
VEGF, VEGF-C and VEGF-D, in a Drosophilaexpressionsystem (DES). To do this, 
cDNAs encoding the VEGF proteins are to be cloned into a specific DES vector. 
When stably transfected into Drosophila cells, the vectors are expected to express the 
desired proteins at high Ievels. This can subsequently permit purification of the 
recombinant VEGF proteins via an engineered C-terminal polyhistidine tag. The 
expressed growth factors should be used to activate their cognate receptors expressed 
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on endothelial cells. These factors could therefore be employed to screen for potential 
inhibitors, and also possibly be useful for establishing endothelial cells in culture for 
other studies. 
VEGF-C and VEGF-D can bind to and activate two receptors VEGFR-2 and 
VEGFR-3 (Joukov et al., 1997; Stacker et a/., 1999). Therefore, as a tool to 
discriminate between activation of these two receptors, I also aimed to make mutated 
VEGF-C and VEGF-D proteins in which one ofthe cysteines would be replaced by 
serine to resemble the published VEGFR-3-specific VEGF-C mutant (Joukov et al., 
1998). These mutated forms should be specific activators ofVEGFR-3, and thus only 
induce LE proliferation. These properties would be useful for the establishment of LE 
in culture. 
3.1 Cloning, expression and purification of recombinant rat VEGFs 
The rat system was chosen for the current study due to the availability of well-
characterised rat tumour models that can be relevant in studying eventual anti-tumour 
effects ofthe anti-angiogenic substances. Therefore, in order to screen the compounds 
on the basis of their ability to inhibit activation of VEGFRs mediated by their specific 
ligands, rat VEGF-C, VEGF-D and VEGF were cloned and subsequently expressed. 
The Drosophila expression system was chosen to produce the recombinant rat VEGFs 
as it has been reported to be both simple and reliable, yielding large amounts of the 
recombinant protein and supporting its post-translational modifications. 
3.1.1 Cloning rat VEGFs 
To create biologically active recombinant rat VEGF-C and VEGF-D proteins, parts 
oftheir respective cDNAs encoding the VEGF-homology domain (VHD) were cloned 
into the pAcS.l expression vector (Jnvitrogen) to permit expression ofthe proteins in 
Drosophila S2 cells. The encoded proteins represent the fully processed forms of 
VEGF-C lacking the N- and C-termini that exhibit highest affinity for VEGFR-3 and 
also activate VEGFR-2 (ANAC proteins). Additional constructs, in which point 
mutation converting the codon encoding cysteine 152 ( or cysteine 141, in case of 
VEGF-D) to serine was introduced into the ANACIVEGF-C and ANACIVEGF-D 
constructs to create ANACNEGF-C(Cys152Ser) and ANACNEGF-D(Cys141 Ser), 
respectively, were produced as it has been reported that such a mutation abrogates the 
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ability of the fully processed form of VEGF-C to activate VEGFR-2 (Joukov et al., 
1998). The Ieader sequence of the Drosophila BiP protein was engineered at the N-
terminus of the ßNßC constructs to ensure secretion of the recombinant protein into 
the culture medium. To produce rat recombinant VEGF, a cDNA encoding rat 
VEGF 190 isoform was cloned into the pAc5.1 expression vector, too. All constructs 
contained six consecutive histidine residues at the C-terminus of the protein to permit 
easy detection and purification. The cloning was done in steps that are described 
below (Table 3.1). 
Construct 
pAc5.l/His/VEGF 
pAc5.l /His/VEGF -C 
pAc5 .l/His/VEGF-0 
pAc5.l/His/BiP/.!lN.!lCIVEGF-C 
pAc5.l/His/BiP/.!lN.!lCIVEGF-C(Cys152Ser) 
pAc5.1 /His/BiP/ .!lN.!lCIVEGF -0 
Description 
pAc5.1 encoding rat VEGF 
pAc5.1 encoding full-length rat VEGF-C 
pAc5.1 encoding full-length rat VEGF-0 
pAc5.1 encoding maturerat VEGF-C 
pAc5.l encoding Cys mutant ofmature rat VEGF-C 
pAc5.1 encoding maturerat VEGF-0 
pAc5.1/His/BiP/.!lN.!lCIVEGF-O(Cys141 Ser) pAc5.1 encoding Cys mutant ofmature rat VEGF-0 
Table 3.1 DES constructs used to produce recombinant rat VEGFs. 
3.1.1.1 Cloning rat VEGF-C, VEGF-D and VEGF 
Firstly, the full-length VEGF-C and VEGF-D constructs were made. Tothis end, 
their corresponding cDNAs were amplified by PCR from the commercially available 
rat spieen marathon cDNA (Clontech) using gene-specific oligonucleotide pairs as 
follows: VEGF-C(5'-G CGA ATT CGG ACC GGC CTC CTC GCT CCC-3' and 5'-
G CAC CGG TGT TCA GAT GTG GTC TTT TCC AAT ATG-3'), VEGF-D (5'-GC 
GAA TTC AAA CAA CTG CTT AGC CAT CAG TGG-3' and 5'-GC ACC GGT 
AGG GGA CAG TGA AAA GAC CAT TGA-3 '). The amplified cDNAs therefore 
contained cDNA sequences (underlined) flanked by restriction endonuclease 
consensus sequences (i.e. EcoRI and Agei) allowing their subsequent cloning into 
EcoRI/Agei sites of DES vectors. Thus after restricting the PCR products, VEGF-C 
and VEGF-D were successfully cloned into pAc5.1N5-HisA vector (Invitrogen) as 
shown in Figure 3.1. 
Rat VEGF was cloned in a similar same way (Fig. 3.1) using the following primer 
pair: 5'-GCG AAT TCA ACC ATG AAC TTT CTG CTC TCT TGG-3' and 5'-G 
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CAC CGG TCC GCC TTG GCT TOT CAC ATC TGC-3'. To ensure that VEGF-C, 
VEGF-D and VEGF were cloned in frame with the polyhistidine tag as weil as to rule 
out any possible PCR mistakes, coding regions for the recombinant proteins in the 
resultant constructs (pAc5.1/HisNEGF, pAc5.1/HisNEGF-C and pAc5.1/HisNEGF-
D) were thoroughly sequenced on both strands . 
PCR amplificatlon 
........ 
s•~3' nlcDNA 
EcoRt~Agel EcoRI~Agel EcoRI~Agel 
VEGF VEGF-C VEGF-D 
/ 
ligalion 
Figure 3.1 Cloning rat VEGF-C, VEGF-D and VEGF cDNAs. 
Legend: Ac5, Ac5 promoter; Ampr, ampicillin resistance gene; 6xHis, polyhistidine 
region (see text for details). 
3.1.1.2 Cloning rat &Vt1CIVEGF-C and &Vt1CIVEGF-C(Cysu2Ser) 
To clone t1Nt1CIVEGF-C cDNA into pAc5.1N5-HisA, the pAc5.1/HisNEGF-C 
construct was used. cDNA corresponding to the VHD of VEGF-C was amplified by 
PCR using the following oligonucleotide pairs: 5'-GCGAATTC GAT CTC AAT 
AIQ_A!.\.Q __ IIA.IO.C.ATA.ITA.C.T.Q __ Q_C_C __ QTC._QIQ_QC.C..IIT.QIT.!J_Q_C __ CIC. 
IC.QJ~IC __ QQQ ACC GGT GAC ACT GTA AAA CTT GCT GCT GC-3' and 5'-
CCGGTTTAAAC TCA ATG GTG ATG GTG ATG ATG AAT AAT TGA ATG 
AAC TTG TCT GT A AAC-3'. The resultant PCR product encompassing EcoRI 
restriction site, BiP Drosophila signal sequence ( dot-underlined), Agel restriction site, 
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flN!J.CIVEGF-C (underlined), His-tag-coding sequence and Pmel restriction site was 
subsequently cloned into EcoRIIPmel site ofthe pAc5.1N5-HisA vector as described 
in Figure 3.2. The final construct was called pAc5.1/His/BiP/ßNßCNEGF-C. 
Recombinant PCR technique was then utilised to introduce the point mutation (i.e. 
change of Cys152 to a Ser) into the ßNßCNEGF-C polypeptide (Fig. 3.2). In the first 
step, PCR fragments were obtained in two independent reactions using the 
pAc5.1/His/BiP/ßNßCNEGF-C construct and the following primer pairs: reaction I 
(50-merl (5'-C ACA AAC ACC TTC TTT AAA CCT CCA AGC GTG TCC GTC 
TAC AGA TGT GGG G-3') and 29-mer (5'-CCG GTT AAA CTC AAT GGT GAT 
GGT GAT G-3')); reaction II (50-mer2 (5'-C CCC ACA TCT GTA GAC GGA 
CAC GCT TGG AGG TTT AAA GAA GGT GTT TGT G-3') and 22-mer (5'-GGG 
ACC GGT GAC ACT GTA AAA C-3')), the target point mutation is underlined. In 
the second step, the resultant PCR fragments were combined in another PCR to 
obtain, with the use of the 22-mer and 29-mer oligonucleotides, the final product 
containing the mutated !J.N!J.CIVEGF-C gene. PCR product of the latter reaction 
containing !J.N!J.C/VEGF-C(Cys152Ser) gene sequence was digested with Agel and 
Pmel and sub-cloned in place of !J.N!J.C/VEGF-C into pAc5.1/His/BiP/ßNßCNEGF-
C. The final construct was thereafter called pAc5.1/His/BiP/ßNßCNEGF-
C(Cys152Ser). 
To ensure that !J.N!J.C/VEGF-C as well as !J.N!J.CIVEGF-C(CysJs2Ser) were cloned 
in frame with the polyhistidine tag as well as to identify any PCR mistakes, the 
corresponding tlN!J.C/VEGF-C and !J.N!J.CIVEGF-C(CysJs2Ser) regions were 
sequenced. 
3.1.1.3 Cloning rat !J.N!J.C/VEGF-D and !J.N!J.CIVEGF-D(Cysu1Ser) 
To clone !J.N!J.C/VEGF-D cDNA into the DES vector, the pAc5.1/His/VEGF-D 
construct was used. Using the VEGF-D gene sequence as a template, !J.N!J.CIVEGF-D 
was amplified by PCR using the following oligonucleotide pairs: 5'-GCACCGGT 
ACC AGA TTT GCG GCA ACT TTC TAT G-3' and 5'-CCGGTTTAAAC TCA 
ATG GTG ATG GTG ATG ATG GAT AAT TGA ATA AGG ATG CCG GGG-3'. 
The resultant PCR product containing Agel restriction site, !J.N!J.CIVEGF-D 
(underlined), His-tag-coding sequence and Pmel restriction site was subsequently 
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cloned in place of Agei-AN.ACIVEGF-C-Pmei into pAc5.1/BiP/L\NL\CNEGF-C. The 
final construct was thereafter called pAc5.11His/BiP/L\NL\CNEGF-D. 
, 
~~· 
EcoRJ Agel 
J PCR amp/ification 
/ Agel EcdU~Pmel BIP-t:.NACIVEGF-C-His 
+ 
restriction and Iiga/ion 
/ 
Agel 
t:=:J.-Pme! 
t:.NACIVEGF-C-His 
pAcS.l/His/BiP/ANACIVEGF-C 
J recombinant PCR 
Cy•ts~• 
Age!---cr::J--PmeJ 
t:.NACIVEGF-C(Cys J s]Setj-His 
+ restriction and Iiga/ion 
pA~S.I/His/BiP/ANACIVEGF-C 
pA~S.I/His/BiP/ANACIVEGF-C(CysJslSer) 
Figure 3.2 Cloning rat MVL\CIVEGF-C and MVL\C/VEGF-C(CysJs2Ser) cDNAs. 
Legend: Ac5, Ac5 promoter; Ampr, ampicillin resistance gene; 6xHis, polyhistidine 
region (see text for details). 
Recombinant PCR technique was also employed to introduce the point mutation 
into the L\NL\CNEGF-D polypeptide. Firstly, PCR fragments were obtained using 
pAc5.11His/BiP/L\NL\CNEGF-D and the following primer pairs:pair I (49-merl, 5'-
CC AAC ACA TTT TTC AAG CCC CCT AGC GTA AAT GTC TTC CGG TOT 
GGA GG-3' and 29-mer, 5'-CCG GTT AAA CTC AAT GGT GAT GGT GAT G-
3'),pair //(49-mer2, 5'-CC TCC ACA CCG GAA GAC ATT TAC GCT AGG GGG 
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CTT GAA AAA TGT GTT GG-3' and 21-mer, 5'-GGG ACC GGT ACC AGA TTT 
GCG-3 '), the target point mutation is underlined. Secondly, they were combined in 
another PCR to produce, with the use ofthe 29-mer and 21-mer oligonucleotides, the 
final product containing the mutated triplet. The resulting PCR fragment containing 
L1Nß.C/VEGF-D!Cys141Ser-specific sequence was digested with Agel and Pmel and 
sub-cloned in place of ß.Nß.CIVEGF-D into pAc5.1/His/BiP/t:lNt:lCNEGF-D. The 
final construct was called pAc5.1/His/BiP/t:lNt:lCNEGF-D(Cys141Ser). The 
L1Nß.C/VEGF-D and L1Nß.CIVEGF-D(CyswSer)-specific cDNA regions were 
sequenced. 
J PCR amp/ijicalion 
Agei~Pmei 
t>NtlC/VEGF-D-His / 
O
EcoRJ Agei I 
AcS 
Amp1 
pAcS.VHiiiBIP/ANACNEGF-D 
~ "'cambinant PCR 
restriet/an and ligation 
CJ•I4ller 
Agei--a:J-Pmel 
+ / 
O
EcoRI Agei p ei 
At5 
Amp• 
pAc5.1/HilllliP/ANACNEGF-C 
, 
",· 
Agei'C:J' Pmel 
t>NACIVEGF-C-His 
t>NACIVEGF-C(Cys 141Ser)-His 
+ "''lriction and /igallon 
O
EcoRlAgei 
Ac 
Amp• 
. 
Jtf' pAcS.I/HilllliP/ANACNEGF-D 
Agel 1 
I=I'Pmel f 
t>NACIVEGF-D-His 
O
EcoRl Agel I 
AcS 
Amp'" 
pAtS.I/HilllliP/ANACNEGF-C(Cysl41Ser) 
Figure 3.3 Cloning rat LlN!l.CIVEGF-D and LlNilCIVEGF-D(Cys141Ser) cDNAs. 
Legend: Ac5, Ac5 promoter; Ampr, ampicillin resistance gene; 6xHis, polyhistidine 
region (see text for details). 
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3.1.2 Expression and purification of recombinant VEGFs 
Drosophila S2 cells were transfected with the expression constructs shown in 
Table 3.1 along with the selection plasmid pHYGRO (Invitrogen) in order to create 
stable transfectants secreting large amounts of the recombinant growth factors. Mass 
cultures of the stably transfected S2 cells were subsequently analysed for the presence 
of the secreted recombinant proteins in their medium supematant by use of anti-His-
tag antiborlies (Fig. 3.4). The analysis showed that the recombinant rat VEGF, 
ßNßCNEGF-C and ßNßCNEGF-D proteins migrated as bands of approximately 19 
kDa, 13 kDa, and 13kDa, respectively. These molecular weights approximately 
correspond to the ones predicted on the basis of the primary protein structure. The 
presence of the lower molecular weight band in some ßN ßC/VEGF -C and 
NßCNEGF-C(Cys152Ser) samples can be attributed to the alternative signal peptide 
cleavage site found 10 aminoacids downstream of the standard cleavage site in the 
ßNßC sequence of VEGF-C (Kirkin et al., submitted). A signi ficant proportion of 
the proteins, when analysed on a non-reducing SDS-PAGE, was found to be present 
as covalent dimers (Fig. 3.4). 
The recombinant proteins were purified on a large scale using Ni-NT A agarose 
matrix (Quiagen). The typical yield of a purified recombinant proteinwas between 5-
20 mg per litre culture medium. The identity of the recombinant proteins was 
confirrned using both anti-His-tag and specific anti-VEGF-C and VEGF -D antiborlies 
on westem blots (Fig. 3.5). 
3.2 Characterisation of recombinant rat VEGF profeins 
The cloned rat VEGFs are fusion proteins that were expressed in a heterologous 
non-mammalian system and therefore may differ from the naturally occurring 
proteins. In order to determine whether the biological activity of the recombinant rat 
proteins was comparable to analogous preparations described in the literature, a 
number of experiments were performed. 
3.2.1 Activation of VEGF receptors 
Once the homodimeric VEGFs bound their specific receptor(s), they should in turn 
be able to cause receptor dimerisation. Dimerised VEGFRs can then 
transphosphorylate their tyrosine residues becoming competent to transduce the signal 
to other downstream cellular effectors (Petrova et al., 1999). Consequently, the ability 
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Figure 3.4 Detection of the His-tagged recombinant VEGFs in the S2-
transfectant medium supernatants. Conditioned medium from the indicated S2 
transfectants expressing the vectors shown in Table 3.1 was incubated with 
Strataclean resin. Resin pellets were then boiled and resolved on a 12% SOS-
PAGE (under either non-reducing or reducing conditions) followed by western 
blotting. The blot was probed with anti-His-tag antibody. 
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Figure 3.5 Identity and purity of the purified recombinant VEGFs. Purified pro-
teins (5 !Jg) were resolved on a reducing 12% SOS-PAGE and subsequently 
analysed by silver staining and western blots probed with either anti-His or spe-
cific (anti-VEGF-C and anti-VEGF-0) antibodies. 
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to demoostrate the induction of phosphorylation of the corresponding receptor 
tyrosine kinase by the recombinant growth factor can serve as a proof for the eventual 
biological activity of the recombinant protein. To this end, a series of cellular 
phosphory lation experiments were performed. 
3.2.1.1 VEGF, MlßCIVEGF-C and MlßCIVEGF-D conditioned medium 
Firstly, the ability of conditioned medium from the stable S2 transfectants to 
induce phosphorylation of VEGF receptors was assessed using porcine aortic 
endothelial cells (PAE) cells expressing either VEGFR-2 (P AENEGFR-2, Kroll and 
Waltenberger, 1997) or VEGFR-3 (PAE/VEGFR-3). To produce PAENEGFR-3, 
PAE cells were transfected with a vector encoding a murine form of VEGFR-3 (a 
kind gift of Dr. Krishnan) and stably transfected cell lines were established as 
described in Materials and Methods. 
In the cellular VEGFR phosphorylation assays, PAENEGFR-2 and PAENEGFR-
3 cells were incubated with 3-day-conditioned medium taken from either S2 
transfectants expressing recombinant rat VEGF, ßNßCNEGF-C, and ßNßCNEGF-
D, respectively, or from non-transfected cells. Following the short period ofinduction, 
the cells were lysed, and the VEGFRs were immunoprecipitated to be analysed on 
reducing SDS-PAGE for the amount of receptor phosphorylation. As shown in Figure 
3.6, the conditioned medium from either rat L\N'ßCNEGF-C- or äNäCNEGF-D-
expressing S2 cells (/anes 5 and 7, respectively) was able to induce phosphorylation 
of both VEGFR-2 and VEGFR-3, whereas VEGF-conditioned medium was able to 
induce VEGFR-2 but not VEGFR-3 phosphorylation (lane 4). Conditioned medium 
of non-transfected S2 cells was not able to induce phosphorylation of either receptor 
(lane 3). These results suggest that recombinant rat VEGFs, similar to their published 
human analogues, can specifically bind to and activate their cognate VEGF receptors. 
3.2.1.2 MißCIVEGF-C(CysJs2Ser) and M//).C/VEGF-D(Cysi,11Ser) conditioned 
medium 
In parallel, it was important to answer the question whether the specific cysteine 
mutations in the mature VEGF-C and VEGF-D proteins do abrogate their VEGFR-2-
binding ability, similarly to the described human VEGF-C mutant (Joukov et al., 
1998). Therefore, PAENEGFR-2 and PAENEGFR-3 cells were incubated with 
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Figure 3.6 Activation of VEGFR-2 and VEGFR-3 by conditioned medium of S2 
cel/s expressing recombinant rat VEGFs. PAE-VEGFR-3 (A) and PAE-VEGFR-2 
(B) cells were stimulated with conditioned medium containing different recombi-
nant VEGFs. VEGF receptors were immunoprecipitated from the cellular lysates, 
resolved on a reducing 6% SOS-PAGE, blotted and probed with anti-
phosphotyrosine (anti-PY) antibody. Stripperl membranes re-probed with anti-
receptor antiborlies were used as a loading control. Lanes: 1. serum-free F-12 
growth medium (negative control); 2. murine VEGF-C (A) or VEGF (B) (positive 
control); 3 non-transfected S2 cells; 4. rat VEGF; 5. rat AN<LYVEGF-C 6. rat 
ANAC/VEGF-C(Cys152Ser); 7. rat ANAC/VEGF-D; 8. rat ANAC/VEGF-
D(Cys141 Ser). 
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conditioned medium from S2 cells expressing the VEGF-C and -D mutants and 
analysed for increased receptor phosphorylation as before. Figure 3.6 illustrates the 
outcome of this experiment. Conditioned medium of ßNßCNEGF-C(Cys152Ser) 
transfectants could only induce VEGFR-3 but not VEGFR-2 phosphorylation (/ane 
6), whereas ßN'ßCNEGF-D(Cysi41Ser)-containing conditioned medium was void of 
any VEGFR activity (lane 8). These data suggest that while the rat Cys152Ser mutant 
has similar properties to the described human ßNßCNEGF-C(Cysts6Ser), a similar 
mutation in rat ßNßCNEGF-D protein destroys the ability to bind any of the studied 
VEGF-D receptors. 
3.2.1.3 Purijied recomhinant rat VEGF proteins 
To prove that the recombinant growth factors in the conditioned medium really 
were responsible for the induced receptor phosphorylation observed in previous 
experiments, I investigated whether VEGFR-2 and VEGFR-3 activation can be 
reproduced with recombinant His-tagged proteins purified from conditioned medium 
via a Ni-NTA agarose column. As shown in Figure 3.7, treatment ofPAENEGFR-2 
and PAENEGFR-3 cells with serum-free F-12 growth medium containing 50 ng/ml 
rat VEGF (/ane 3) or 200 ng/ml ßNßCNEGF-C (/ane 4) had similar effect as the 
corresponding conditioned medium. However, unlike the ßNßC/VEGF-D 
conditioned medium, the purified ßNßCNEGF-D protein, when dissolved in serum-
free F-12 growth medium, failed to induce phosphorylation of its receptors (/ane 6) 
suggesting loss of activity upon purification. The purified ßNßCNEGF-C(Cys152Ser) 
mutant preserved its specific VEGFR-3 activating property (lane 5). These data 
suggest that recombinant VEGF-C in conditioned medium from S2 transfectants is the 
specific activator of VEGFR-2 and VEGFR-3. In the case of ßNßCNEGF-D, 
although purified protein was not biologically active, clearly the conditioned medium 
contained active VEGF-D. Thus, for both VEGF-C and VEGF-D, conditioned 
medium was predominantly used in subsequent experiments for convenience. 
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Figure 3.7 Activation of VEGFR-2 and VEGFR-3 by purified recombinant rat 
VEGFs. PAENEGFR-3 (A) and PAENEGFR-2 (B) cells were stimulated with 
either purified recombinant rat VEGFs re-suspended in F-12 growth medium or 
conditioned medium from 293 transfectants expressing murine VEGFs (positive 
control). VEGF receptors were immunoprecipitated from the cellular lysates, 
resolved on a reducing 6% SOS-PAGE, blotted and probed with anti-
phosphotyrosine (anti-PY) antibody. Stripperl membranes re-probed with anti-
receptor antiborlies were used as a loading control. Lanes: 1. serum-free F12-
growth medium (negative control); 2. murine VEGF-C (A) or VEGF (B) (positive 
control); 3. rat VEGF (50 ng/ml); 4. rat ANAC/VEGF-C (200 ng/ml); 5. rat 
ANACNEGF-C(Cys152Ser (200 ng/ml); 6. rat ANACNEGF-D (200 ng/ml); 7. 
rat ANACNEGF-D(Cys141 Ser) (200 ng/ml). 
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3.2.2 Stimulation of vascular endothelial cell proliferation 
One of the important consequences of VEGF signals is the induction of cellular 
proliferation. Human dermal microvascular cells (HDMEC) are primary endothelial 
cells that were used to check the ability of recombinant rat VEGFs to stimulate their 
proliferation. A proliferation assay based on measuring incorporation of eH)-Iabelied 
thymidine into DNA in the course of DNA replication was used for this purpose. 
Figure 3.8 shows that HDMECs incubated for 24 hours with culture medium 
containing increasing concentrations of purified rat ßNßCNEGF -C exhibited a 
consistent increase in proliferation, as was reflected by higher amounts of 
incorporated radioactivity. Consistent with published data (Joukov et a/., 1997), 
recombinant VEGF was 20-to 30-fold more active as compared to L\NACNEGF-C. 
Also, the ANACNEGF-C(Cys1s2Ser) mutant was only weakly active, as was 
described for the human VEGF-C mutant (Joukov et al., 1998). Due to inactivity of 
the purified VEGF-D proteins in the cellular phosphorylation assay, their ability to 
induce HDMEC proliferation was not studied. The results of this experiment suggest 
that the purified recombinant rat VEGFs are biologically active. 
3.3 Establishment of rat lymphatic endothelium (LE) in culture 
The ability to maintain LE in culture would provide a powerful tool for screening 
anti-lymphangiogenic substances in vitro. It would also permit the study of 
interactions between tumour cells and LE in vitro as weil as to measure the effects of 
anti-lymphangiogenic substances on tumour-induced lymphangiogenesis. 
Unfortunately, whilst there are several blood vascular endothelial cell culture methods 
available, as yet there has not been a single report on the generation of LE cells from 
peripheral tissues in vitro. The biological activity of the recombinant rat VEGF-C 
protein demonstrates that it should be able to induce lymphangiogenesis and LE 
proliferation. I therefore attempted to utilise the lymphangiogenic properties of the 
recombinant rat ßNßCNEGF-C and the VEGFR-3-specific mutant ßNßCNEGF-
C(Cys152Ser) to establish LE in culture. Another strategy was followed in parallel, 
where adjuvant-induced lymphangiomas were used as a source for LE. 
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Figure 3.8 Stimulation of HDMEC proliferation by recombinant rat VEGFs. 
Starved HDMEC were stimulated for 24 hours with increasing concentrations of 
the indicated recombinant VEGFs. A pulse of tritium was given to the cells for the 
last 4-6 hours of the stimulation after which the cells were harvested and the 
amount of incorporated radioactivity was measured. Data are expressed as percent 
of non-stimulated cell proliferation (% of control). 
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3.3.1 Use of recombinant L\NL\CNEGF-C in vivo 
VEGF-C and VEGF-D are the only lymphangiogenic proteins described to date 
(Jeltsch et al., 1997; Oh et a/., 1997; Veikkola et a/., 2001). The recombinant rat 
L\NL\CNEGF-C and 8N8CNEGF-C(Cys152Ser) proteins, which were shown tobe 
biologically active in vitro, were therefore used in an attempt to obtain lymphatic 
endothelial cells in culture. Matrigel, a soluble basement membrane extract of the 
EHS (Engelbreth-Holm-Swarm) sarcoma, containing different concentrations of the 
recombinant L\NL\C/VEGF-C and 8N8C/VEGF-C(Cys, 52Ser) was injected 
subcutaneously into the back of rats. Matrigel containing recombinant rat VEGF was 
also injected for controlling purposes. It was anticipated that the entrapped lymphatic 
endothelial growth factor would diffuse into the surrounding tissue, induce 
lymphangiogenesis and later permit the extraction of the LE into culture, as shown in 
Figure 3.9. 
.. 
1 2 3 
Figure 3.9 Use ofrecombinant MVL\CIVEGF-C and llNL\C/VEGF-C(CysJ52Ser) to 
estab/ish LE in culture. Recombinant proteins are entrapped within an inert support, 
for instance matrigel. The support is then implanted subcutaneously into the back of 
an experimental animal (I). The entrapped growth factors diffuse into the surrounding 
tissue, inducing lymphangiogenesis (2). The support containing newly formed 
lymphatic vessels is extracted and used to obtain the LE in culture. The cells, which 
have grown into the support and in tissue culture, are analysed for the expression of 
LE-specific markerssuch as VEGFR-3. 
Two weeks after the matrigel injection, the matrigel plugs were extracted, fixed, 
cut into sections and subsequently analysed for the presence of new vessel-like 
structures within the gels. Masson's trichrome staining that allows unambiguous 
discrimination of vessel structures from the surrounding matrix (Grant et al., 1993) 
was employed to detect any newly grown vessels and VEGFR-3-specific anti-serum 
was used to detect any putative lymphatic capillaries within or in the proximity of the 
matrigel plugs. It was observed that none of the recombinant growth factors 
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specifically induced lymphangiogenesis or angiogenesis in vivo ( data not shown). 
Several attempts were made with different batches of the purified recombinant 
proteins but none of them succeeded. Intriguingly, during these experiments it was 
noted that about 14 days after subcutaneous injection of matrigel containing no 
growth factors, vacuoles formed which were lined with cells (Fig. 3.10). These cells 
stained positively for VEGFR-3 (Fig. 3.10, C and D), suggesting their possible 
lymphatic endothelial origin. Cells were extracted from such matrigel plugs and put 
into culture. However, such cultures were heavily overgrown with fibroblast-like 
cells, which did not allow further characterisation of the cells. 
3.3.2 Use of adjuvant-induced lymphangiomas 
It has recently been published that the intraperitoneal injection of incomplete 
Freund's adjuvant in mice results in the appearance of lymphangiomas on the surface 
of the diaphragm and the liver (Mancardi et al., 1999). The lymphangiomas were 
positive for VEGFR-3 and cells derived from the tumours expressed endothelial cell-
specific markers. In order to fmd out whether such lymphangiomas can be induced in 
rats and whether it is possible to use them as a source of LE cells, the published 
experiment was repeated in rats. As described for mice, white tumours were found on 
the surface of the liver and the diaphragm in all the rats that received the adjuvant 
(Fig. 3.lla). Tumours were extracted and analysed by immunohistochemistry. They 
were found to contain VEGFR-3 (Fig. 3.11b) and CD31 (endothelial cell marker, data 
not shown) positive cells. The lymphangioma cells were extracted and put into 
culture. However, when cultured they could not be propagated for more than few 
passages (Fig. 3.11c and d) after which they apparently became senescent as 
indicated by loss of proliferation and gross changes in cellular morphology ( data not 
shown). It seems therefore that in order to grow in vitro cells derived by either 
method, the LE cells would need to be immortalised. Due to time constraints, this 
aspect of the work had to be discontinued. 
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Figure 3.10 Appearance of growth factor-free matrigel 14 days post-
implantation. Sections A (low magnification) and B (higher 
magnification), stained with Masson's trichrome, show the appearance of 
the vacuoles inside the matrigel. Sections C and D demonstrate VEGFR-3 
positive staining of the vacuoles with VEGFR-3-specific rabbit polyclonal 
antiserum. Sections E and F (secondary antibody control) are given for 
comparison. 
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Figure 3.11 Adjuvant-induced lymphangioma and lymphangioma-
derived cells. White tumour masses were observed on the surface of 
the diaphragm and the liver in 100% of animals. Panel A shows H&E 
staining of a paraffin section of the well-defined lymphangioma rest-
ing on the surface of the liver. Panel B shows a frozen section of the 
lymphangioma stained with anti-VEGFR-3 rabbit polyclonal serum. 
Panels C-D demoostrate the cells derived from the adjuvant-induced 
lymphangioma (C: a 12-hour-old primary cell colony, phase-contrast 
microscopy; D: a 7-day-old cells, phase-contrast microscopy). 
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PART II 
Selection and characterisation of anti-tumour substances 
with anti-angiogenic and/or anti-lymphangiogenic properfies 
Inappropriate RTK signaHing is implicated in a variety of pathological conditions 
such as tumour growth and tumour-induced angiogenesis and lymphangiogenesis 
(Saaristo et al., 2000). Compounds that mirnie ATP structure such as those based on 
an oxindole core called indolinones have been shown to inhibit activity of a number 
ofRTKs such as those implicated in angiogenesis (Sun et al., 1998; Sun et al., 1999; 
Mendel et al., 2000; Sun et al., 2000). Structure vs. activity analysis for these 
compounds demonstrated that the oxindole occupies the kinase site that binds the 
adenine of ATP. In contrast, the moieties that extend from the oxindole core interact 
with residues in the hinge region between the kinase Iobes, thereby determining the 
selectivity and affmity for the individual receptor (Mohammadi et al., 1997). This 
principle can be employed to develop indolinones with the ability to inhibit a range of 
RTKs involved in different aspects oftumour progression. 
As a step in this direction, a panel of potential kinase-inhibiting indolinones 
synthesised by the group ofProfessor Dr. Athanassios Giannis, Institut fiir Organische 
Chemie, Karlsruhe University, using chemical synthesis (Fig. 3.12) was screened for 
their potential to inhibit VEGFRs and other tumour-related RTKs. The potential 
VEGFR inhibitors were subjected to further selection using the cellular system I 
established (see Part I), in which activation of VEGFR family members and its 
inhibition can be studied. The most potent inhibitors of VEGFR-2 and VEGFR-3 
were also tested for their direct anti-tumour effect. These indolinones were ultimately 
used to inhibit tumour growth in vivo. 
Hyperforin is another candidate anti-cancer drug with possible direct anti-tumour 
and anti-angiogenic properties. Besides being an effective anti-depressant, it 
possesses potent anti-proliferative properties (Schempp et al., 1999 and 2000) and 
therefore may target tumour and proliferating endothelial cells. The anti-tumour effect 
of hyperforin was therefore explored. 
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Figure 3.12 Principle of 3-substituted indolin-2-one (indolinone) synthesis. 
Legend: i. piperidine/ethanol/reflux/5 hrs; R1. indoline-2-one; R2. target 
substitution group (takenfrom Sun et al., 1998). 
3.4 Selection of indolinones inhibiting activation of tumour-related RTKs 
In order to select the most useful compounds from the panel of synthesised 
indolinones, a screening procedure was developed. First, the substances were assessed 
for their ability to inhibit substrate phosphorylation catalysed by recombinant GST-
fusion receptor tyrosine kinases in vitro; and second, they were checked for their 
ability to block activation of VEGFRs in my established cellular system where they 
are present in their natural conformation. 
3.4.1 Primary screening of indolinones for their inhibitory activity 
In order to screen the panel ofindolinones for their potential as RTK inhibitors, an 
in vitro tyrosine kinase assay was established, which had previously been described to 
be a valuable tool for the crude selection of other RTK inhibitors (Laird et al., 2000). 
In this assay, indolinanes were added at 2 concentrations (i. e. 1 Jlg/ml and 10 Jlg/ml) 
to in vitro substrate phosphorylation reactions catalysed by recombinant GST fusion 
kinases containing only the catalytic domain of the respective kinases (purchased 
from KTB Tumorforschungs GmbH, Freiburg). The amount of the subsequent 
substrate phosphorylation was then measured by use of anti-phosphotyrosine 
antibodies and secondary antibodies linked to the horse radish peroxydase. The 
amount of the chromogenic substrate hydrolysed by the latter enzyme, as assessed 
with a spectrophotometer, directly correlates with the amount of substrate 
phosphorylation catalysed by the GST fusion kinase. 
In the screen, 32 indolinanes were tested for their ability to inhibit the substrate 
phosphorylation catalysed by six different tyrosine kinases. The chosen recombinant 
GST fusion proteins constitute analogues of some cellular RTKs that have been 
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implicated in angiogenesis (VEGFR-2, Tie-2), lymphangiogenesis (VEGFR-3) and 
tumorigenesis (EGFR, ErbB2, and IGFRI; Eccles, 2000; Wells, I999; Happerfield et 
al., I997). As shown in Figures 3.13 - 3.18 and summarised in Table 3.2, at I 0 J.t.g/ml 
many of the indolinones could inhibit one or more tyrosine kinases by more than 
50%. However, because the primary goal of the screening was the identification of 
preferential inhibitors of VEGFR family members, the I5 compounds that at I 0 J.t.g/ml 
showed inhibition of either VEGFR-2 or VEGFR-3 (or both) by more than 50% 
(asterisk, Table 3.2) were selected for further studies. 
No Name VEGFR-3 VEGFR-2 Tie2 EGFR ErbB2 IGFRl 
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Table 3.2 Inhibitory action of 32 indolinanes on different recombinant GST-receptor 
tyrosine kinases. Data are expressed as percent of control (1st value: 1 J.Lg/ml; 2nd 
value: 10 J.Lg/ml); shaded cells indicate the inhibition of 50% or higher; the 
compounds showing inhibition of at least one VEGFR by more than 50% are marked 
with an asterisk. 
3.4.2 Screening of indolinones for inhibition of cellular VEGFR activity 
In the next step, it was necessary to determine whether the indolinones selected on 
the basis of the in vitro kinase assay could also inhibit VEGFR phosphorylation in a 
cell-based assay. PAE celllines transfected with VEGFR-1, VEGFR-2 or VEGFR-3 
were used for this purpose. 
3.4.2.1 Cellular VEGFR-3 phosphorylation assay 
a) Inhibition o[VEGF-C-mediated VEGFR-3 activation 
Stimulation of PAENEGFR-3 cells with VEGF-C conditioned medium induced 
tyrosine phosphorylation of VEGFR-3 (see Part 1). Using this system, the 9 
indolinones which inhibited GST-VEGFR-3 phosphorylation, were further screened 
for their ability to inhibit VEGFR-3 phosphorylation in PAE cells. PAENEGFR-3 
cells were stimulated with VEGF-C conditioned medium in the presence ofincreasing 
concentrations of the test indolinones. Cells stimulated without inhibitors were used a 
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Figure 3.14 Inhibition of GST-VEGFR-2 activity by indolinones. In vitro substrate phosphorylation reactions catalysed by recombi-
nant GST-VEGFR-2 kinase were performed in the presence of lf.lg/ml or 10 f.lg/ml indicated indolinones and 5% DMSO. The 
amount of substrate phosphorylation was measured using a colorimetric assay. Data areexpressedas % of substrate phosphorylation 
in the presence of 5% DMSO only (% of control). 
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amount of substrate phosphorylation was measured using a colorimetric assay. Data are expressed as % of substrate phos-
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Figure 3.17 Inhibition ofGST-ErbB2 activity by indolinones. In vitro substrate phosphorylation reactions catalysed by recom-
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amount of substrate phosphorylation was measured using a colorimetric assay. Data areexpressedas% of substrate phospho-
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Figure 3.18 Inhibition of GST-IGFR-1 activity by indolinones. In vitro substrate phosphorylation reactions catalysed by 
recombinant GST-IGFR-1 kinase were performed in the presence of 1Jlg/ml or 10 Jlg/ml indicated indolinones and 5% 
DMSO. The amount of substrate phosphorylation was measured using a colorimetric assay. Data areexpressedas% of sub-
strate phosphorylation in the presence of 5% DMSO only (% of control). 
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positive control. As shown in Figure 3.19, only some ofthe tested indolinanes could 
exert their inhibitory action in such a cellular assay. Among those that inhibited 
VEGFR-3 phosphorylation in a dose-dependent manner were AE87 (blocked 
VEGFR-3 phosphorylation at 50 11M), AE106 (at 5 11M), MAZ51. (at 5 11M) and 
MAZ51-2 (at 5 11M). 
b) Inhibition o(VEGF-D-mediated VEGFR-3 activation 
AE87, AE106, MAZ51 and MAZ51-2 could block VEGFR-3 activation in PAE 
cells stimulated with VEGF-C conditioned medium. To verify that this inhibition is 
receptor-specific and independent of the Iigand, the same experiment was repeated 
using VEGF-D conditioned medium. Figure 3.20 demonstrates that the inhibitory 
effect of AE87, AE106, MAZ51 and MAZ51-2 on VEGFR-3 phosphorylation is 
equal irrespective of whether VEGFR-3 is activated by VEGF-D (Fig. 3.20, B) or by 
VEGF-C (Fig. 3.20, A). 
3.4.2.2 Ce/lu/ar VEGFR-2 phosphorylation assay 
PAENEGFR-2 cells were used to check whether the 15 inhibitors of VEGFR-2 
picked by the in vitro kirrase assay could also block VEGFR-2 phosphorylation in 
PAE cells stimulated with VEGF conditioned medium. As before, PAENEGFR-2 
cells were stimulated with VEGF conditioned medium in the presence of increasing 
concentrations of the test indolinones. Cells stimulated without inhibitors were used a 
positive control. 
The experiment clearly demonstrated that only few of the indolinanes (namely, 
MAZ51 and MAZ51-2) could significantly inhibit VEGFR-2 phosphorylation in the 
cellular context (Fig. 3.21). Interestingly, in comparison to the PAENEGFR-3 
system, the inhibition ofVEGFR-2 phosphorylation by MAZ51 and MAZ51-2 could 
only be achieved at a relatively high concentration (50 11M). Even at 50 11M AE87 and 
AE106 could inhibit VEGFR-2 phosphorylation only partially. These findings suggest 
that AE106, MAZ51 and MAZ51-2 act as inhibitors that may specifically block 
VEGFR-3 and not VEGFR-2 at the concentrations tested. Additionally, MAZ51 and 
MAZ51-2 seem tobe the mostpotent inhibitors ofthe screened array ofindolinones. 
94 
AE87 AEI06 Hll Hl2 
Compound (JJM) I o.s 5 50 I 0.5 5 50 I o.s 5 50 I 0.5 5 50 I 
VEGF -C - + + + + + + + + + + + + + 
anti-PY 
••••• 
·-·---· 
.-' ·'' . . . . - ', --
-~.~~==~~,,i ~~,~ ~.·~·=-·-=·t:~ 
- =~ _- --=:Sc~-
...... ,, •. ~;~~~---~~~~: anti-VEGFR-3 
Hl3 MAZ49 MAZSI-2 MAZ60-2 
lo.s s solo.s s so I o.s 5 50 I o.s s so I 
"'!"·-----::: 
-~'=c-,;-.- ~ -~-~ ~';...,_. --_ -...... "·_-"-' -::=-;-~~- -...... _'4.. -----'-"-- .-";·' ._ ·=-, 
anti-VEGFR-3 
-·-····-···"··-a.· ___ - '• . - :_ ,__;.·_,. - -- . 
MAZ51 
Compound (pM) I 0.5 5 50 I 
VEGF-C - + + + + 
anti-PY 
anti-VEGFR-3 
Figure 3.19 Inhibition of cellular VEGFR-3 phosphorylation by 
indolinones. PAENEGFR-3 cells were stimulated with VEGF-C condi-
tioned medium in the presence of increasing concentrations of the indicat-
ed indolinones. VEGFR-3 receptors were immunoprecipitated from the 
cell lysates, resolved on a reducing 6% SDS-PAGE, blotted and probed 
with anti-phosphotyrosine (anti-PY) antibody. Stripperl membranes re-
probed with anti-receptor antibody were used as a loading control. 
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Figure 3.20 Inhibition ofVEGF-C- anti VEGF-D-mediated VEGFR-3 phospho-
rylation by AE87, AE106, MAZ51 anti MAZ51-2. PAE-VEGFR-3 cells were stim-
ulated with VEGF-C (A) or VEGF-D (B) conditioned medium in the presence of 
the indicated concentrations of the indolinones. VEGFR-3 receptors were 
immunoprecipitated from the celllysates, resolved on a reducing 6% SDS-PAGE, 
blotted and probed with anti-phosphotyrosine (anti-PY) antibody. Stripped mem-
branes re-probed with anti-receptor antiborlies were used as a loading control. 
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Figure 3.21 Inhibition of cellular VEGFR-2 phosphorylation by indolinones. 
PAENEGFR-2 cells were stimulaterl with VEGF conrlitionerl medium in the pres-
ence of increasing concentrations of the inrlicaterl inrlolinones. VEGFR-2 recep-
tors were immunoprecipitaterl from the cell lysates, resolverl on a rerlucing 6% 
SOS-PAGE, blotterl anrl proberl with anti-phosphotyrosine antiborly (anti-PY). 
Stripperl membranes re-proberl with anti-receptor antiborlies were userl as loarling 
control. 
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Figure 3.22 Effect of AE87, AE106, MAZ51 and MAZ51-2 on phosphorylation 
of cellular VEGFR-1. PAE-VEGFR-1 cells were stimulated with VEGF condi-
tioned medium in the presence of increasing concentrations of the indolinones. 
VEGFR-1 receptors were immunoprecipitated from the cell lysates, resolved on 
a reducing 6% SOS-PAGE, blotted and probed with anti-phosphotyrosine (anti-
PY) antibody. Stripperl membranes re-probed with anti-receptor antiborlies were 
used as a loading control. 
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3.4.2.3 Cellular VEGFR-1 phosphorylation assay 
It is apparent that 4 of the indolinanes analysed in the cellular assays differentially 
block VEGFR-2 and VEGFR-3 activation. VEGFR-1 isanother member ofVEGFR 
family known to play an important role in angiogenesis (Fong et a/., 1995). The 
possible inhibitory effect of the 4 most potent indolinanes on the activation of 
VEGFR-1 was therefore tested using PAE cells expressing VEGFR-1 (PAENEGFR-
1, Kroll and Waltenberger, 1997). Similar to the previous experiments, PAENEGFR-
1 cells were stimulated with the VEGFR-1 Iigand VEGF in the presence of three 
different concentrations of AE87, AE106, MAZ51 and MAZ51-2. As shown in 
Figure 3.22, AE106, MAZ51 and MAZ51-2 inhibited VEGFR-1 phosphorylation 
even at a 5-f..lM concentration. In contrast, AE87 seems to stimulate phosphorylation 
of VEGFR-1 in a dose-dependent manner. The data suggest that at similar 
concentrations AE106, MAZ51 and MAZ51-2 are capable of inhibiting VEGFR-1 
and VEGFR-3 phosphorylation, but inhibit VEGFR-2 phosphorylation less potently. 
In contrast, AE87 is a weak inhibitor of VEGFR-3, which is able to stimulate 
VEGFR-1 phosphorylation. 
3.5 Characterisation ofthe effect of AE87, AE106, MAZ51 and MAZ51-2 
on angiogenesis. lymphangiogenesis and tumour growth 
From my previous data, it is clear that AE87, AE106, MAZ51 and MAZ51-2 (Fig. 
3.23) might have the potential to block tumour growth directly or by inhibiting 
angiogenesis/lymphangiogenesis. I therefore investigated the effects of these 
substances on endothelial cell and tumour cell growth in culture. I then checked in 
vivo whether the growth of solid rat tumours could also be blocked by these 
indolinones. 
3.5.1 Anti-angiogenic properties of AE87, AE106, MAZ51 and MAZ51-2 
3.5.1.1 Inhibition of endothelial cell proliferation 
Triggering of endothelial cell proliferation is a major event in angiogenesis and 
lymphangiogenesis in which the members of VEGFR have been shown to play a 
centrat role (Saaristo et al., 2000). Consequently, the ability to inhibit endothelial cell 
proliferation indicates an anti-angiogenesis potential of a given substance. AE87, 
AE106, MAZ51 and MAZ51-2 were therefore tested for their inhibitory effect on 
proliferation of endothelial cells using an endothelial cell proliferation assay. In this 
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experiment, HUVEC and HDMEC cells were starved and then stimulated by the 
addition of serum-containing culture medium. Serum contains a variety of growth 
factors necessary for endothelial cell proliferation. Before and during the stimulation, 
increasing concentrations of indolinanes were present in the medium. After 24-hour 
incubation time, tritiated thymidine was added to the cells for several hours. The 
amount of the incorporated into DNA tritium was measured and proliferation of 
indolinone-treated versus non-treated cells was determined. As depicted in Figure 
3.24, in both types of cells, AE106, MAZ51 and MAZ51-2 exerted a potent anti-
proliferative action on endothelial cells with an estimated IC5o between 3-4 J.lM 
(HDMEC, Figure 3.24, B) and 7-9 J.lM (HUVEC, Figure 3.24, A). Consistent with 
the weaker inhibitory action of AE87 on VEGFR-2 and VEGFR-3, AE87 was only 
weakly inhibitory in the endothelial cell proliferation assay (ICso, >15-20 J.lM). 
OH 
AE87 
MAZ51-2 
OMe 
F 
AE106 MAZ51 
Figure 3.23 Chemical structure of AE87, 
AE106, MAZ51, and MAZ51-2. 
3.5.1.2 Differentialinhibition of VEGF- and FGF-mediated vascular endothelial 
cell proliferation 
It is possible that angiogenesis-related RTKs other than VEGFR family members 
may be inhibited by AE87, AE106, MAZ51 and MAZ51-2, which would also result 
in suppression of endothelial cell proliferation. lndeed, these inhibitors bad some 
activity against other RTKs in in vitro kinase assays (see Table 3.2) and also FGFR 
(Ralph Mazitschek, personal communication). The experiment in 3.5.1.1 in which 
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serum was used to stimulate endothelial cells could not differentiate between which 
RTK(s) was being inhibited by the various indolinanes used. The effect of the 
indolinanes on endothelial cell proliferation stimulated by defined factors was 
therefore tested. 
Starved HDMEC cells were stimulated with 100 ng/ml VEGF, 32.5 ng/ml aFGF or 
12.5 ng/ml bFGF diluted in serum and growth factor-free culture medium. Before and 
during the stimulation increasing concentrations of the indolinanes were present in the 
medium. After 24-hour incubation time, eH)-thymidine was added to the cells for 4-6 
hours. The amount of tritium incorporated into DNA was measured and proliferation 
of indolinone-treated versus non-treated cells was determined. As shown in Figure 
3.25, only AE106 could potently inhibit the FGF receptor signalling in HDMEC 
(ICso, 1.5-2 J.lM). This effect was comparable to the inhibition of VEGF-specific 
proliferation by AE106 (IC5o, 1 J.lM). In contrast, MAZ51 and MAZ51-2 did not 
cause considerable suppression of FGF-mediated proliferation, whereas its VEGFR-
specific effect as reflected by inhibition of VEGF-stimulated proliferation was quite 
pronounced (ICso, 2.5-3 J.lM). Although AE87 did inhibit FGF-stimulated 
proliferation (ICso, >9 J.lM), its inhibitory effect on VEGFR signalling was about two 
times stronger (ICso, 5 J.lM). In conclusion, under the tested conditions, MAZ51 and 
MAZ51-2 did not affect FGFR, AE87 acted as a weak FGFR inhibitor, whereas 
AE106 potently blocks FGFR function. In contrast, VEGF-stimulated proliferation, 
which is mediated via VEGFR-1 and VEGFR-2, could be inhibited by all the 
indolinones, with again AE87 being the weakest inhibitor ofVEGFR-2 function. 
3.5.1.3 Induction of apoptosis in endothelial cells 
Inhibition of RTK signaHing and thus EC proliferation observed in 3.5.1.1 and 
3.5 .1.2 by the indolinanes may lead to cell cycle arrest or induction of programmed 
cell death (apoptosis)- both would be detectable by inhibition ofproliferation. To get 
an insight into whether the observed anti-proliferative effect of the four indolinones is 
associated with programmed cell death in the endothelial cells, an in vitro apoptosis 
assay was performed. As before, starved HDMEC cells were stimulated with normal 
culture medium in the presence of different concentrations of the indolinones. After 
24 hour culturing the cells were lysed and the induction of programmed cell death was 
quantified by specific detection of apoptosis-associated cytoplasmic mono- and 
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Figure 3.24 Inhibition of vascular endothelial cell proliferation by AE87, 
AEJ06, MAZ51 and MAZ51-2. Starved HUVEC (A) and HDMEC (B) 
cells were stimulated by normal culture medium and cultured for 24 hours 
in the presence of the indicated concentrations of the test compounds. A 
pulse of tritium was given to the cells for the last 4-6 hours of the Stimula-
tion after which the cells were harvested onto a filter and the amount of 
incorporated radioactivity was measured. Data are expressed as percent of 
proliferation of non-treated cell (% of control). 
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Figure 3.25 Differentialinhibition ofVEGF- and FGF-stimulated endothelial cell 
proliferation by indolinones. Starved HDMEC cells were stimulated for 24 hour s 
with 100 ng .tnl VEGF, 32.5 ng .tnl aFGF or 12.5 ng .tnl bFGF in the presence of 
the indicated concentrations of AE87 (A}, AE106 (B}, MAZ51 (C}, MAZ51-2 
(D). A pulse of tritium was given to the cells for the last 4-6 hours of the Stimula-
tion after which the cells were harvested and the amount of incorporated radioac-
tivity was measured. Data are expressed as percent of non-treated cell prolifera-
tion (% of control). 
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oligonucleosomes with an antibody coupled to peroxidase. The amount of the 
chromogenic substrate produced in the subsequent colorimetric reaction catalysed by 
the antibody-coupled enzymewas quantified using a spectrophotometer at 405 nm. 
Thus the OD4o5 reading directly correlates with the amount of mono- and 
oligonucleosomes in the celllysates. The experiment revealed (see Fig. 3.26) that 
MAZ-51 and MAZ51-2 had a strong dose-dependent apoptogenic effect in HDMEC, 
whereas AE87 and AE106 induced very little cell death. 
3.5.1.4 Inhibition of endothelial cell sprouting 
Endothelial cell sprouting is independent of cell proliferation and caused by 
elongation of individual endothelial cells upon receipt of an appropriate angiogenic 
stimulus (e.g. VEGF). It was therefore important to check whether the identified anti-
angiogenic indolinones could also block endothelial sprouting. To this end, the effect 
of AE87, AE106, MAZ51 and MAZ51-2 on the formation of sprouts during the 
culturing of HUVEC spheroids in collagen gels was assessed. Endothelial spheroids 
were obtained by culturing HUVECs in a round-bottomed plate in the presence of an 
anti-adhesive substance (i.e. methylcellulose). Upon 3-day stimulation with VEGF, 
the collagen-embedded spheroids gave rise to long endothelial processes such as those 
shown in Figure 3.27 (a, arrows). However, when 10 J.l.M AE106 (Fig. 3.27, c), 
MAZ51 (Fig. 3.27, d), or MAZ51-2 (Fig. 3.27, e) was present in the collagen gels 
such sprouting was dramatically suppressed. Consistent with its overall weak 
inhibitory properties AE87 exhibited the weakest effect in the spheroid cultures, as 
some sprouts still persisted after 3 days of culture (Fig. 3.27, b ). 
3.5.2 Anti-tumour properties of AE87, AE106, MAZSl 
Angiogenesis is a very irnportant aspect of turnour progression and metastasis. My 
previous experiments demoostrate that this process is likely to be blocked by the 
indolinones AE87, AE106, MAZ51, MAZ51-2. However, theseinhibitorsalso are 
active against other RTKs in in vitro assays (Table 3.1). They rnay therefore also 
interfere with turnour growth directly. I therefore next investigated (a) whether 
tumour cell proliferation is directly affected by the indolinones, and (b) whether 
tumour growth in vivo can be reduced or stopped by the inhibitors. According to all 
the experiments performed previously, MAZ51 and MAZ51-2 possess virtually 
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Figure 3.26 lnduction of apoptosis in HDMEC by the indolinones. Starved 
HDMEC cells were stimulated with normal culture medium for 24 hours in the 
presence of different concentrations of AE87, AE106, MAZ51 and MAZ51-2. 
Apoptosis was quantified using anti-DNA-peroxidase antibody. The amount of 
chromophoric substrate produced in a chromogenic reaction catalysed by peroxi-
dase was measured photometrically at 405 nm and correlated with the amount of 
apoptosis-associated cytoplasmic mono- and oligonucleosomes present in the cell 
lysate. Data are expressed as relative absorbance at 405 nm, using non-treated cell 
sample as a blank. 
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identical inhibitory properties. Moreover, these two indolinones have very similar 
chemical structure. Only MAZ51 was therefore used in the following tumour 
experiments. 
Tumour cellline 
Bsp73 rat pancreatic carcinoma system 
lAS 
ASML 
Dunning rat prostatic carcinoma system 
G 
AT6.1 
13762NF rat mammary carcinoma system 
MTLN3 
MTLY 
Other mammary carcinomas 
NM081 
MT450 
Metastatic potential 
+ 
+ 
+ 
+ 
+ 
+ 
Table 3.3 Rat tumour celllines usedfor the study ofthe direct anti-tumour effect 
of indolinones. Legend: -, non-metastatic cell lines; +, cell lines with different 
metastatic potential. Data are taken from Nestlet al. (2001). 
3.5.2.1 Inhibition of tumour ce/1 proliferation in vitro 
In order to determine the direct effect of the indolinones on tumour cells, a panel of 
rat tumour cell lines which differ in their metastatic potential was used (see Table 
3.3). In the experiment, the indicated rat tumour cells were cultured for 24 hours in 
standard growth media supplemented with 2.5 J.1M or 10 J.l.M AE87, AE106, and 
MAZ51, respectively. Cells which were grown in medium containing 1% DMSO 
(solvent control) were used as a control. To determine proliferation rate, tritiated 
thymidine was present in the cell medium for the last 4-6 hours of incubation. Then 
the amount of incorporated tritium was quantified and interpreted as a measure of 
cellular proliferation. As shown in Figure 3.28, AE87 did not have any measurable 
anti-proliferative effect on the cell lines tested. AE106 exhibited weak inhibitory 
effects. In contrast, MAZ51 exhibited a strong inhibitory effect, and proliferation of 
most ofthe tested celllines was inhibited by 50% even at a concentration of2.5 J.1M. 
The notable exceptions are the G and MTLN3 celllines, which were less sensitive to 
the action of MAZ 51. Thus, MAZ51 is a potent inhibitor of tumour cell proliferation, 
in addition to blocking endothelial cell proliferation. 
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Figure 3.27 Inhibition of sprouting formation by AE87, AEJ06, MAZ51 and 
MAZ51-2. HUVEC spheroids were cultured in 50% collagen gel containing either 
t% DMSO (A) or 10 ~M one of the inhibitors: AE87 (B), AE106 (C), MAZ5 t 
(D), MAZ5 t -2 (E). Disappearance of most sprouts from inhibitor-containing gels 
but present in DMSO control gel(arrows) is apparent. 
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Figure 3.28 Direct effect of AE87, AEJ 06 and MAZ51 on rat tumour cells. Cells from the indicated rat tumour cell 
lines were grown for 24 hours in the presence of 1% DMSO (solvent control), 2.5 !JM or 10 !JM of the indolinones. 
Tritiated thymidine was added to the medium for the last 4-6 hours of incubation. Cells were harvested and the amount 
of incorporated into DNA radioactivity was quantified. Data are expressed as percent of proliferation of cells treated 
with solvent control (% of control). 
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3.5.2.2 lnduction of apoptosis in tumour cells in vitro 
MAZ51 inactivates a range of RTKs, which is probably the cause of the observed 
suppression of tumour cell proliferation. In the next step, I tested whether this 
reduction in the proliferation rate is accompanied by an increase in tumour cell 
apoptosis. The same panel of rat tumour cells was used for this purpose as for the 
proliferation experiment. Rat tumour cells were cultured for 24 hours in standard 
growth media supplemented with 2.5 JlM or 10 J.!.M AE87, AE106, and MAZ51, 
respectively. Cells which were grown in medium containing 1% DMSO (solvent 
control) were used as a control. The amount of apoptosis in a given cell culture was 
quantified as described for HDMEC (see 3.5.1.3). The experiment (Fig. 3.29) 
demonstrated that in the majority of cell lines, MAZ51 had strong apoptotic effect, 
with the lAS, AT6.1 and MT450 being the most susceptible celllines. Interestingly, 
ASML and MTL Y did not show much apoptosis in response to MAZ51. The anti-
proliferative effect of MAZ51 on these cells may therefore be explained as a cell 
cycle arrest. Consistent with the weak anti-proliferative action seen in the previous 
experiment, AE87 and AE106 did not induce apoptosis in the given tumour celllines. 
An exception is AT6.1, which seems to have a particularly high sensitivity to 
indolinone treatment. 
3.5.2.3 E/fect of indolinones on JAS rat pancreatic carcinoma tumour growth in 
vivo 
The previous experiments established that AE87 and AE106 have anti-angiogenic 
properties and that MAZ51 is a strong inhibitor of both angiogenesis and tumour cell 
growth in vitro. I therefore tested whether these indolinones can also affect in vivo 
tumour growth. The 1 AS rat pancreatic carcinoma cell line was used for the initial 
experiment, because these cells form rapidly growing non-metastasising tumours in 
vivo. Four groups of male and female BD 10 rats were injected subcutaneously with 
1 AS cells. Treatment with 100 J.ll of 1 0 mg/ml indolinones (AE87, eight per group; 
AE106, eight per group; MAZ51, eight per group) or the solvent (100% DMSO, eight 
per group) was commenced on the 2nd day after tumour cell injection and 
corresponded to approximately 4 mg indolinone per kg body weight per day. The 
injections were performed intraperitoneally until the tumours reached the maximal 
legal size (50 mm) in diameter, with the tumours measured every 5 days. As shown in 
Figure 3.30, tumours of the rats treated with MAZ51 were significantly smaller than 
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Figure 3.29 lnduction of apoptosis in rat tumour cells by AE87, AE106 and MAZ51. Cells from the indicated rat tumour cell 
lines were grown for 24 hours in the presence of 1% DMSO (solvent control), 2.5 J.IM or 10 J.IM of the indolinones. Apoptosis 
was quantified using anti-DNA-peroxidase antibody. The amount of chromophoric substrate produced in a chromogenic reac-
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Figure 3.30 Effect of AE87, AE106 and MAZ51 on the growth of JAS rat 
pancreatic carcinoma tumours in vivo. lAS rat pancreatic carcinoma 
cells were injected subcutaneously into BD 10 rats. Intraperitoneal injec-
tions of the indolinanes (1 mg/animallday) or solvent were initiated on the 
following day and Iasted until the tumours reached legal size. The tumours 
were measured every 5 days. The mean tumour volumes measured in 8 
animals per group are presented. 
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the control ones treated with DMSO. However, rats which received AE87 or AE106 
developed tumours bigger than in the control group. Autopsies showed that a 
significant proportion of the injected substance in the AE 106 and MAZ51 groups had 
precipitated and was deposited on the outer surface of the guts. This may explain why 
the anti-tumour effect ofMAZ51 was comparatively modest compared to its effects in 
cell toxicity. During the course of injections, none of the manifestations of acute 
toxicity such as changes in body weight were noted. 
3.5.2.4 Effect of MAZ51 on MT450 rat mammary carcinoma tumour growth in 
vivo 
Although lAS tumours are non-metastatic, the lAS model has a major drawback 
in that the lAS tumours exhibit considerable size variation, which results in relatively 
large standard error values. MAZ51, which showed an effect on lAS tumour growth 
in vivo, was therefore used in an attempt to inhibit the growth ofMT450 rat mammary 
carcinoma tumours, which are metastatic but show a consistent and uniform tumour 
growth in vivo. Two groups of male and female Wistar Furth rats were injected 
subcutaneously with MT450 cells. Due to the extensive precipitation of the 
indolinones noted in the earlier experiments, animals were treated with a higher dose 
of the inhibitor (200 J.ll of 10 mg/ml MAZ51, eight per group) or the solvent (200 J.ll 
of 100% DMSO, eight per group). Intraperitoneal injections were initiated on the 2"d 
day after tumour cell injection and corresponded to approximately 8 mg indolinone 
per kg body weight per day. The indolinone and control injections are on-going 
experiments and will be stopped when the tumours will have reached the maximal 
legal size (50 mm) in diameter. As shown in Figure 3.31, the interim results 
demonstrate that MT450 tumours are considerably smaller when the animals received 
MAZ51. Due to time constraints, the metastasis rate of the MAZ51-treated and 
control tumours have not yet been measured. It tumed out that at 8 mg/kg/day 
MAZ51 had a noticeable toxic effect. Several animals within the MAZ51 group 
developed anaemia characterised by a pale colour of corneas and muscular weakness. 
Subsequently, approximately 1 week after the start of MAZ 51 injections, one animal 
ofthe MAZ51 group died. The remaining animals, however, have tolerated MAZ51 at 
this concentration. So far it is not possible to determine whether the toxicity was due 
to MAZ 51 or due to the extensive intraperitoneal precipitation of the substances in the 
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Figure 3.31 Inhibitory effect of MAZ51 on the growth of MT450 rat mammary 
carcinoma tumours in vivo. MT450 rat mammary carcinoma cells were injected 
subcutaneosly into Wistar Furth rats. Drug treatment with 8 mglk:g/day of MAZ51 
in 100% DMSO or solvent control (100% DMSO) was commenced on the next 
day after tumour cell injection. Tumours were measured every 4-5 days. The mean 
tumour volumes measured in 8 animals per group are presented. 
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abdominal cavity of the injected rats. 
3.5.2.5 Effect of MAZ51 on the growth of established MT450 rat mammary 
carcinoma tumours in vivo 
In the final experiment, I wanted to verify that the in vivo effect of MAZ51 on 
MT450 tumours observed when the indolinone was injected starting from the first day 
post tumour injection can be reproduced in the case of already established tumours. In 
parallel with the animals used in the previous experiment, two groups of male and 
female Wistar Furth rats were injected subcutaneously with MT450 cells. Animals 
received 200 J.ll of 10 mg/ml MAZ51 (eight per group) or 200 J.ll 100% DMSO 
solvent ( eight per group ). This dose equates to approximately 8 mg MAZ51 per kg 
body weight per day. Intraperitoneal injections were initiated on the 151h day after 
tumour cell injection when the tumours were already of 1 cm in diameter. The 
experiment is still ongoing and will be stopped when the tumours have become 50 
mm in diameter or the animals have become moribund. Figure 3.32 demonstrates the 
interim result of this experiment. Tumours of the animals, which received 
intraperitoneal injections ofMAZ51, again are smaller that those ofthe control group, 
suggesting that at the given concentration MAZ51 can also inhibit the growth of 
already established tumours. However, as before, MAZ51 exhibited general toxicity 
that led to the death of one animal in the experimental group. Due to time constraints, 
the metastasis rate of the MAZ51-treated and control tumours have not yet been 
measured. 
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Figure 3.32 Inhibitory effect of MAZ51 on the growth of established MT450 rat 
mammary carcinoma tumours in vivo. MT450 rat mammary carcinoma cells were 
injected subcutaneosly into Wistar Furth rats. Drug treatment with 8 mglkg/day of 
MAZ51 in 100% DMSO or solvent control (100% DMSO) was cornmenced 15 
days after tumour cell injection. Tumours were measured every 4-5 days. The 
mean tumour volumes measured in 8 animals per group are presented. 
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3.6 Characterisation of anti-tumour properties of plant-derived hyperforin 
Hyperforin is a major active constituent of St. John's Wort (Hypericurn perforaturn 
L.), which has long been known as a folk remedy for bums and skin injuries (Hänsel 
et al., 1993) and lately gained a reputation as an effective anti-depressant (Linde et 
al., 1996). An acylphloroglucinol-type compound that consists of a phloroglucinol 
skeleton substituted with lipophilic isoprene-chains (Bystrov et al., 1975; Erdelmeier, 
1998; Fig. 3.33), hyperforin isanatural antibiotic that inhibits the growth of several 
gram-positive bacteria (Gurevich et al., 1971; Schempp et al., 1999). Recent sturlies 
also implicate hyperforin as a potent antiproliferative agent for mammalian cells in 
vitro (Schempp et al., 2000). This latter property prompted me, in collaboration with 
the group of Dr. Jan Simon, Department of Dermatology, University of Freiburg, to 
test the anti-tumour activity ofhyperforin bothin vitro andin vivo. 
Figure 3.33 Chernical structure of hyperforin, a rnajor active constituent of St. John 's 
Wort (Hypericurn perforaturn L.). 
3.6.1 Anti-proliferative action of hyperforin on tumour cells and vascular 
endothelial cells in vitro 
Before undertaking in vivo tumour studies, I wanted to test whether hyperform has 
any direct anti-tumour effect and whether it may also be anti-angiogenic in vitro. For 
this purpose, an in vitro proliferation assay using MT450 rat mammary carcinoma and 
HDMEC cells was performed. The two types of cells were grown for 24 hours in 
normal culture medium containing either 0-200 Jlg/ml hyperforin or the 
corresponding solvent, namely 10% DMSO. Tritiated thymidine was added to the 
medium for the last 4-6 hours of the incubation a:fter which the cells were harvested 
and the incorporated radioactivity was counted. As demonstrated in Figure 3.34, 
hyperforin but not the solvent had a strong anti-proliferative effect on both tumour 
cells and endothelial cells. Interestingly, the HDMECs were two times more sensitive 
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Figure 3.34 Inhibition of tumour and endothelial cell proliferation by hyperforin. 
MT450 and HDMEC were incubated with increasing concentrations of 
hyperforin or solvent control for 24 hours. A pulse of tritium was given to the 
cells for the last 4-6 hours of the incubation after which the cells were harvested 
and the amount of incorporated radioactivity was measured. Data are expressed 
as percent of non-treated cell proliferation (% of control). 
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to the action of hyperforin than the MT450 cells: IC5o 65 f..lg/ml (HDMEC) as opposed 
to ICso 145 fJg/ml (MT450). It seems therefore that hyperforin isapotent anti-tumour 
agent which may also target tumour-induced angiogenesis. 
3.6.2 Induction of apoptosis by hyperforin in vitro 
To detennine whether the inhibitory action of hyperforin on tumour cells and 
endothelial cells is associated with the induction of apoptosis, an in vitro apoptosis 
assay was perfonned (Fig. 3.35). As described previously, cells were grown for 24 
hours in normal culture medium containing either 0-200 f..lg/ml hyperforin or the 
corresponding solvent after which the amount of apoptosis was quantified. In this 
experiment, hyperforin specifically induced apoptosis in MT450 tumour cells. 
However, neither the hyperforin treatment nor the treatment with solvent induced 
apoptosis in the HDMECs. When the endothelial cells treated with 200 f..lg/ml 
hyperforin were observed under the microscope, overwhelming proportion of cells 
were found dead. These cells could be stained with 0.2% trypan blue, which is tak:en 
up mainly by necrotic cells and therefore is used to detennine cellular viability. This 
experiment thus raises the interesting question of whether hyperforin is a cell-specific 
inhibitor acting in some cases as an apoptosis-inducing agent and in others such as 
endothelial cells by causing necrosis. 
3.6.3 Anti-tumour activity of hyperforin in vivo 
To assess the potential of hyperforin to inhibit tumour growth in vivo, female 
Wistar Furth rats were injected subcutaneously with rat mammary carcinoma MT450 
cells. Drug treatment with 2 mM hyperforin (8 animals per group) was commenced 15 
days after tumour cell injection when tumours were readily detectable and could 
easily be measured. The control group of eight animals received 10% DMSO (solvent 
control). To compare the effect ofhyperforin with that of a clinically used anti-cancer 
drug, injections with an equimolar concentration of paclitaxel were administered to 
another group of 8 animals in parallel. Daily injections of the drug/control were 
administered subcutaneously at the site of the tumour cell injection for two weeks. As 
shown in Figure 3.36, hyperforin inhibited tumour growth to a similar extent as 
paclitaxel. These data suggest that the potential of hyperforin to inhibit tumour growth 
in vivo is commensurate with that of an established anti-cancer drug. The survival rate 
ofthe animals after the completion ofthe treatmentwas established (Fig. 3.37). 
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Figure 3.35 Di.fference in the apoptogenic ejjects of hyperforin on MT-450 rat 
mammary carcinoma cells and HDMECs. MT -450 and HDMECs were incubated 
for 24 hours with 0-200 J.lg/ml hyperforin or corresponding solvent control. 
Apoptosis was quantified using anti-DNA-peroxidase antibody. The amount of 
chromophoric substrate produced in a chromogenic reaction catalysed by peroxi-
dase was measured photometrically at 405 nm and correlated with the amount of 
apoptosis-associated cytoplasmic mono- and oligonucleosomes present in the cell 
lysate. Data are expressed as relative absorbance at 405 nm, using non-treated 
cell sample as a blank. 
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Figure 3.36 Inhibition of MT450 rat mammary carcinoma tumour growth in vivo 
by hyperforin MT450 rat mammary carcinoma cells were injected subcutaneosly 
into female Wistar Furth rats. Drug treatment with 100 J.ll of equimolar (2 mM ) 
concentrations of hyperforin or paclitaxel (clinically-used drug) or solvent control 
was commenced 15 days after tumour cell injection and Iasted for a period of two 
weeks. Tumours were measured every 4-5 days and the mean tumour volumes 
measured in 8 animals per group are presented. 
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Figure 3.37 Survival curve for the hyperforin-treated animals. After the treatment 
had been completed the animals were observed and killed when the size of the pri-
mary tumour reached the legal Iimit (50 mm in diameter) or the animals became 
moribund. 
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Consistent with the tumour-inhibiting effect of hyperforin, animals that had 
received the hyperforin treatment survived for a Ionger time, as compared to the 
control group of animals. During the course of injections, none of the manifestations 
of acute toxicity such as changes in body weight were noted. 
3. 7 Publications and patents 
The following publications have been the result ofthe work described in the thesis: 
Patent application to the Forschungszentrum Karlsruhe (AE87, AE106 and 
MAZ51 kinase inhibitors). Chirchin, V., Giannis, A., Mazitschek, R., Sleeman, J. 
(2001). 
Kirkin, V., Mazitschek, R., Krishnan, J., Steffen, A., Mandriota, S., J., 
Waltenberger, J., Pepper, M., S., Giannis, A., and Sleeman, J., P. (2001) 
Characterisation of indolinanes which specifically inhibit VEGF-C- and VEGF-D-
induced activation ofVEGFR-3 but not VEGFR-2. Eur. J. Biochem. (submitted). 
Schempp, C., M., Kirkin, V., Simon-Haarhaus, B., Kersten, A., Termeer, C., C., 
Wissel, S., Sleeman, J., P., and Simon, J, C. (2001) Hyperforin is anovel anti-cancer 
drug that inhibits tumour cell growth by induction of apoptosis. J. Natl. Cancer Inst. 
(submitted). 
Sleeman, J., Krishnan, J., Kirkin, V., and Baumann, P. (2001) Markers for the 
lymphatic endothelium: in search of the Holy Grail? Microscopy Research and 
Technique (in press). 
Kirkin, V. and Sleeman, J., P. (2000) Establishment of lymphatic endothelial cells 
in culture. In 241h Annual Meeting oftheGerman Society for Cell Biology, Karlsruhe, 
March 261h-301h, 2000. Eur. J Cell Bio/. Supplement 50 (Volume 79). 
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The primary goal of my work was to identify novel anti-cancer drugs that would 
inhibit either tumour growth directly or would affect tumour-associated angiogenesis 
and lymphangiogenesis. In the initial part of my thesis work, recombinant rat VEGF, 
VEGF-C and VEGF-D proteins were produced and characterised, and were found 
possess full biological activity. Together with in vitro kinase assays, these proteins 
allowed me to establish system for screening a panel of novel indolinones for their 
ability to inhibit the activity of a number of RTKs. Of 32 indolinones screened, I 
identified four potential inhibitors of tumour growth. One of them, namely MAZ51, 
could suppress tumour growth in rats, while the others could inhibit angiogenesis in 
vitro. An investigation into whether hyperforin has any anti-tumour properties was 
also performed. It was found to be able to reduce tumour growth directly by inducing 
tumour cells to apoptose and indirectly via inhibition of endothelial cell proliferation. 
Thus, the compounds identified in the course of this work may be of pharmaceutical 
value and should contribute to development of better cancer treatment. 
4.1 Creation of cellular assays for RTK activitv 
4.1.1 Rat VEGF-C and VEGF-D 
The recombinant rat VEGF-C and VEGF-D proteins I made in Drosophila cells are 
biologically active. This could be proven by the cellular phosphorylation assays in 
which both VEGFR-2 and VEGFR-3, the cognate receptors for VEGF-C and VEGF-
D, became phosphorylated in response to activation by VEGF-C and VEGF-D present 
in the conditioned medium of the relevant transfectants. Furthermore, the purified 
mature VEGF-C protein induced DNA synthesis in primary vascular endothelial cells. 
These data are consistent with the fact that a biologically active VEGF protein has 
been produced in an insect system by others (Fiebich et a/., 1993). 
Although biologically active in conditioned medium, purified rat ßNßCNEGF-D 
loses its ability to activate VEGFR-2 and VEGFR-3. One reason for this could be that 
VEGF-D is especially sensitive to the purification procedure which itself causes the 
loss of VEGF-D activity. Nevertheless, purified ßNßCNEGF-C and ßNßCNEGF-
C(Cysi52Ser) proteins retained their biological activity. There may therefore be an 
alternative explanation to the loss of activity of VEGF-D: rat VEGF-D may require 
some receptor-binding cofactors that are present in the medium and become lost upon 
purification. Consistent with this notion, when proteins present in the conditioned 
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medium of the appropriate S2 transfectants were analysed on non-reducing SOS-
PAGE gels, ~N~CNEGF-C and ~N~CNEGF-D sarnples contained multiple bands 
(Fig. 3.4). Besides the ones corresponding in size to the monomeric forms of the 
proteins (13 kDa) and to covalent dimers (26 kDa), some intermediate bands of 
approximately 20 kDa were apparent in both the ~N~CNEGF-C and ßN~CNEGF-D 
sarnples. Preliminary data suggest that such intermediate bands are missing in the 
non-reducing sarnples of the inactive purified ~N~CNEGF-D protein. The presence 
of these intermediate protein bands specifically recognised by anti-His antibody as 
weil as by specific VEGF-C and VEGF-D anti-sera (data not shown) may therefore be 
attributed to the formation of covalently linked protein complexes in the transfeetaut 
medium. This possibility deserves further investigation. 
Although human VEGF-C and VEGF-D have been described to be very 
homologous in their structure and properties (Achen et a/., 1998; Stacker et a/., 1999), 
their rodent counterparts seem to exhibit less similarity especially in their receptor 
specificity. Thus, it has very recently been shown that, unlike murine VEGF-C, 
murine VEGF-D cannot bind murine VEGFR-2 receptor despite its ability to bind 
murine VEGFR-3 and human VEGFR-2NEGFR-3 (Baldwin et al., 2001). Due to the 
unavailability of rat VEGFR-2 and VEGFR-3, I used human VEGFR-2 and murine 
VEGFR-3 receptors in this thesis. The binding of the rat ligands to these receptors 
was not affected by the species-specific differences and therefore it is obscure 
whether rat VEGF-C and VEGF-D bind to rat VEGFR-2 differently. Furthermore, the 
presence of the covalent dimers in the non-reducing rat recombinant ~N~C protein 
sarnples is at odds with the published observations that human ~N~CNEGF-C and 
ßN~CNEGF-D form strictly non-covalent dimers (Joukov et al., 1997; Stacker et a/., 
1999). Moreover, differences between rodent VEGF-C and VEGF-D also exist as the 
mutation of Cysl4I completely destroyed biological activity of ~N~CNEGF-D, 
whereas the analogous mutation in ~N~CNEGF-C does not influence the ability of 
VEGF-C to bind to and activate VEGFR-3. 
4.1.2 Attempts to establish LE cultures 
The Iack of availability of LE in culture is limiting for experiments aimed at 
understanding the processes of physiological and pathological lymphangiogenesis. 
Such cultures would also permit selection of potential inhibitors of 
lymphangiogenesis. LE cells from large lymphatic ducts, such as thoracic and 
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mesenteric ducts, have been successively grown in culture (Johnston and Walker, 
1984; Gnepp and Chandler, 1985; Leak and Jones, 1993; Weber et a/., 1994; Yong 
and Jones, 1991; Borron and Hay, 1994). However, these LE cells are 
morphologically and functionally different from the LE derived from peripheral 
tissues. They would therefore not be appropriate for studying lymphangiogenesis. In 
my thesis work, I made attempts to establish LE cultures from peripheral tissues. One 
of them was to make use of the biologically active rat ßNßCNEGF-C and 
ßNßCNEGF-C(Cys152Ser) I made to induce lymphangiogenesis in rats. 
Matrigel has successfully been used in different experimental settings where 
angiogenic growth factors such as FGFs (Passaniti et a/., 1992) and SFIHGF (Grant et 
al., 1993) were used to induce angiogenesis in vivo. I attempted to induce LE growth 
into matrigel using recombinant VEGF-C proteins, basing my experimental approach 
on a method shown to work for SFIHGF-induced angiogenesis (Grant et al., 1993). 
Matrigel was mixed with ßNßCNEGF-C and ßNßCNEGF-C(Cys152Ser) and 
injected subcutaneously into rats. Following the extraction and sectioning of the 
plugs, however, no specific induction of lymphangiogenesis occurred, based on the 
observation that the amount of the VEGFR-3-positive cellular structures found in all 
the analysed gelswas similar in both VEGF-C-containing and control gels containing 
no recombinant growth factors. The failure of the ßNßC/VEGF-C to induce 
lymphangiogenesis may be due to the Iack of the putative ECM-binding domains 
present in the full-length VEGFs, which might Iead to quick release of the growth 
factor from matrigel. This presumption, however, is weakened by the inability of the 
recombinant rat VEGF to induce angiogenesis in the same experiment. The rat VEGF 
protein used corresponds to the described human VEGF 189 species known to be 
almost completely sequestered in the ECM and hence expected to bind to matrigel 
which resembles the ECM. Such bound VEGF should be gradually released from the 
gel to induce proliferation of vascular endothelial cells. Therefore, an unidentified 
technical problern probably accounts for the failure of this approach. Nevertheless, the 
VEGFR-3-positive structures also observed in the growth-factor deficient matrigel 
deserve further investigation. Two questions remain tobe answered: a) Is matrigel on 
its own lymphangiogenic? and b) Is VEGFR-3 expression up-regulated on cell types 
other than LE which invade matrigel? lf matrigel proves to be lymphangiogenic, it 
could be used as a model system to study lymphangiogenesis in vivo. 
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The conditional lymphangiomas seem to be a more reliable source of peripheral 
LE. The experiments with rats demonstrated high reproducibility of the method 
originally described for mice (Mancardi et al., 1999). The lymphatic endothelial 
origin of the white adjuvant-induced tumours in rats was assumed on the basis of 
immunohistochemistry. Indeed, most of the cells forming lymphangiomas stained 
positiv:ely for the putative LE marker VEGFR-3 and the pan-endothelial marker 
CD31. However, the major obstacle in this approach was the short life span of the 
lymphangioma-derived cells in culture, which resulted in the inability to achieve large 
numbers of cells for their characterisation and further experiments. Additional work 
needs to be performed to establish culturing conditions that permit the propagation of 
LE in culture. Altematively, or in addition, approaches could be made to immortalise 
the LE cells. In fact, I made attempts to immortalise the cells derived from the 
lymphangiomas by a) infecting them with a retrovirus whose genome encodes E6 and 
E7 proteins of human papillomavirus 16 and b) their transfection with a telomerase 
construct. Both the immortalisation protocols have been described to work in certain 
cell types (e.g. epithelial cells, Halbert et al., 1991 and T cells, Hooijberg et al., 
2000). However, these measures did not Iead to a delay in the onset of senescence as 
judged by morphological observations. Further, investigations are required to study 
the sequence of events necessary torender LE cells immortal. Recently, the ability to 
cause differentiation of embryonie stem (ES) cells into endothelial cell in vitro has 
been demonstrated (Hirashima et al., 1999). This opens another perspective for LE 
culturing. It would be of great interest to check whether VEGFR-3+ ES cells can be 
induced to differentiate into a LE lineage using the lymphangiogenic factors VEGF-C 
andVEGF-D. 
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4.2 Selection and characterisation of indolinones 
4.2.1 Screening procedure 
To getan initial indication ofthe possible RTK targets ofthe available indolinones 
a screening procedure was developed. As a first step, bacterial recombinant GST 
fusion proteins containing the catalytic domains ofvarious RTKs were used in in vitro 
kinase assays. This allowed me to select among the 32 indolinones a group of 16 
substances with a good inhibitory activity (~ 50% inhibition) towards potential RTK 
targets. Thus, the number of the candidates for the further studies was halved, which 
eliminated the necessity to use the large quantity of samples in further more 
sophisticated experiments. However, this screening method employed rather artificial 
conditions because the substrate phosphorylation reaction has a limited number of 
components and is performed out of the cellular context. Moreover, the catalytic 
domains of bacterial GST fusion proteins, due to the Iack of other functional RTK 
domains and compromised post-translational modification, are likely to have a 
different conformation in comparison to the intact membrane-bound protein expressed 
in eukaryotic cells. Such a method therefore cannot reflect the real affinity of the 
indolinones for a particular RTK. Furthermore, the ability of the indolinones to 
permeate membrane in cellular assays is a critical factor for their cellular activity. 
Also, solubility tests demonstrated that the indolinones are poorly soluble in water 
(data not shown). For these reasons, the overwhelming majority of the indolinones 
selected on the basis of the in vitro kinase assays did not have any inhibitory effect on 
the activation ofcellular VEGFR-2 and VEGFR-3. 
The affinity ofthe same indolinone for different RTKs is largely dependent on the 
conformation of the reactive centre of the protein (Mohammadi et al., 1997). Even 
such closely related RTKs as the members of the VEGFR family revealed different 
affinity for the same indolinones. Thus, in the cellular experiments, AE87, for 
instance, was weakly inhibitory for VEGFR-3 but did not affect VEGFR-2, and 
intriguingly, at a high concentration (50 f.1M) it seems to have stimulated VEGFR-1 
phosphorylation. As the experimentwas performed twice and every time yielded the 
same result, the possibility of an artefact was excluded. lt is difficult to explain how 
indolinones might stimulate RTK phosphorylation because these molecules, unlike 
adenosine-phosphates whose structure they mimic, normally do not contain phosphate 
groups. One possibility may be that AE87 down-regulates some phosphatases, which 
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results in the prolonged retention ofthe phosphatein the VEGFR-1 kinase. The ability 
of AE87 to stimulate VEGFR-1 and not VEGFR-2 phosphorylation could potentially 
be useful, as VEGFR-1 biological function is poorly understood and seems to be 
involved in the negative regulation of angiogenesis (Karkkainen and Petrova, 2000). 
Interestingly, while many ofthe indolinones could inhibit RTK phosphorylation in 
the in vitro kinase assay and not in the cellular assays some of them behaved in an 
opposite fashion. Thus, MAZ51 was weakly inhibiting for VEGFR-3 phosphorylation 
in the in vitro kinase assay (35% inhibition) but proved to be a potent inhibitor of 
VEGFR-3 in the subsequent experiments. It can therefore be concluded that in order 
to gain more objective data, use of more than one screening method should be used. 
4.2.2 Properties of AE87, AE106, MAZ51 and MAZSl-2 
The unambiguously active indolinones that could inhibit many RTKs including the 
VEGFRs bothin the in vitro kinase assays andin the cellular phosphorylation assays 
are AE87, AE 1 06, MAZ 51 and MAZ51-2. The especially prominent, though 
differential, VEGFR-3-inhibiting potential makes them a useful tool to study the 
VEGFR-3 signalling. Unfortunately, due to the failure to establish LE cultures, it was 
impossible to verify whether the identified VEGFR-3 inhibitors could inhibit 
lymphangiogenesis in a LE model system. Currently the compounds are being tested 
by Dr. Wilting (Albert-Ludwigs-Universitat, Freiburg) for their ability to inhibit 
lymphangiogenesis in a chicken chorioallantoic membrane (CAM) assay. Once 
successful, such sturlies could help further elucidate the role of VEGFR-3 m 
pathophysiologicallymphangiogenesis. 
Another useful feature of these indolinanes is their obvious anti-angiogenic 
potential that could be demonstrated in the in vitro experiments. In line with the 
differential VEGFR inhibitory potential of the four indolinones, their anti-angiogenic 
effect is also variable. Thus, AE87 is weak, AE 106 - moderate, whereas MAZ51 and 
MAZ51-2 are the strongest anti-angiogenic substances. Interestingly, while being 
unable to inhibit VEGFR-2 phosphorylation in the cellular assay when present in 
medium AE106 could inhibit VEGF-stimulated proliferation of endothelial cells with 
lCso about 1 JJ.M (Fig. 3.25, B). One explanation may be based on the fact that AE106 
inhibited VEGFR-1 phosphorylation in the cell as was shown in the cellular 
phosphorylation assay. Since VEGF activates two receptors VEGFR-1 and VEGFR-2 
(Hanahan, 1997), it is likely that inhibition of VEGFR-1, which is known to form 
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functional heterodimers with VEGFR-2 (Huang et al., 2001), or of some kinases 
downstream of the two VEGF receptors will cause suppression of endothelial cell 
proliferation. 
MAZ51 and MAZ51-2 are quite distinct from AE87 and AEI06 in their anti-
angiogenic properties. For instance, they apparently do not block FGFR signalling, 
whereas AE87 and AE 1 06 do have weak and moderate, respectively, inhibitory 
effects on FGFRs, as was assessed indirectly by measuring FGF-induced proliferation 
of HDMECs. In order to prove this directly it would be necessary to perform FGFR 
cellular phosphorylation studies analogous to the described VEGFR experiments. On 
the other hand, the MAZs and not the AEs killed endothelial cells by inducing them to 
undergo apoptosis. It also appears that MAZ51 and MAZ5 I -2 are very strong and 
probably broad-range kinase inhibitors. Thus, in addition to its anti-angiogenic 
properties, MAZ51 could strongly inhibit proliferation of a variety of tumour cell 
lines. In the most cases, this reduction in proliferation was again accompanied by an 
increase in cellular apoptosis. The induction of programmed cell death by the MAZs 
in endothelial and tumour cells might be explained by the blockade of some key 
kinases such as serine/threonine kinases PKA and PKB/ Akt. The latter are found 
downstream of RTKs, where they play pivotal roles in cell survival (Cross et a/., 
2000). In contrast, AE87 and AEI06, which may inhibit only certain receptor tyrosine 
kinases, while not perturbing the balance of pro-apoptotic and survival signals inside 
the cell, might cause the depletion of mitogenic signals and the ensuing withdrawal of 
the cell from the cell cycle. In order to further study this hypothesis, it would be 
necessary to check the inhibitory potential ofthe indolinanes on a range of 'survival-
related' kinases in in vitro kinase assays. 
The fact that not all the tumour cell lines tested became apoptotic after MAZ5 I 
treatment may be due to cell type-specific differences existing in the cellular 
responses to indolinanes as described for some other anti-cancer drugs such as 
betulinic acid (Pisha et a/., 1995). Thus, the independence of a particular tumour cell 
from survival factor signalling may render the cell insensitive to the action of RTK 
inhibitors. Nevertheless, the growth of tumours formed by cells with a good apoptotic 
response to MAZ51 such as 1 AS and MT450 could be significantly retarded by 
MAZ51. It is still unclear though why AE87 ~nd AEI 06 that inhibited proliferation in 
endothelial cells did not affect tumour growth in vivo. To address this question, the 
analysis of tumours is necessary. Staining of the tumour sections for markers of 
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apoptosis, angiogenesis and lymphangiogenesis shall also allow me to decipher 
whether the tumour cells or endothelial cells of blood and lymphatic vessels are 
affected by MAZ51. Due to the time limitations, this analysis could not be performed 
in the frames of the thesis. 
Given its potency to inhibit tumour growth in vivo MAZ51 deserves further 
research. lt is necessary to determine exactly what the other cellular targets for this 
indolinone are. This question could be addressed with help of in vitro kinase assays 
using a range of candidate RTKs. The broad spectrum of MAZ51 activity is 
potentially advantageous. Thus, inhibition of a range of kinases may ensure that the 
tumours will not be able to circumvent its activity. Moreover, a number of tumour-
related processes such as uncontrolled cell proliferation, angiogenesis and 
lymphangiogenesis (the Ietter two also accompanied by hyperproliferation) are likely 
to be inhibited at the same time. A major disadvantage of such broad specificity, 
however, can also be envisaged. The animal experiments showed that at higher doses 
(8 mg/kg/day) the toxic effect of MAZ51 becomes noticeable. It will therefore be 
necessary to test whether other proliferating cells of the organism are also susceptible 
to the action of MAZ51. However, it should also be noted that at this point it is not 
possible to say whether the toxic effects are direct, or due to the precipitation of 
MAZ51 in the abdominal cavity. 
As mentioned earlier, the solubility of indolinones seems tobe the majorproblern 
in both their characterisation and their possible clinical applicability. For instance, the 
two most potent indolinones MAZ51 and MAZ51-2 have the poorest solubility 
among the four indolinone candidates for anti-cancer treatment. In the in vitro 
experiments 1 to 5% DMSO was used to keep the substances in solution. In the 
animal experiments, 100% DMSO solutions were used to allow higher concentrations 
of AE87, AE106 and MAZ51 tobe delivered. Nevertheless, upon autopsy a great deal 
of precipitation of the substances was observed in the peritoneal cavity. Clumps of 
crystalline indolinones were detected on the surface of the intestinal tract and the 
peritoneum. While such clumps might serve as drug depots for slow release, their 
presence indicates overall reduction in bioavailability of the indolinones. A minor 
chemical modification such as the addition of hydrophilic groups to the 3-substituents 
of the core oxindole structure is likely to improve the solubility and hence 
bioavailability of the indolinones. Thus, other pre-clinical studies such as 
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improvement of the substance delivery methods as weil as bioavailability are 
necessary. 
MAZ51 may have the potential to enter clinical trials upon the completion of its 
characterisation. Although AE87 and AE106 do not seem to inhibit tumour growth in 
vivo, they are definitely worth further research in terms of their ability to block 
angiogenesis and lymphangiogenesis as they may prove to be useful for studying 
these processes. 
4.3 Hyperforin: a novel anti-cancer drug 
Given the potent anti-proliferative effect of hyperforin on mammalian cells in vitro 
(Schempp et al., 2000), the hypothesis that hyperforin may inhibit tumour growth was 
tested. The in vitro experiments demonstrated that hyperforin is a potent anti-
proliferative agent, which however may have a different mode of action in different 
cells. Thus, tumour cells were killed through induction of the programmed cell death, 
which is consistent with the mode of action of other cytotoxic drugs (Hickman, 1992; 
Debatin, 1999). Unlike the tumour cells, endothelial cell death did not exhibit obvious 
features of apoptosis. This observation is consistent with the notion that many other 
cytotoxic drugs are known to induce apoptosis with selectivity for certain tissues. For 
example, mentioned earlier betulinic acid selectively inhibits the growth of malignant 
melanoma (Pisha et al., 1995). 
The exact mechanism of how hyperforin induces apoptosis in tumour cells is not 
known, although there is an opinion that it activates the intrinsic apoptosis pathway 
(Schempp et al., manuscript submitted). Consistent with its anti-tumour and 
angiogenic effects in vitro, when injected subcutaneously at the site of MT450 rat 
mammary carcinoma tumours in Wistar Furth rats, hyperforin inhibited growth of 
already established tumours (15 days post-implantation) to a similar extent as the 
cytotoxic drug paclitaxel. An important advantage of hyperforin seems to be its ability 
to block both tumour cell proliferation and angiogenesis. Remarkably, no signs of 
acute toxicity in rats were noticed, suggesting that hyperforin might be suitable for 
clinical use. In fact, hyperforin is an already established drug used to treat depression 
and therefore should be easily adopted for anti-cancer use. 
Recent studies on hyperforin, however, indicate that it may also have some adverse 
properties for potential use in tumour therapy. Thus, it has been shown to activate the 
pregnane X receptor, which mediates hepatic cytochrome P450 gene expression. The 
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cytochrome P450 is an active player in drug metabolism and hyperforin may thereby 
actuate the metabolism of co-administered drugs (Moore et a/., 2000; Obach, 2000; 
Wentworth et a/., 2000). Furthermore, it is likely that hyperforin may suppress 
proliferation of cells other than tumour and endothelial cells. These aspects need to be 
analysed in more detail. 
4.4 Conclusion 
In the course of this thesis work several potential anti-cancer drugs have been 
identified. Four of them are small synthetic compounds that are capable of inhibiting 
angiogenesis and presumably lymphangiogenesis. MAZ51 is especially prominent as 
it can suppress the growth of established tumours in vivo. Since MAZSl is likely to 
have a broad specificity, it has the potential to interfere with both tumour cell 
proliferation and tumour-host interactions - a desirable property of an anti-cancer 
drug. Hyperforin characterised here for its anti-tumour potential is another example of 
an anti-cancer agent with a broad spectrum of activity. Due to its established clinical 
use, this drug seems to be particularly suitable for treating cancer. Further studies are 
necessary to define the exact mechanism of action of the identified substances as weil 
as to reduce their possible side effects. 
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